Subject: Human Research Protections Program

Prepared by:
Danielle Lewis, MD, MPH
IRB Management Analyst

Kevin L. Nellis, MS, CIP
Executive Director, Human Research Protections and Quality Assurance

Approved by:
Heidi Aronin, MPA
Senior VP and Chief Administrative Officer
Institutional Official

Clinton D. Brown, MD, FASN, FAHA, FNLA
IRB Chair

Committee Approval:
IRB & Privacy Board

Reviewed by:
Shoshana Milstein, RHIA, CHP, CCS
Assistant Vice President, Compliance and Audit
Privacy Officer

No. IRB-01

Revision Date: 12/20/2018
Original Issue Date: 03/30/2017
Supersedes: 01/19/2018
Effective Date: 01/21/2019

The JC Standards: IM.01.01.01, IM.01.01.01, LD.04.01.01, LD.04.02.03, MM.03.01.01, MM.06.01.05, RC.02.01.01, RI.01.01.01, RI.01.03.05,PI.03.01.01

Issued by: Research Foundation for SUNY – Downstate Medical Center; Office of Research Administration – Institutional Review Board & Privacy Board
Collection and Analysis of Information, Biospecimens, or Records by or for a Criminal
Justice Agency ........................................................................................................ 25

Authorized Operational Activities ........................................................................ 25

Clinical Care ............................................................................................................. 25

Off-Label Use of an FDA Approved Drug or Biologic .............................................. 25

Changes Necessary to Eliminate Apparent Immediate Hazards or to Protect the Life or
Physical Well-Being of the Research Participant Enrolled in Previously Approved Research
........................................................................................................................................ 26

Emergency Use of an Investigational or Unlicensed Drug, Biologic, or Device ........ 26

Other Activities That Do Not Require DMC IRB Approval ........................................ 28

IRB Application Submission Process ...................................................................... 28

IRB and Privacy Board Meeting Schedule ............................................................... 28

IRB Consultations ..................................................................................................... 29

Electronic Submissions and Management of DMC IRB Activities ....................... 29

Considerations for Research Submissions and IRB Review .................................. 29

Categories of DMC IRB Submissions .................................................................... 29

Determination that IRB Review is Not Required .................................................... 29

Exempt IRB Review ................................................................................................. 29

Common Rule Exemptions (Including Limited IRB Review) .................................. 30

Expedited IRB Review ............................................................................................ 35

Full (Convened) IRB Review ................................................................................... 38

Humanitarian Use Device (HUD) For Clinical Purposes ........................................ 38

Review For Expanded Access (Compassionate Use Or Preapproval Access) to An
Investigational Drug/Biologic For Treatment Use ....................................................... 39

Request to Use an External IRB or sIRB for Multi-Site Research Projects ............ 40

Investigator Qualifications ....................................................................................... 44

Applicable Clinical Trials and Registration on ClinicalTrials.Gov ......................... 45

Investigators and Research Team ............................................................................ 46
IDE Exempted Investigations ............................................................................................................. 66

Determining Which Device Studies Pose a Significant Risk or Non-Significant Risk ........... 67

Responsibilities for Device studies ................................................................................................. 67

Drugs and Biologicals ....................................................................................................................... 68

Investigational New Drug (IND) Requirements ............................................................................. 68

IND Exemption ............................................................................................................................... 69

Responsibilities Associated with an IND ....................................................................................... 69

Bioavailability and Bioequivalence Research .................................................................................. 69

Research Involving Endogenous Compounds, Live Organisms, Cosmetics, Dietary Supplements, Food, Food-Derived Products, Spices, Herbs, or Electronic Cigarettes ........ 69

Gene Transfer Research .................................................................................................................. 70

Research Involving Marijuana (Cannabis) ...................................................................................... 70

Planned Emergency Human Research or Clinical Trials ............................................................. 70

Exception Form Informed Consent Requirements For Emergency Research ......................... 71

Enrollment List ................................................................................................................................ 73

Medical Record Research Note For Clinical Trials ..................................................................... 74

Legally Effective Informed Consent and HIPAA Research Authorization ..................................... 74

Requirements .................................................................................................................................... 74

Legally Authorized Representative (LAR) or Surrogate ............................................................... 75

Form Requirements for Informed Consent and HIPAA Research Authorization ........................ 75

Informed Consent Requirements ........................................................................................................ 76

Basic Elements of Informed Consent .............................................................................................. 76

HIPAA Authorization ....................................................................................................................... 77

EU General Data Protection Regulation (GDPR) Requirements ................................................ 78

Additional Elements of Informed Consent ..................................................................................... 79

Elements of Informed Consent for Diagnostic Genetic Tests ......................................................... 79

Future Use of Specimens or Information ....................................................................................... 80
Consent Addendum for SUNY RF Payment ........................................................................................................... 81
Posting Consent Forms for a Federally Conducted or Funded Clinical Trial to a Federal Website .................................................................................................................................................. 81
Broad Consent for Storage, Maintenance, and Secondary Research of Identifiable Private Information or Identifiable Biospecimens .......................................................................................................................................................... 82
Obtaining Informed Consent from Individuals with Limited English-Speaking Proficiency (LEP) ........................................................................................................................................................................... 82

Informed Consent Process ........................................................................................................................................... 82
Waiving the Requirements of Informed Consent or HIPAA Authorization ................................................................. 83
Waiver of the Process for Informed Consent .................................................................................................................. 83
Waiver of Parental Permission ................................................................................................................................. 84
Waivers of Child Assent ............................................................................................................................................. 84
Waiver of Documentation of Informed Consent ........................................................................................................... 84
Waiver of Required Elements of Informed Consent ................................................................................................ 85
HIPAA Waivers .......................................................................................................................................................... 85
Full HIPAA Waiver ................................................................................................................................................... 86
Partial HIPAA Waiver ............................................................................................................................................. 86
HIPAA Alteration ......................................................................................................................................................... 86
Screening, Recruiting, or Determining Eligibility ...................................................................................................... 87
Distribution of Copies of Signed Informed Consent Materials .................................................................................... 87
Ancillary Reviews ............................................................................................................................................................ 87
Institutional Review Board (IRB) .................................................................................................................................. 90
IRB Chair .................................................................................................................................................................... 91
IRB Vice-Chairs .......................................................................................................................................................... 91
IRB Members .............................................................................................................................................................. 91
IRB Review Process ....................................................................................................................................................... 92
Review and Reviewer Assignment ............................................................................................................................ 92
Recusals .................................................................................................................................................................... 93
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Board Meetings</td>
<td>93</td>
</tr>
<tr>
<td>Other Review Activities</td>
<td>93</td>
</tr>
<tr>
<td><strong>Process For IRB Determinations</strong></td>
<td>93</td>
</tr>
<tr>
<td><strong>Process For Exempt, Expedited, or Full IRB Review</strong></td>
<td>93</td>
</tr>
<tr>
<td>Exempt Research Review Process</td>
<td>93</td>
</tr>
<tr>
<td>Limited IRB Review Process</td>
<td>94</td>
</tr>
<tr>
<td>Expedited Review Process</td>
<td>94</td>
</tr>
<tr>
<td><strong>Expeditred Review of Continuing Review (Progress Reports), Amendments, Reportable Events, and Other Considerations</strong></td>
<td>95</td>
</tr>
<tr>
<td>Serious Adverse Event (SAE) Review Process</td>
<td>95</td>
</tr>
<tr>
<td><strong>Full (Convened) IRB Review Process</strong></td>
<td>95</td>
</tr>
<tr>
<td><strong>Risk Assessment and Minimization</strong></td>
<td>97</td>
</tr>
<tr>
<td>Assessment of Benefits</td>
<td>98</td>
</tr>
<tr>
<td>Determining Which Projects Require Review More Often Than Annually</td>
<td>98</td>
</tr>
<tr>
<td><strong>Determining Effective Date of Initial IRB Approval and Date for Continuing Review or Check-In</strong></td>
<td>99</td>
</tr>
<tr>
<td>Verification That No Material Changes Have Occurred</td>
<td>100</td>
</tr>
<tr>
<td><strong>Consent Monitoring</strong></td>
<td>100</td>
</tr>
<tr>
<td><strong>Stamping Requirements of IRB Approved Materials</strong></td>
<td>101</td>
</tr>
<tr>
<td><strong>IRB Letters and Notifications</strong></td>
<td>102</td>
</tr>
<tr>
<td><strong>Possible IRB Actions or Approvals</strong></td>
<td>103</td>
</tr>
<tr>
<td>Approved</td>
<td>103</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>103</td>
</tr>
<tr>
<td>Acknowledgement Pending External IRB Approval</td>
<td>103</td>
</tr>
<tr>
<td>Approved with Conditions</td>
<td>104</td>
</tr>
<tr>
<td>Final Approval</td>
<td>104</td>
</tr>
<tr>
<td>Modifications Required</td>
<td>104</td>
</tr>
</tbody>
</table>
Disapproved / Not Approved .................................................................................................................. 105
Deferred / Tabled ................................................................................................................................. 105
Withdrawn Submission ........................................................................................................................... 105
Closed .................................................................................................................................................. 105
Expired .................................................................................................................................................. 105
Suspension or Termination ...................................................................................................................... 105
Not Human Research ............................................................................................................................. 106
Not Engaged in Human Research ......................................................................................................... 106
IRB Minutes ......................................................................................................................................... 106
Distribution of IRB Meeting Minutes .................................................................................................... 106
Post IRB Approval ............................................................................................................................... 106
General Requirements .......................................................................................................................... 106
**Reportable Events** ............................................................................................................................ 107
Amendments ....................................................................................................................................... 119
Amendment to Transition Existing IRB Approved Research to the 2018 Common Rule ................................................................................................................................. 120
Changes in Exempt Research .............................................................................................................. 121
Acknowledgement Requests and Other Considerations ...................................................................... 121
Administrative Corrections ................................................................................................................... 121
Check-In Report .................................................................................................................................. 121
**Continuing Review (Progress Report)** ............................................................................................ 122
Research Progress Report Form ........................................................................................................... 123
Lapse in Continuing Review/Expired IRB Approval ............................................................................ 123
Expiration Impacting the Safety, Rights, or Welfare of Any Research Participants ......................... 124
Re-Activation of Expired or Closed Studies .......................................................................................... 125
**Study Closure (Final Report)** .......................................................................................................... 125
Request to Re-activate (Re-Open) a Study ............................................................................................... 126
POLICY AND PURPOSE

This policy manual includes procedures for the preparation and submission of research protocols, including informed consent documents, for review by the State University of New York (SUNY) Health Science Center at Brooklyn [Downstate Medical Center (DMC)] Institutional Review Board (IRB) and Privacy Board (DMC IRB). This policy outlines the responsibilities of investigators and key personnel during the conduct of human research and after a study is closed.

This policy helps to ensure compliance with the terms of a Federal Wide Assurance (FWA00003624) with the US Department of Health and Human Services, Office for Human Research Protections (OHRP). This assurance applies to all human research when DMC is engaged in human research, including when the workforce conducts research outside of DMC in connection with their institutional responsibilities.

The DMC IRB registration with OHRP is IORG#0000064 for IRB# 00011521, and serves as the primary IRB for DMC research. External IRBs with review and oversight of DMC research must register with OHRP.

Activities requiring IRB review must have IRB approval and meet all other applicable requirements before they begin. This policy ensures compliance with policies, regulations, and laws pertaining to human research, including the requirements of the local jurisdiction where research takes place or the local jurisdiction for the source of specimens or data. DMC applies federal, state, and tribal regulations as indicated in the section below.

The U.S. Department of Health and Human Services and fifteen other Federal Departments and Agencies’ published revisions to the Federal Policy for the Protection of Human Subjects (the Common Rule) on July 19, 2018. These revisions are an effort to modernize, simplify, and enhance the current system of oversight. The compliance date for the revision of the Common Rule and this version of IRB-01 policy is January 21, 2019. Refer to the OHRP website regarding the Revised Common Rule for additional information.

Research approvals granted prior to January 21, 2019 comply with previous policy. However, when there is a compelling reason to transition the research, the IRB or an investigator may amend the research to comply with this version of the policy on or after January 21, 2019.

When the DMC IRB approves research with investigators or key personal from an external site, such investigators or key personal must follow DMC policies and the policies of their own institution.

When regulations or policies conflict with one another, DMC generally abides by the most stringent rule to allow the most protection to research participants and maintain regulatory compliance. Investigators who face a conflict about which regulation or policy to apply are directed to consult with the IRB to determine how to proceed.
The IRB anticipates additional changes to the FDA, DOJ, HIPAA, and NYS Article 24A regulations in efforts to harmonize with the changes of the Common Rule outlined in this policy. The IRB will revise this policy as soon as possible after a new regulation goes into effect. However, prior to making a policy change, the IRB may approve research under a provision of any new regulation when the Convened IRB, IRB Chair, or IRB Vice-Chair approves the change and the IRB documents the reason for such approval in an IRB approval letter.

Copies of any referenced documents or forms are available on the IRB Resources Website. When this policy does not address a situation, investigators should review IRB guidance materials or contact the IRB Office at (718) 613-8480 to discuss the specific situation.

The use of the word “must” in this policy means something is required under this policy or is a regulatory requirement. The use of the words “in general” or “should” in this policy, mean that something is recommended, suggested, or is a best practice, but not always required. An investigator may use an alternative approach if the approach satisfies the policy or regulatory requirement. The IRB is available to discuss alternative approaches by telephone at (718) 270-8480, or by e-mail at IRB@downstate.edu.

**APPLICABILITY OF SPECIFIC REGULATIONS AND POLICIES**

**KEY REGULATIONS**

Use the table below to determine which key regulations apply to a specific human research study:

<table>
<thead>
<tr>
<th>Guidelines:</th>
<th>Key Regulations:</th>
</tr>
</thead>
<tbody>
<tr>
<td>All research, including FDA regulated research, except for certain provisions as noted for FDA or DOJ regulated research.</td>
<td>Follow the provisions of the July 21, 2018 Common Rule (45 CFR 46, Subpart A) as outlined in this policy.</td>
</tr>
<tr>
<td></td>
<td>The Common Rule Exemptions (categories 1-6) can apply, when applicable, except most of these exemptions cannot be applied to FDA or DOJ regulated research (see below).</td>
</tr>
<tr>
<td></td>
<td><strong>Note:</strong> At the time of this writing, DMC does not apply exemption category 7 or 8 to research, as the policy for Broad Consent does not exist.</td>
</tr>
</tbody>
</table>
Federal Expedited review categories apply, when applicable.

The Federal Government did not revise subparts B, C, D, and E and therefore remain in effect, as indicated within the regulations.

<table>
<thead>
<tr>
<th>Research category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. Department of Justice (DOJ) regulated research.</td>
<td>The DOJ is not a signatory to the July 21, 2018 Common Rule; however, they intend to become an official signatory in the future. DMC must follow both the July 19, 2018 Common Rule and the policies of the National Institute of Justice (NIJ) for NIJ funded studies. When discrepancies exist between the 2018 Common Rule and the prior version of the Common Rule for DOJ requirements, follow the more restrictive requirement, such as the following requirements of the 2018 Common Rule: a) Exemption category #1, b) new elements of informed consent, c) Clinical Trial informed consent web-posting requirement.</td>
</tr>
<tr>
<td>Investigational studies involving research participants (including specimens) and FDA regulated articles (e.g., drugs including biologics, food or color additives, and medical devices), including bioavailability and bioequivalence studies.</td>
<td>Applicable FDA regulations apply to the research as defined by the FDA (e.g., clinical investigations that must comply with 21 CFR 50, 56, 312, 320, 812, 814, etc.) Except for Common Rule Exemptions, FDA regulated research must also follow the above requirements for the Common Rule. FDA exemptions apply to FDA regulated clinical investigations, when applicable. Federal Expedited review categories apply, when applicable.</td>
</tr>
<tr>
<td>Research conducted or supported by a Federal Department or Agency.</td>
<td>Apply any additional requirements from Federal Departments or Agencies, when they fund or conduct the research.</td>
</tr>
</tbody>
</table>
OTHER REGULATIONS AND POLICY

Regardless of the key regulation that applies to the research as indicated above, other regulations and policy apply as noted below:

- The HIPAA Privacy Rule (45 CFR Parts 160, 162, and 164) applies to any research involving Protected Health Information (PHI), also known as Individually Identifiable Health Information (IIHI).
- When required by the NIH or sponsor, investigators must follow the principles of Good Clinical Practices when conducting clinical trials.
- The IRB and investigators must comply with this policy and all other applicable DMC policies pertaining to research, including those of the DMC Office of Compliance and Audit Services (OCAS).
- Principal Investigators (PI) and investigators for the purposes of conflict of interest (COI), as determined by the PI, must follow the NIH regulations on financial Conflicts of Interest, as outlined in DMC Conflict of Interest Policy. Investigators who are not employees of DMC must comply with their institution’s COI policy. For additional information, please see the IRB guidance: Training and COI Disclosures.
- The DMC follows law passed by the official governing body of an American Indian or Alaska Native tribe and any foreign law or regulation when applicable to the research that provide additional protections for research participants.
- Additional regulations, which may be applicable to certain research, as determined by the IRB.

ETHICAL PRINCIPLES IN HUMAN RESEARCH

As a standard practice, the DMC IRB applies the ethical principles set forth in the Belmont Report to all research, as created by the National Commission for the Protection of Research Participants of Biomedical and Behavioral research. The three quintessential requirements for the ethical conduct of Human research are:

- **Respect for persons:** Recognition of the personal dignity and autonomy of individuals, and special protection of those persons with diminished autonomy.
- **Beneficence:** Obligation to do no harm and to protect persons from harm by maximizing the anticipated benefits and minimizing possible risks.
- **Justice:** Distribute the benefits and burdens of research fairly.
The principles of the Belmont Report are the foundation for the development of the US Federal regulations. When applicable, the principles of the Nuremburg Code and the Declaration of Helsinki may also apply to the research, particularly for transnational research.

All DMC staff must follow the DMC Code of Ethics. In addition, research professionals follow the ethical principles of their scientific and professional disciplines.

**SCOPE**

This policy applies to all DMC’s workforce and to investigators and key personnel approved to do research by the DMC IRB.

*Note: NYC H + H, Kings County and BRANY have established IRB Reliance Agreements with the DMC IRB.*

This policy applies to all research conducted by the DMC workforce (regardless of whether or not compensation is received) while on DMC time, utilizing DMC resources (e.g., equipment), or DMC property (including space leased or used by the DMC).

This policy applies to the following:

- All activities which make DMC engaged in human research.
- All FDA regulated investigational studies (clinical trials) involving research participants (or any human specimens, including de-identified specimens) and FDA regulated articles (e.g., drugs including biologics, food or color additives, and medical devices),
- All activities for which an IRB determination is made by the DMC IRB,
- Any activity overseen by the DMC IRB, including research non-compliance, research audits, and IRB review of investigational agents (including HUDs) for treatment purposes, and,
- Preparatory to research activities.

External employees should consult with their institution’s policies; however, when the DMC IRB oversees human research carried out by employees from an external site (i.e., is not a legal entity of DMC) the external site must do one of the following:

1. If the study is FDA regulated or federally supported/conducted, either of the following must occur:
   - The external employees can seek IRB approval from their institution, or
   - The external institution must establish an IRB Authorization (Reliance) Agreement with the DMC IRB. The external IRB may designate the DMC IRB on their FWA or any IRB that they rely on the most.
2. If the study is NOT FDA regulated nor federally supported/conducted any of the following options apply:
   - The external employees may seek IRB approval from their institution.
The external institution may rely on the DMC IRB; however, the external site (or a Sponsor or Contract Research Organization) may require the establishment of an IRB Reliance (Authorization) Agreement with the DMC IRB. The DMC IRB will process reliance agreements whenever required.

DEFINITIONS

This policy describes relevant definitions within specific sections as applicable to this policy. The IRB follows any additional definitions described pertinent or applicable regulations.

DETERMINING WHETHER IRB APPROVAL IS REQUIRED

In addition to meeting other applicable requirements, a PI must obtain IRB approval before beginning any activity that requires IRB review.

ACTIVITIES REQUIRING IRB REVIEW AND APPROVAL

The IRB must review and approve investigational studies involving research participants (including specimens) and FDA regulated articles (e.g., drugs including biologics, food or color additives, and medical devices. This includes the use of specimens to validate a medical device, diagnostic instrument, or laboratory test.

FDA provides the following definitions:

**Clinical investigation** means any experiment in which a drug is administered or dispensed to, or used involving, one or more research participants. An experiment is any use of a drug except for the use of a marketed drug in the course of medical practice.

**Clinical investigation** means any experiment that involves a test article and one or more research participants and that either is subject to requirements for prior submission to the FDA, or is not subject to requirements for prior submission to the FDA, but the results of which are intended to be submitted later to, or held for inspection by, the FDA as part of an application for a research or marketing permit. The term does not include experiments that are subject to FDA provisions regarding nonclinical laboratory studies (e.g., in vivo or in vitro experiments).

**Investigation** means a clinical investigation or research involving one or more research participants (or any human specimens, including de-identified specimens) to determine the safety or effectiveness of a device (e.g., to validate a medical device, diagnostic test, or laboratory test).
In order for a non-FDA regulated activity to be considered research under the Common Rule, it must be both 1) a systematic investigation (including research development, testing, and evaluation) and 2) be designed to develop or contribute to generalizable knowledge. Some demonstration and service programs may include research activities. In order for research to be considered human research (and thus requiring IRB approval before the study begins), the research must involve living individuals about whom an investigator (whether professional or student) conducting research either 1) obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens; or 2) obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens.

The following federal definitions in the Common Rule (45 CFR 46) provide clarity when making the determination as to whether IRB approval is required:

**Intervention** includes both physical procedures by which information or biospecimens are gathered (e.g., venipuncture) and manipulations of the research participant or the research participant’s environment that are performed for research purposes.

Examples of interventions include:
- Physical procedures through which data are gathered
  - Collecting blood
  - Obtaining vital signs
- Behavioral interventions
  - Evaluating an unknown psychotherapy procedure
- Manipulation of research participants’ environment
  - Playing music in operating room to determine influence on patient outcomes

**CAUTION:** In general, the scientific definition of an intervention is the act of purposefully intervening, interfering or interceding with the intent of modifying some outcome. The above regulatory definition, which applies to determining when IRB approval is required, is much broader than the scientific definition of an intervention.

**Interaction** includes communication or interpersonal contact between investigator and research participant.

Examples of interactions include:
- Communication
  - Face-to-face
  - Electronic (including online surveys without identifiers)
- Interpersonal contact
- Observations
- Interviews

**Private information** includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information that has been provided for specific purposes by an individual and that the individual can reasonably expect will not be made public (e.g., a medical record).
**Identifiable private information** is private information for which the identity of the research participant is or may readily be ascertained by the investigator or associated with the information.

**TIP:**

*Private information must be individually identifiable* in order for obtaining the information to constitute human research. For example, if an investigator is collecting information associated with a medical record number, the investigator is collecting individually identifiable private information.

An *identifiable biospecimen* is a biospecimen for which the identity of the research participant is or may readily be ascertained by the investigator or associated with the biospecimen.

**Note:** On a periodic basis, federal departments or agencies implementing the Common Rule will reexamine the meaning of identifiable private information and identifiable biospecimen and review analytic technologies or techniques that may generate identifiable private information. The DMC IRB plans to adopt any new regulatory provisions for these definitions, once available in the Federal Register.

**SYSTEMATIC INVESTIGATION**

For the purpose of this policy, a *systematic investigation* is generally an activity that is planned, orderly, methodical, and uses data collection and analysis to answer a question, even if the activity is limited to the following:

- development, testing, evaluation of future research (including a pilot study)
- internal training or educational activity
- oral history, ethnography, or journalism,
- performance or quality improvement or similar healthcare operations activity

Although research must include systematic investigation, non-research operations activities also include systematic investigation to ensure reliable outcomes. A systemactic investigation does not, in and of itself, define research.

**GENERALIZABLE KNOWLEDGE**

For the purposes of this policy, activities designed to develop or contribute to *generalizable knowledge* are those designed to draw general conclusions or inform policy (i.e., knowledge gained from a study may be applied to populations outside of the specific study population). Conclusions must actually be disseminated for research purposes (or be part of a program of investigation that will be disseminated) to be generalizable. A useful definition of dissemination is that the material includes sharing beyond the local setting.
• Obvious examples of dissemination are publication in a scholarly journal, presentation at a professional conference, or placement of a report in a library.

• Examples that are not dissemination include oral presentation to a DMC Department in fulfillment of a DMC requirement, sharing of results with an agency that cooperated in information collection, or internal presentation for utilization and review purposes.

Examples of generalizable knowledge:

• Applying the findings from the activity involving a patient population at DMC to a population outside of DMC.

• Applying the findings from a population within a DMC healthcare network to a population outside of the DMC network.

• Applying the findings of a DMC student research project to other students in another school.

• When the outcomes are generalizable to other organizations, programs or services.

• If the activity is limited to oral history, ethnographic, or journalism, it is generalizable when the project involves stories that will or may draw broad conclusions about the population, cultures, norms and practices, even if no research hypothesis is being tested or validated.

IRB applications are not required for quality improvement activities conducted by one or more institutions whose purposes are limited to: (a) implementing a practice to improve the quality of patient care, and (b) collecting patient or provider data regarding the implementation of the practice for clinical, practical, or administrative purposes. For more information on quality improvement activities, see HHS/OHRP FAQs on Quality Improvement Activities.

Intent to publish is an insufficient criterion for determining whether a quality improvement activity involves research. Planning to publish an account of a quality improvement project does not necessarily mean that the project fits the definition of research; people seek to publish descriptions of non-research activities for a variety of reasons, if they believe, others may be interested in learning about those activities. Conversely, a quality improvement project may involve research even if there is no intent to publish the results.

The following are examples of activities that are NOT generalizable:

• When the activity is limited to oral history, ethnographic, or journalism, when published materials will be limited to documenting or reporting on events, situations, policies, institutions or systems without the intent to form hypotheses, draw conclusions, or generalize findings.

• When the outcomes of the activity will remain specific to the SUNY Downstate programs or services, although other organizations may use the results for their own programs.

• When the activity is limited to an internal training or educational activity that is not designed to develop or contribute to generalizable knowledge (e.g., project with sole intent to meet course requirements, classroom activity that develops a survey tool without the intent to use the tool for research purposes).

HEALTH CARE OPERATIONS
Health care operations means any of the following activities to the extent the activities relate to the functions of the institution:

- Quality assessment and improvement activities, including outcomes evaluation and development of clinical guidelines providing that the obtaining of generalizable knowledge is not the primary purpose of such activity,
- Patient safety activities,
- Population based activities related to improving health or reducing health care costs
- Clinical protocol development,
- Case management,
- Care coordination,
- Contacting of health care providers and patients with information about treatment alternatives,
- Related functions that do not include treatment,
- Reviewing the competence or qualifications of health care professionals,
- Conducting training programs in which students, trainees, or practitioners in the areas of health care learn under supervision to practice or improve their skills as health care providers,
- Training of non-health care professionals,
- Accreditation, certification, licensing, or credentialing activities,
- Conducting or arranging for medical review, legal services, and auditing functions,
- Business planning and development,
- Business management and general administrative activities,
- Compliance activities,
- Customer service activities, including data analysis, provided PHI is not disclosed to a policy holder, plan sponsor, or customer,
- Resolution of internal grievances,
- Sale, transfer, merger, or consolidation of the parts of the institution, including due diligence related to such,
- Creating de-identified health information or a limited data set, or
- Fundraising for the benefit of the institution.

PROTECTED HEALTH INFORMATION

For the purpose of this policy, Protected Health Information (PHI) includes individually identifiable health information transmitted or maintained in any form or medium pertaining to the past, present or future physical or mental health or condition of an individual.

Note: PHI does not apply to an individual who has been deceased for more than 50 years.

ALCOHOL OR SUBSTANCE ABUSE INFORMATION

For the purpose of this policy, alcohol or substance abuse information includes information regarding an individual’s diagnosis, treatment, or referral of treatment for alcohol abuse, substance abuse, or chemical dependency.
GENETIC INFORMATION

For the purpose of this policy, genetic information includes the following:

- An individual's genetic test;
- Genetic test of family members (including an embryo or fetus);
- The manifestation of a disease or disorder of an individual or a family member;
- Any request for, or receipt of, genetic services, or genetic test; or
- Participation in clinical research including genetic services, by the individual or any family member of the individual.

IDENTIFIABLE INFORMATION

For the purpose of this policy, data (including data about specimens) is identifiable information under any of the following circumstances:

- Investigators can readily ascertain the identity of the research participant.
- There is actual knowledge that it would be possible to identify the research participant.
- The identity of the research participants can be associated with the information.
- Any data containing any HIPAA identifiers listed in HIPAA-6 policy is identifiable, unless it is for PHI of an individual who has been deceased for more than 50 years.

DE-IDENTIFIED DATA AND DE-IDENTIFIED SPECIMENS

For the purpose of this policy, de-identified describes data sets (including data about specimens) that meet the following criteria:

- All HIPAA identifiers listed in HIPAA-6 policy are removed from the data set OR a qualified statistician has 1) determined that the risk is very small that research participants can be identified and 2) documented the methods and results of the analysis, AND
- The identity of the research participants cannot be readily ascertained by the investigator or be associated with the information, AND
- There is no actual knowledge that it would be possible to identify the participant.

Note: For FDA regulated studies (e.g., in-vitro device studies using de-identified specimens), the FDA may exercise enforcement discretion to not require informed consent as described in the FDA Guidance for "In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable". Therefore, the DMC IRB generally does not require informed consent for the use of discarded de-identified remnants of specimens collected for routine clinical care or analysis for in vitro diagnostic device studies.

CODED MATERIALS

For the purposes of this policy, coded refers to:

1) identifying information (such as name or social security number) that would enable the investigator to readily ascertain the identity of the individual to whom the private
information or specimens pertain has been replaced with a number, letter, symbol, or combination thereof (i.e., the code); and
2) a key to decipher the code exists, enabling linkage of the identifying information to the private information or specimens.

Coded data or specimens are identifiable unless the research follows the rules below to convert it to a de-identified format.

RULES TO CONVERT “CODED” PRIVATE INFORMATION OR SPECIMENS TO “DE-IDENTIFIED”:

The following rules apply for changing the status of private information or specimens from “coded” to “de-identified”; however, the IRB strongly recommends requesting an IRB determination to document whether such activities require IRB approval:

• Do NOT collect data or specimens specifically for the currently proposed research project through an interaction or intervention with the individual(s) about whom the data pertains.
• Establish an agreement, statement for the record, or a written document that prohibits the release of the key to code to the investigators under any circumstances.
• The re-identification code:
  o may not be derived from or related to information about the individual or otherwise be capable of being translated to identify the individual (e.g., patient initials, DOB, SSN, partial SSN, scrambled SSN, Medical Record #, etc.),
  o cannot be used or disclosed for any other purpose, and
  o the mechanism for re-identification cannot be disclosed.
• The individual creating the coded or de-identified data or specimens must be a member of the workforce with a right to access the identifiable materials for a non-research purpose (e.g., clinical purpose, health care operations activity) and CANNOT be an investigator for the project.

Important notes, regarding investigators:

✓ The IRB considers the term investigator to include anyone involved in conducting the research.
✓ The IRB does not consider the act of solely providing coded private information or specimens (for example, by a tissue repository) to constitute involvement in the conduct of the research. However, if an individual who provides coded information or specimens collaborates on other activities related to the conduct of this research with the investigators who receive such information or specimens, then the IRB would consider such additional activities to constitute involvement in the conduct of the research. Examples of such additional activities include, but are not limited to: (1) the study, interpretation, or analysis of the data resulting from the coded information or specimens; and (2) authorship of presentations or manuscripts related to the research.
• The individual providing the data set removes all HIPAA identifiers listed in HIPAA-6 policy:
  o Names;
  o All geographic subdivisions smaller than a State, including street address, city, county, precinct, zip code (except for the initial three digits if according to publicly available data from the Bureau of the Census the geographic unit formed by
combining all zip codes with the same three initials digits contains more than 20,000 people);

- All elements of dates (except year) for dates directly related to the patient, including date of birth, admission and discharge dates, date of death and all elements of dates indicative of ages over 89, except that such ages and elements may be aggregated into a single category of age 90 or older;
  - Telephone numbers;
  - Fax numbers;
  - E-mail addresses;
  - Social security numbers;
  - Medical record numbers;
  - Health plan beneficiary numbers;
  - Account numbers;
  - Certificate/license numbers;
  - Vehicle identifiers and serial numbers (including license plates);
  - Device identifiers and serial numbers;
  - Web Universal Resource Locators (URL’s);
  - Internet Protocol (IP) address numbers;
  - Biometric identifiers, including finger and voice prints;
  - Full face photographic images and any comparable images; and
  - Any other unique identifying number, characteristic or code.

LIMITED DATA SET

A limited data set allows retention of specific elements of identifying private information.

A limited data set is PHI that excludes the following direct identifiers of the individual, or of relatives, employees, or household members of the individuals:

1) Names;
2) Postal address information, other than town or city, State, and zip code;
3) Telephone numbers;
4) Fax numbers
5) Electronic mail addresses
6) Social security numbers
7) Medical record numbers;
8) Health plan beneficiary numbers
9) Account numbers
10) Certificate/license numbers
11) Vehicle identifiers and serial numbers, including license plate numbers;
12) Device identifiers and serial numbers;
13) Web Universal Resource Locators (URLs);
14) Internet Protocol (IP) address numbers;
15) Biometric identifiers, including finger and voice prints; and
16) Full face photographic images and any comparable images.

Note: The IRB considers a Limited data set as identifiable data under the HIPAA regulations. However, the IRB considers it a de-identified data set under the Common Rule if an Investigator cannot readily identify the individuals about whom the data pertains and does not have access to the key to any codes to identify the individuals.
Investigators at DMC may use or disclose a limited data set when it enters into a Data Use Agreement (DUA).

SUMMARY OF ACTIVITIES REQUIRING IRB APPROVAL

IRB approval is required for all FDA regulated investigations.

The DMC IRB uses the definitions in the Common Rule and the HIPAA regulations to determine if any non-FDA regulated activity requires IRB approval. The IRB retains final judgment as to whether a particular activity must obtain IRB approval under this policy consistent with the ethical principles of the Belmont Report.

Even when research is exempt from the federal regulations or when the activity does not meet the definition of human research, the HIPAA regulations still apply, if PHI is involved in a research activity. If PHI is involved, a HIPAA Waiver, HIPAA Authorization, BAA, DUA, Certification for PHI of Decedents, Subject Recruitment Authorizations or other HIPAA instrument is usually required.

The activities that require prospective IRB review and approval are:

- Human research (including pilot studies, exempt research, clinical trials, or other clinical investigations, planned emergency research);
- The use of human specimens to evaluate the safety and effectiveness of an investigational agent;
- Use of an Humanitarian Use Device (HUD) for a clinical or research purpose (except IRB approval is not needed for certain exceptions for emergency use, but notification to the IRB is required within 5 days of use);
- Expanded access (compassionate use, preapproval access) to an investigational drug/biologic for treatment (except IRB approval is not needed for certain exceptions for emergency use, but notification to the IRB is required within 5 days of use);
- Research activities that involve an interaction or intervention with a living individual;
- Research activities that involve obtaining, accessing, using, reviewing, sharing, analyzing, or disclosing PHI, individually identifiable private data, identifiable sensitive information, or personal data, regardless of whether it is recorded or eventually de-identified;
- Research activities involving the use, analysis or generation of identifiable biospecimens;
- Research requiring IRB approval as required by NYS Article 24A, the Common Rule, FDA regulations, or tribal law passed by an official governing body of the American Indian or Alaskan Native tribe; and,
- Any activity which meets the definition of research under the Common Rule, regardless of whether it is supported or conducted by a federal department or agency or regulated by the FDA or NY State.

Activities that require IRB review and approval beyond the initial review include:

- Amendments (any and all changes) to previously approved non-exempt research;
- Amendments (some changes) to previously approved exempt research, when required by this policy;
- Continuing review/progress reports, when required;
- Check-In reports, when required by the IRB;
- Reportable events;
• Closure (final) reports; or
• Other considerations, as described in this policy or regulations.

ACTIVITIES THAT DO NOT REQUIRE IRB REVIEW AND APPROVAL

For the purposes of this policy, the following DMC activities DO NOT require IRB review and approval:

PREPARATORY TO RESEARCH ACTIVITIES

If an activity is limited to a "preparatory to research activity" (e.g., review of protected health information in preparation for research to determine if there are enough patients to recruit or records to review), IRB approval is not required. HOWEVER, if someone other than the patients' clinicians are accessing the patient records, the investigator must complete the Researcher Certification for Reviews Preparatory to Research form and save it in the research record.

Example: An investigator needs to determine whether she will have enough patients to enroll into a new clinical trial with an inclusion criteria of sickle cell trait. She reviews the medical records to determine the number of active sickle cell trait patients at the University Hospital Brooklyn; however, she cannot contact the patients or record any patient identifiers. If she is not the clinician for the patients for whom the data pertains, she completes the Researcher Certification for Reviews Preparatory to Research form and saves it in her research records. Upon subsequently submitting an IRB application, she includes a copy of the completed form with the submission.

Under the Common Rule and this policy, a "preparatory to research activity" is automatically "exempt" because identifiers are not recorded and therefore does not require IRB approval.

TIP: When carrying out a "preparatory to research activity" HIPAA identifiers CANNOT be recorded! For more information on how to keep the data de-identified, refer to the list of identifiers in the De-Identification of Information (HIPAA-6 policy).

CASE REPORTS OR CASE SERIES INVOLVING UP TO THREE INDIVIDUALS

IRB approval is not required for an activity that is limited to patient case reports or case series involving up to three (3) individuals (including relatives). The presentation or publication cannot have any identifiable information.

ACTIVITIES THAT DO NOT MAKE DMC ENGAGED IN HUMAN RESEARCH

DMC IRB approval is not required when the workforce conducts activities which DO NOT make DMC engaged in human research (see OHRP guidance: Engagement of Institutions in Human Subjects Research (2008)). However, the IRB recommends the project lead obtain a copy of the
external IRB approval for the activity if it includes human research and approval from the Department Chair or Dean when an activity involves interactions or interventions by the outside investigators.

SCHOLARLY AND JOURNALISTIC ACTIVITIES

Scholarly and journalistic activities (e.g., oral history, journalism, biography, literary criticism, legal research, and historical scholarship), including the collection and use of information, that focus directly on the specific individuals about whom the information is collected, do not need IRB approval.

PUBLIC HEALTH SURVEILLANCE ACTIVITIES

Public health surveillance activities may include the collection and testing of information or biospecimens, conducted, supported, requested, ordered, required, or authorized by a public health authority. When such activities are limited to those necessary to allow a public health authority to identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health importance (including trends, signals, risk factors, patterns in diseases, or increases in injuries from using consumer products), the activities do not require IRB approval. Such activities, including those associated with providing timely situational awareness and priority setting during the course of an event or crisis that threatens public health (including natural or man-made disasters), do not need IRB approval.

COLLECTION AND ANALYSIS OF INFORMATION, BIOSPECIMENS, OR RECORDS BY OR FOR A CRIMINAL JUSTICE AGENCY

Collection and analysis of information, biospecimens, or records by or for a criminal justice agency for activities authorized by law or court order solely for criminal justice or criminal investigative purposes, do not need IRB approval.

AUTHORIZED OPERATIONAL ACTIVITIES

Authorized operational activities (as determined by each agency) in support of intelligence, homeland security, defense, or other national security missions, do not need IRB approval.

CLINICAL CARE

Nothing in this policy is intended to limit the authority of a clinician to provide medical care, including to the extent the clinician is permitted to do so under applicable federal, state, local law (including tribal law passed by the official governing body of an American Indian or Alaskan Native tribe) or DMC policy.

OFF-LABEL USE OF AN FDA APPROVED DRUG OR BIOLOGIC

If a clinician wishes to use an FDA approved drug/biologic off-label for non-research purposes, the decision to do so is a clinical decision that does not require IRB approval; however, the
clinician must comply with any necessary hospital policies including, when applicable, obtaining approval from the Pharmacy.

Off-label use for non-research purposes does not constitute research; therefore, the patient who receives the off-label drug or device cannot be a research participant. However, interventions or use of data from an off-label use for research must have IRB approval and may require an IND. For more information, see FDA Information Sheet: “Off-Label” and Investigational Use of Marked Drugs, Biologics, and Medical Devices.

<table>
<thead>
<tr>
<th>CHANGES NECESSARY TO ELIMINATE APPARENT IMMEDIATE HAZARDS OR TO PROTECT THE LIFE OR PHYSICAL WELL-BEING OF THE RESEARCH PARTICIPANT ENROLLED IN PREVIOUSLY APPROVED RESEARCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changes in a previously IRB approved research activity may be initiated without IRB review and approval of an amendment when the change is necessary to eliminate apparent immediate hazards or to protect the life or physical well-being of the research participant. However, the Principal Investigator must report any non-IRB approved changes to eliminate a hazard or protect the life or physical well-being of a research participant to the IRB, as outlined in the section on Reportable Events.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EMERGENCY USE OF AN INVESTIGATIONAL OR UNLICENSED DRUG, BIOLOGIC, OR DEVICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency use is the use of a test article (investigational or unlicensed drug, biologic, or device) for a patient in a life-threatening situation in which no standard acceptable treatment is available and in which there is not sufficient time to obtain IRB approval.</td>
</tr>
</tbody>
</table>

**Life-threatening**, as defined by FDA, includes the scope of both life-threatening and severely debilitating, as defined below.

- **Life-threatening** means diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and diseases or conditions with potentially fatal outcomes, where the end point of clinical trial analysis is survival. The criteria for life-threatening do not require the condition to be immediately life-threatening or to immediately result in death. Rather, the subjects must be in a life-threatening situation requiring intervention before review at a convened meeting of the IRB is feasible.

- **Severely debilitating** means diseases or conditions that cause major irreversible morbidity. Examples of severely debilitating conditions include blindness, loss of arm, leg, hand or foot, loss of hearing, paralysis or stroke.

<table>
<thead>
<tr>
<th>TIP: The IRB can only authorize a single emergency use of an investigational agent per institution.</th>
</tr>
</thead>
<tbody>
<tr>
<td>The clinician should contact the IRB to determine if the IRB has previously approved the one-time use mechanism.</td>
</tr>
</tbody>
</table>
In general, the IRB will acknowledge the use of a test article more than once if it is in the best interest of a patient. However, subsequent use without IRB approval may represent serious or continued non-compliance. If considered by the IRB to be serious or continuing non-compliance, the IRB must report the serious or continued non-compliance to the FDA.

FDA acknowledges, however, that it would be inappropriate to deny emergency treatment to a second individual if the only obstacle is that the IRB has not had sufficient time to convene a meeting to review the issue.

If a clinician wishes to prescribe a test article, the clinician must do the following:

- Obtain permission from the Medical Director (or designate) and Department Chair (or designate) before undertaking the emergency use. The IRB recommends the Clinician obtain written documentation or an e-mail of the approval.
- Notify the IRB Chair of any intent for emergency use.
- Comply with all pertinent FDA regulations.
- Contact the manufacturer to make arrangements for delivery of the test article and make sure they are willing to release the test article in accordance with FDA regulations. The supplier of the unapproved test article may require assurance from the DMC that the Clinician is following the rules and regulations that apply to emergency use before agreeing to provide the unapproved article.
- If required by the manufacturer, the IRB can release a letter stating there is not sufficient time to obtain IRB approval.
- Contact the FDA to obtain an emergency IND or an emergency IDE, when required, if the manufacturer does not provide one.
- When feasible, prospectively obtain informed consent (and assent, when applicable) for the emergency use of an investigational agent. Obtaining informed consent shall be deemed feasible unless, before use of the test article, both the treating physician and another physician who is not otherwise involved in the use of the investigational product certify in writing all of the following, in the patient’s medical record:
  - The patient is confronted by a life-threatening situation necessitating the use of the test article;
  - Informed consent cannot be obtained from the patient because of an inability to communicate with, or obtain legally effective consent from, the patient;
  - Time is not sufficient to obtain consent from the patient’s Legally Authorized Representative (LAR/surrogate); and
  - There is no available alternative method of approved (or generally recognized therapy) that provides an equal or greater likelihood of saving the life of the patient.
- **Notify the IRB within 5 days after the administration of the test article** via e-mail to the IRB Chair and IRB or within the electronic IRB submission and reporting system using the Application for Reportable Event. Such written notification shall include the identification of the patient involved, the administration date, and the reason for the use. The IRB will acknowledge the emergency use.
- Comply with any FDA post approval and reporting requirements.
  - For requirements for drugs and biologics see 21 CFR Part 312
  - For medical device requirements see 21 CFR Part 812
  - For HUD/HDE requirements see 21 CFR Part 814
• Submit an IRB application to the IRB when anticipating the future need for use of the test article under similar circumstances.

OTHER ACTIVITIES THAT DO NOT REQUIRE DMC IRB APPROVAL

In general, the following activities do not require DMC IRB approval:

• A Healthcare Operations Activity (HOA) (e.g., Performance Improvement, Resident Training) NOT designed to develop NOR contribute to generalizable knowledge. For more information, refer the definition of “generalizable” and the examples provided with the definition.

• Activities that do not involve systematic investigations.

• Activities limited to using data from deceased individuals, provided the data does not contain any PHI or involve accessing or using PHI.

• Activities limited to using data from individuals who have been deceased for more than 50 years.

• Activities that includes using or accessing PHI from individuals who have been deceased for less than 50 years, when a Researcher Certification for PHI of Decedents Form is submitted and approved by the Privacy Officer (or DMC IRB).

• Activities limited to de-identified specimens obtained from a producer or supplier (e.g., commercial cell line).

• Activities are limited to a pilot activity, feasibility activity, or evidence based practice activity not involving human research as defined by this policy.

• Activities that DO NOT involve interactions or interventions, but include the following types of data sets, including when such data is about any specimens:
  o Limited data set when a Data Use Agreement (DUA) is in place, assuming the investigator cannot readily identify the individuals about whom the data pertains and does not have access to the key to any codes to identify the individuals (as noted below),
  o De-identified data, or
  o Coded private information when the code cannot be released to the investigators, for example through one of the following:
    ▪ An agreement is in place to prohibit the release of the code to the investigators
    ▪ A written document or policy is in place to prohibit the release of the code to the investigators, or
    ▪ An Independent Honest Brokers Assurance Agreement is in place to prohibit the release of the code to the investigators.

IRB APPLICATION SUBMISSION PROCESS

IRB AND PRIVACY BOARD MEETING SCHEDULE

The IRB posts the meeting schedule and deadlines for submitting a full board IRB application on the DMC IRB website.
Note: Exempt and expedited studies are not reviewed by the full board unless an IRB Member refers the review to the full board process, or as otherwise required by this policy.

IRB CONSULTATIONS

An investigator may consult with the IRB to answer specific questions about the IRB policies and procedures at any time. The IRB encourages individual appointments with the IRB administrative staff for first-time submissions.

ELECTRONIC SUBMISSIONS AND MANAGEMENT OF DMC IRB ACTIVITIES

DMC uses an electronic IRB submission and reporting system for the electronic submissions and management of its IRB activities. Please refer to IRB guidance: IRB Application and Reporting System for more details on how to use the system.

CONSIDERATIONS FOR RESEARCH SUBMISSIONS AND IRB REVIEW

Investigators and IRB members should consider the following when designing or reviewing a research project.

CATEGORIES OF DMC IRB SUBMISSIONS

There are eight types of IRB submissions at DMC:
1. Determination that IRB review is not required (IRB Decision Aid)
2. Exempt IRB review (including limited IRB review)
3. Expedited IRB review
4. Full (convened board) IRB review
5. Humanitarian Use Device (HUD) for clinical purposes
6. Expanded Access (also known as Compassionate Use or Preapproval Access) to investigational drugs (including biologics) for treatment use
7. Request to use an external IRB
8. Cooperative research review (“Single IRB” review of federally supported or conducted study)

Refer to the following information for a description of each type of IRB application.

DETERMINATION THAT IRB REVIEW IS NOT REQUIRED

When applicable, an individual may request an IRB determination letter to document activities that do not need IRB approval. Please refer to the information outlined above or the “IRB Decision Aid – Application for a Determination Letter to State IRB Approval is Not Required” for guidance.

EXEMPT IRB REVIEW
The IRB makes an *exempt* determination when human research meets the conditions for exempt human research of one or more of the categories outlined below. When the exempt research involves PHI, the standard HIPAA requirements (HIPAA research authorization, HIPAA waiver, DUA, or BAA) apply to the research.

**FDA EXEMPTIONS**

When eligible, the following exemptions apply to FDA regulated studies (Clinical trials or device studies as defined by FDA, taste and food quality evaluation, etc.):

- **FDA Exemption A [21 CFR 56.104 (a)]:** Any investigation which commenced before July 27, 1981 and was subject to requirements for IRB review under FDA regulations before that date, provided that the investigation remains subject to review of an IRB which meets the FDA requirements in effect before July 27, 1981.

- **FDA Exemption B [21 CFR 56.104 (b)]:** Any investigation commenced before July 27, 1981 and was not otherwise subject to requirements for IRB review under Food and Drug Administration regulations before that date.

- **FDA Exemption C [21 CFR 56.104 (c)]:** Emergency use of a test article, provided that such emergency use is reported to the IRB within 5 working days. Any subsequent use of the test article at the institution is subject to IRB review. *Note: For more information, see the section on Emergency Use.*

- **FDA Exemption D [21 CFR 56.104 (d)]:** Taste and food quality evaluations and consumer acceptance studies, if wholesome foods without additives are consumed or if a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural, chemical, or environmental contaminant at or below the level found to be safe, by the Food and Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture.

**COMMON RULE EXEMPTIONS (INCLUDING LIMITED IRB REVIEW)**

When eligible, the Common Rule Exemptions (categories 1-6) can apply to the research, except for FDA regulated research.

*Note: Of these exemptions, only exemption category #1 applies to DOJ regulated research, as it is more restrictive than the DOJ exemptions, but does not apply to DOJ research involving prisoners.*

For OHRP guidance on how to interpret the exemptions, see [OHRP Revised Common Rule Q&As](#) regarding the exemptions.

These Common Rule exemptions can apply to research involving pregnant women, fetuses, neonates. These exemptions apply to research involving children except as otherwise noted below. These exemptions do not apply to prisoners except for research aimed at involving a broader research participant population that only incidentally includes prisoners.
For the purposes of this policy, **Prisoner** means any individual involuntarily confined or detained in a penal institution. The intent of the term is to encompass individuals sentenced to such an institution under a criminal or civil statute, individuals detained in other facilities by virtue of statutes or commitment procedures that provide alternatives to criminal prosecution or incarceration in a penal institution, and individuals detained pending arraignment, trial, or sentencing.

For the purposes of this policy and the applicability of the regulations pertaining to prisoner research, a prisoner is anyone that is involuntarily confined or detained in a penal institution, such as a prison, jail, or juvenile offender facility, and their ability to leave the institution is restricted. In general, the IRB does not consider individuals sentenced to community-supervised monitoring, or individuals wearing monitoring devices to be prisoners, but the specific situation may require further analysis. For more information, see the OHRP FAQs on Prisoner research.

- **Common Rule Exemption Category 1 [45 CFR 46.104 (d)(1)]:**
  Research, conducted in established or commonly accepted educational settings, that specifically involves normal educational practices that are not likely to adversely impact students’ opportunity to learn required educational content or the assessment of educators who provide instruction. This includes most research on regular and special education instructional strategies, and research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods.

- **Common Rule Exemption Category 2 [45 CFR 46.104 (d) (i), (ii), or (iii)]:**
  Research that only includes interactions involving educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior (including visual or auditory recording) if it meets at least one of the following criteria:
  - **[45 CFR 46.104 (d)(2)(i)]:** The information obtained is recorded by the investigator in such a manner that the identity of the research participants cannot readily be ascertained, directly or through identifiers linked to the research participants;
    - This exemption can only apply to research involving children that involves educational tests or the observation of public behavior when the investigator(s) do not participate in the observation of the activities.
  - **[45 CFR 46.104 (d)(2)(ii)]:** Any disclosure of the research participants’ responses outside the research would not reasonably place the research participants at risk of criminal or civil liability or be damaging to the research participants’ financial standing, employability, educational advancement, or reputation;
    - This exemption can only apply to research involving children that involves educational tests or the observation of public behavior when the investigator(s) do not participate in the observation of the activities.
  - **[45 CFR 46.104 (d)(2) (iii)]:** The information obtained is recorded by the investigator in such a manner that the identity of the research participants can
readily be ascertained, directly or through identifiers linked to the research participants.
- This exemption **DOES NOT** apply to research involving children.
- Limited IRB review must take to ensure there are adequate provisions to protect the privacy of research participants and to maintain the confidentiality of the data.

- **Common Rule Exemption Category 3 [45 CFR 46.104 (d)(3) (i) (A or B or C) or (ii) or (iii)]:**

This exemption **DOES NOT** apply to research involving children.

i. **[45 CFR 46.104 (d)(3) (i) (A) (B) or (C)]:** Research involving benign behavioral interventions in conjunction with the collection of information from an adult research participant through verbal or written responses (including data entry) or audiovisual recording if the research participant prospectively agrees to the intervention and information collection and at least one of the following criteria is met:

   A. **[45 CFR 46.104 (d)(3) (i) (A)]:** The information obtained is recorded in such a manner that human research participants cannot be identified, directly or through identifiers linked to the participants; or

   B. **[45 CFR 46.104 (d)(3) (i) (B)]:** Any disclosure of the human research participants' responses outside the research could not reasonably place the participants at risk of criminal or civil liability or be damaging to the participants' financial standing, employability, educational advancement or reputation; or

   C. **[45 CFR 46.104 (d)(3) (i) (C)]:** Information obtained is recorded in such a manner that human research participants can be identified, directly or through identifiers linked to the participants.

   Limited IRB review must take place for exempt research approved under [45 CFR 46.104 (d) (3) (i) (C)] to ensure, when appropriate, there are adequate provisions to protect the privacy of research participants and to maintain the confidentiality of the data.

ii. **[45 CFR 46.104 (d)(3) (ii)]:**

For the purpose of this provision, benign behavioral interventions are brief in duration, harmless, painless, not physically invasive, not likely to have a significant adverse lasting impact on the research participants, and the investigator has no reason to think the research participants will find the interventions offensive or embarrassing. Provided all such criteria are met, examples of such benign behavioral interventions would include having the
research participants play an online game, having them solve puzzles under various noise conditions, or having them decide how to allocate a nominal amount of received cash between themselves and someone else.

iii. [45 CFR 46.104 (d)(3) (iii)]:
If the research involves deceiving the research participants regarding the nature or purposes of the research, this exemption is not applicable unless the research participant authorizes the deception through a prospective agreement to participate in research in circumstances in which the research participant is informed that he or she will be unaware of or misled regarding the nature or purposes of the research.

• Common Rule Exemption Category 4 [45 CFR 46.104 (d)(4) (i) or (ii) or (iii) or (iv)]:

Secondary research for which consent is not required: Secondary research uses of identifiable private information or identifiable biospecimens, if at least one of the following criteria is met:

i. [45 CFR 46.104 (d)(4) (i)]: The identifiable private information or identifiable biospecimens are publicly available;

ii. [45 CFR 46.104 (d)(4) (ii)]: Information, which may include information about biospecimens, is recorded by the investigator in such a manner that the identity of the research participants cannot readily be ascertained directly or through identifiers linked to the research participants, the investigator does not contact the research participants, and the investigator will not re-identify research participants;

iii. [45 CFR 46.104 (d)(4) (iii)]: The research involves only information collection and analysis involving the investigator's use of identifiable health information when that use is regulated under 45 CFR parts 160 and 164, subparts A and E, for the purposes of "health care operations" or "research" as those terms are defined at 45 CFR 164.501 or for "public health activities and purposes" as described under 45 CFR 164.512(b); or

iv. [45 CFR 46.104 (d)(4) (iv)]: The research is conducted by, or on behalf of, a Federal department or agency using government-generated or government-collected information obtained for non-research activities, if the research generates identifiable private information that is or will be maintained on information technology that is subject to and in compliance with section 208(b) of the E-Government Act of 2002, 44 U.S.C. 3501 note, if all of the identifiable private information collected, used, or generated as part of the activity will be maintained in systems of records subject to the Privacy Act of 1974, 5 U.S.C.
552a, and, if applicable, the information used in the research was collected subject to the Paperwork Reduction Act of 1995, 44 U.S.C. 3501 et seq.

• **Common Rule Exemption Category 5 [45 CFR 46.104 (d)(5)(i) or (ii)]:**
  Research and demonstration projects that are conducted or supported by a Federal department or agency, or otherwise subject to the approval of department or agency heads (or the approval of the heads of bureaus or other subordinate agencies that have been delegated authority to conduct the research and demonstration projects), and that are designed to study, evaluate, improve, or otherwise examine public benefit or service programs, including procedures for obtaining benefits or services under those programs, possible changes in or alternatives to those programs or procedures, or possible changes in methods or levels of payment for benefits or services under those programs. Such projects include, but are not limited to, internal studies by Federal employees, and studies under contracts or consulting arrangements, cooperative agreements, or grants. Exempt projects also include waivers of otherwise mandatory requirements using authorities such as sections 1115 and 1115A of the Social Security Act, as amended.

(i) [45 CFR 46.104 (d) (5) (i)] Each Federal department or agency conducting or supporting the research and demonstration projects must establish, on a publicly accessible Federal Web site or in such other manner as the department or agency head may determine, a list of the research and demonstration projects that the Federal department or agency conducts or supports under this provision. The research or demonstration project must be published on this list prior to commencing the research involving research participants.

(ii) [45 CFR 46.104 (d) (5) (ii)] [Reserved]

• **Common Rule Exemption Category 6 [45 CFR 46.104 (d)(6)(i) or (ii)]:**
  Taste and food quality evaluation and consumer acceptance studies,
  i. [45 CFR 46.104 (d)(6)(i)] if wholesome foods without additives are consumed, or
  ii. [45 CFR 46.104 (d) (6) (ii)] if a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by the Food and Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture.

• **Common Rule Exemption Category 7 [45 CFR 46.104 (d)(7)]:**

The SUNY Downstate IRB will not approve research under category 7 at this time. However, the IRB may consider this exemption in the future, after the IRB establishes policies regarding broad consent.
• **Common Rule Exemption Category 8 [45 CFR 46.104 (d) (8)]:**

The SUNY Downstate IRB will not approve research under category 8 at this time. However, the IRB may consider this exemption in the future, after the IRB establishes policies regarding broad consent.

---

**EXPEDITED IRB REVIEW**

The DMC IRB may use the expedited review procedure to review any of the following:

- Some or all of the research appearing in the expedited review categories below, unless the reviewer determines the study involves more than minimal risk;
- Minor changes in previously approved research during the authorized approval period; or
- Research for which limited IRB review is a condition of exemption (see above).

Do not use expedited review procedures to circumvent the convened meeting requirements. Examples of such misuse may be any of the following actions:

- Interim expedited approval pending review of the proposed study at a later convened meeting.
- Approval granted for the one-patient nonemergency use when the protocol does not meet the requirements of expedited review.
- Expedited approval based on IRB approval of the protocol at another institution for which no cooperative agreement exists
- Expedited review of a claimed emergency use when the circumstances do not meet the requirements for emergency use.

---

**MEETING THE REQUIREMENTS OF FEDERAL EXPEDITED REVIEW CATEGORIES**

A new study may qualify for expedited review if it presents no more than minimal risk to the research participants and it meets the criteria for expedited review as fully described within the [Federal Register: November 9, 1998 (Volume 63, Number 216)](https://frwebgate.access.gpo.gov/cgi-bin/getfr.cgi? unaware=1998-36653). The categories in this list apply regardless of the age of the research participants, except as noted.

The standard requirements for informed consent (or its waiver, alteration, or exceptions) apply to expedited review.

The following types of studies may not undergo expedited review at the time of initial or continuing review:

- Research where the identification of the participants and/or their response would reasonably place them at risk of criminal or civil liability or be damaging to the participants’ financial standing, employability, insurability, reputation, or be stigmatizing, unless reasonable and appropriate protections are implemented so that the risks related to invasion of privacy and breach of confidentiality are no greater than minimal.
- Classified research.
DMC does not permit expedited review under category 1 or category 2 at the time of initial review, when the research includes an intervention with children, pregnant women, neonates, prisoners, or cognitively impaired adults. However, subsequent review or follow-up review to the after the initial review by the full board may be reviewed by expedited review for research involving these populations, unless otherwise determined and documented by the full IRB.

When a study qualifies for expedited review, the IRB may refer the initial review to the convened (full) board (for sensitive issues, study design concerns, etc.) or as required above for category 1 and 2. In these situations, the study may continue to be reviewed by expedited review procedures for any follow-up required by the convened IRB, unless the IRB otherwise determines the response to the initial review must be carried out by the convened board.

When the IRB approves a study via expedited review on or after January 21, 2019 and the IRB determines the approved study meets the all of the provisions of the July 19, 2018 version of the Common Rule, continuing review is not required, unless:

- the study is FDA regulated,
- the study is DOJ regulated, or
- the IRB determines otherwise and documents continuing review is requirement.

The following expedited review categories can apply to the initial and continuing review, unless otherwise noted above:

Note: HHS will review the list of expedited review categories at least every 8 years and amend the list, as appropriate.

- **Federal expedited research review category #1A:** Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required.

- **Federal expedited research review category #1B:** Research on medical devices for which
  - An investigational device exemption application (21 CFR Part 812) is not required; or
  - The medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.

  **NOTE:** For a device study to be eligible for expedited review, it must be an NSR study AND present no more than minimal risk to the research participant.

- **Federal expedited research review category #2A:** Collection of blood samples by finger-stick, heel-stick, ear-stick, or venipuncture from healthy, non-pregnant adults who weigh at least 110 pounds.

  For these research participants, the amounts drawn may not exceed 550 ml in an 8-week period and collection may not occur more frequently than 2 times per week.
• **Federal expedited research review category #2B**: Collection of blood samples by finger-stick, heel-stick, ear-stick, or venipuncture from adults and children, considering the age, weight, and health of the research participants, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected.

  *For these research participants, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8-week period and collection may not occur more frequently than 2 times per week.*

  This category may include non-healthy adults, pregnant adults, and adults who weigh less than 110 lbs., if requested in the IRB application materials.

• **Federal expedited research review category #3**: Prospective collection of biological specimens for research purposes by noninvasive means, not limited to the following examples, which are generally considered noninvasive:
  - Hair and nail clippings in a non-disfiguring manner;
  - Deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction;
  - Permanent teeth if routine patient care indicates a need for extraction;
  - Excreta and external secretions (including sweat);
  - Un-cannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue;
  - Placenta removed at delivery;
  - Amniotic fluid obtained at the time of rupture of the membrane prior to or during labor;
  - Supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques;
  - Mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings;
  - Sputum collected after saline mist nebulization;

• **Federal expedited research review category #4**: Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing.

  Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.

• **Federal expedited research review category #5**: Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for non-research purposes, such as medical treatment or diagnosis.

  *Note: As permitted by OHRP, this category includes research involving materials that were previously collected for either non-research or research purposes, provided that*
any materials collected for research were not collected for the currently proposed research. Research may involve materials that will be collected solely for non-research purposes.

- **Federal expedited research review category #6**: Collection of data from voice, video, digital, or image recordings made for research purposes.

- **Federal expedited research review category #7**: Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies.

When applicable, the following expedited review categories apply for continuing review of previously approved research:

- **Federal expedited research review category #8A**: research that is permanently closed to the enrollment of new research participants; when all of the research participants have completed all research-related interventions; and the research remains active only for long-term follow-up of research participants.

- **Federal expedited research review category #8B**: research where no research participants have been enrolled and no additional risks have been identified.

- **Federal expedited research review category #8C**: research where the remaining research activities are limited to data analysis.

- **Federal expedited research review category #9**: Continuing review of research, that is not conducted under an investigational new drug application (IND) or investigational device exemption (IDE) where categories two (2) through eight (8) do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

**FULL (CONVENED) IRB REVIEW**

The full board reviews a study that does not meet the criteria for exempt (including limited IRB review) or expedited review.

**HUMANITARIAN USE DEVICE (HUD) FOR CLINICAL PURPOSES**

A HUD is a medical device intended to benefit patients in the treatment or diagnosis of a disease or condition that affects or manifests in fewer than 4,000 individuals in the United States per year. An HDE is an application like a premarket approval (PMA) application but is exempt from the reasonable assurance of effectiveness standard. FDA bases the HDE approval, in part, on evidence that the device will not expose patients to an unreasonable or significant risk of illness.
or injury and the probable benefit from use of the device outweighs the risk of injury or illness. The decision considers the probable risk and benefits of currently available devices and alternative forms of treatment. FDA approval of a HDE authorizes an applicant to market a HUD, subject to certain profit and use restrictions. Specifically, HUDs cannot be sold for profit, except in narrow circumstance and they can only be used in a facility after an IRB has approved their use in the facility, except in certain emergencies (see section on Emergency Use).

A physician may request approval to use a Humanitarian Use Device (HUD) for clinical purposes. Complete a HUD IRB Application when submitting a request for the IRB approval to use a HUD for clinical purposes. The initial review must take place by a convened (full) board. In general, the IRB expects the clinician to obtain written informed consent when using a HUD for clinical use; however, the IRB may not require it. The IRB has the authority to set restrictions or limitations of the HUD by the clinician.

When requesting the use of a HUD for clinical use only, the application does not need to go through the Scientific Review Committee (SRC), nor are COI disclosures required, unless a clinician on the IRB application has or declares a conflict of interest. Human research protections training is not required but recommended.

The IRB may review the progress report for the use of a HUD by expedited review at the time of continuing review, unless an IRB Member or an IRB Chair or Vice-Chair determines it must go to the full board.

For additional guidance see the FDA guidance for IRB review of a HUD; however, be aware that this FDA guidance is under review to be in accordance with the 21st Century Cure’s Act.

**NOTE:** There is a distinction between “use” of a HUD and “investigational use/clinical investigation” of a HUD. If a HUD will be used for a clinical investigation (e.g., safety and effectiveness data is collected for a FDA Premarket Approval), a full board IRB application must be completed and reviewed under an IDE if it is SR device study. An informed consent document is always required for a clinical investigation of a HUD.

**REVIEW FOR EXPANDED ACCESS (COMPASSIONATE USE OR PREAPPROVAL ACCESS) TO AN INVESTIGATIONAL DRUG/BIOLOGIC FOR TREATMENT USE**

Full IRB review and approval is required for Expanded Access (Compassionate Use) to investigational drug/biologic for treatment use, except for Emergency Use situations or when Form FDA 3926 is approved by the FDA. Please submit the Application for IRB Approval of Expanded Access Of An Investigational Drug/Biologic For Treatment Use for this specific process.

**TIP:** The FDA has created a new mechanism for IRB Chair approval of individual patient expanded access treatment use of investigational drugs. To request this, the physician (or sponsor) must complete Form FDA 3926. For more information, see FDA Guidance: Expanded Access to Investigational Drugs for Treatment Use – Q&A.
When requesting the IRB approval for expanded access for treatment use, the application does not need to go through the Scientific Review Committee (SRC), nor are COI disclosures required, unless a clinician on the IRB application has or declares a conflict of interest. Human research protections training is not required, but recommended.

**REQUEST TO USE AN EXTERNAL IRB OR SIRB FOR MULTI-SITE RESEARCH PROJECTS**

An external IRB is any IRB other than the DMC IRB that reviews and approves a multi-site research project that includes DMC. This can be a Central IRB, a Commercial IRB, a Main Study Site IRB, or a Single IRB; however, the DMC IRB may be required to establish an IRB Authorization (Reliance) Agreement with the external IRB. The DMC IRB must acknowledge external IRB approval, and confirm the study meets any local research context requirements, before the research may begin at DMC.

Any external IRB that oversees DMC research must enter into an IRB Reliance (Authorization) Agreement with SUNY DMC for all FDA regulated or federally funded research. At the time of this writing, the SUNY DMC has entered into IRB Reliance (Authorization) Agreement with the following IRBs:

- National Cancer Center Central IRB (1, 2, 3, & 4)
- Biomedical Research Alliance of New York (BRANY) IRB

*Note: Contact the IRB for other sites not listed above.*

Unless the DMC IRB refers review to an external IRB, **DO NOT** use an external IRB for any research involving any of the following:

- DMC as a single research site; or
- Research previously disapproved by the DMC IRB.

When using an external IRB, the research team must follow the procedures, policies, directives, and practices of the external IRB, the DMC, the IRB Authorization (Reliance) Agreement, and the sponsor.

The PI and research staff must comply with the determinations and requirements of the both the external IRB and the DMC IRB. DMC is responsible for ensuring compliance with the IRB’s requirements at the DMC.

Each institution involved in the multi-site project is responsible for ensuring compliance at their site. Research staff from external sites must consult their own institutional policies to determine if other requirements apply.

**PROCEDURES FOR REQUESTING AN EXTERNAL IRB REVIEW AND APPROVAL**
**IMPORTANT:** When requesting the review and approval of human research by an external IRB, the PI must complete the required external IRB Application (according to the guidance and directions of the external IRB). In addition, the PI MUST also submit the DMC IRB’s “Application for External IRB Oversight.”

**CAUTION:** The DMC often collaborates with employees from NYC H + H, Kings County. If employees from NYC H + H, Kings County are included as investigators on a **federally funded study**, please use the BRANY IRB or collaborate with NYC H + H, Kings County to establish an IRB Reliance (Authorization) Agreement with the External IRB and NYC H + H, Kings County.

**TIP:** While waiting for approval of the external IRB application, one may wish to begin the submission to the DMC IRB to ensure the research meets all local requirements by submitting the DMC IRB’s “Request to Use an External IRB Application.” In particular, please ensure completion of the following on a timely basis: 1) Ancillary reviews, if required 2) Training 3) Conflict of Interest (COI) disclosures.

The IRB Office will forward the IRB Reliance Agreement to the IO for signature. The DMC IRB will acknowledge the approval of the external IRB’s approval once it has certified that the research meets all local research context requirements, including all local training and conflict of interest requirements. In general, the DMC IRB will not require changes to the research approved by the external IRB; however, the DMC IRB may require or recommend changes or an addendum for submission to the external IRB for approval.

The external IRB must approve the research and the DMC IRB must acknowledge the external IRB approval before any research activities at the DMC site may begin. The PI or IRB may provide the external IRB with the “**Local Research Context for External IRB**” guidance document, to clarify DMC requirements.

The external IRB determines the expiration date of IRB approval.

All required ancillary reviews must take place before the research may begin.

If required by the External IRB, the DMC IRB can issue a preliminary letter to indicate it meets all local research context requirements or list any pending requirements.

If the DMC IRB receives a notice of approval of continuing review, yet not all of the investigators have updated their local training or conflict of interest requirements, the delinquent investigators cannot participate in the research, until they meet all of the local pending requirements.
DMC ACKNOWLEDGEMENT PROCESS AFTER EXTERNAL IRB APPROVAL

Before acknowledging the external IRB approval, the DMC will confirm:

- An IRB Authorization (Reliance) Agreement, when required, has been fully executed between DMC (and NYC H+H, Kings County Hospital Center, if applicable) and the external IRB.
  
  **Note:** When the external IRB and DMC agree to apportion IRB review responsibilities, the external IRB should have written procedures describing how it implements its responsibilities under the agreement.

- All required ancillary reviews are complete or the DMC IRB may indicate the research cannot begin until the required ancillary review is complete,

- All required training is complete, and

- All required conflict of interest disclosures are complete and approved.

In order for the DMC IRB to accept the review of an external IRB, the PI must provide information about the external IRB to demonstrate it meets the following criteria:

1. Unless it is an IRB organization, the institution must maintain a Federalwide Assurance (FWA) approved by the OHRP.
2. The IRB must maintain an active registration with OHRP.
3. The IRB must be AAHRPP accredited, be a member of the SMART IRB network, or it must have undergone or initiated an assessment of the quality of the IRB within five years (e.g., participation in OHRP’s Quality Assessment Program, internal audit, FDA inspection, ORHP inspection, or equivalent approach).
   
   **Note:** The DMC reserves the right to request documentation for the above.

4. The external IRB must provide a point of contact who will be responsible for communication with the DMC IRB.
5. Information on how the external IRB intends to communicate with the investigators and the DMC IRB.
6. For FDA regulated research, provide a description of the external IRB’s ability to evaluate the institution’s ability to participate in the study (e.g., whether the institution has medical services appropriate for the complexity of the study).

ADDITIONAL PROTECTIONS REQUIRED BY THE DMC IRB WHEN USING AN EXTERNAL IRB (INCLUDING SIRB).

In general, an External IRB serves as a Privacy Board to approve HIPAA authorizations or HIPAA waivers, under the HIPAA regulations. If an External IRB does not serve as a Privacy Board, such as the NCI CIRB, it does not have the authority to approve HIPAA authorizations or HIPAA waivers. When an external IRB does not have the authority to approve any HIPAA documents, the DMC IRB must approve any HIPAA documents.

If boiler plate language or addendum documents are required to be added to the informed consent or information sheet documents by the DMC IRB, the external IRB must also approve of the additional requirements.

DMC leadership and the DMC IRB reserve the right to place enrollment on hold, suspend or terminate the research activity or request additional protections at the DMC site at any time. At
such time, the DMC IRB or Institutional Official will promptly notify the external IRB of these actions; however, the PI may also be required to notify the external IRB, within the external IRB’s specified reporting deadlines.

Promptly submit any amendments requested by the DMC IRB to the external IRB, within the timeframe requested by the DMC IRB and follow-up with the DMC IRB, based on the response from the external IRB determination:

1. If the external IRB issues a disapproval, report the findings, including the reasons for the disapproval to the DMC IRB within 5 days. The DMC IRB, IRB Chair, or Vice Chair will determine whether the research may continue at DMC.
2. If the external IRB issues a disapproval, report the findings to the DMC IRB within 30 days for DMC IRB acknowledgement prior to starting the research.

Although a study is under the primary jurisdiction of the external IRB, the following also apply:

- When requested by the DMC IRB, submit progress reports for continuing review and/or IRB notices or letters from the external IRB to the DMC IRB for local acknowledgement. This request may take place at the time of initial local research context review or may be required throughout the duration of the entire study, or on a case-by-case request.
- Whenever there are changes to materials that require an IRB stamp prior to use (as required by this policy) and the external IRB does not provide a stamp, submit a request to the DMC IRB to request to stamp the materials. This request can be in the form or an amendment or it can take place during the initial review of local research context.
- Whenever there are changes to the local study site personnel, submit an IRB amendment to the DMC IRB. When adding research staff, please indicate whether the new research staff are investigators for the purposes of COI as defined by the DMC COI policy. New study site personnel may not participate in the research until the DMC IRB acknowledges the addition of study staff.
- When the external IRB requires continuing review:
  - The research may continue, once the external IRB approves the continuation; however, maintain the IRB approval letter in the research record so that it is readily available to the DMC IRB.
  - If requested by the DMC IRB, as noted above, the DMC PI must complete an abbreviated continuing review (progress) report for the DMC IRB; however, the DMC IRB review will focus on local research context.
- Either the External IRB or the DMC IRB may require, conduct, or request post approval monitoring or audits.

In addition to the reporting requirements of the external IRB, immediately report the following events to the DMC IRB:

- Any privacy breach that occurs at DMC.  
  *Note: Immediately report this event to the DMC Privacy Officer, as well.*
- Any information security breach that occurs at DMC.  
  *Note: Immediately report this to the DMC Data Security Officer, as well.*
- Any event involving the death of a research participant from the DMC site, when the death is related, probably related, or possibly related to participation in the research.
- Whenever there is a discovery of the incarceration of a research participant from the DMC site, if any research interventions must take place while under incarceration.
- Any event that occurs at DMC that requires mandated reporting to a State or Federal Department or Agency, including:
  - Suspension or termination of IRB approval of research
Cooperative research projects are those projects that involve more than one institution. In the conduct of cooperative research projects, each institution is responsible for safeguarding the rights and welfare of research participants and for complying with federal regulations.

**NIH Policy** requires the use of a single IRB (sIRB) for multi-site research for all human research covered by a grant application on or after January 25, 2018.

When the DMC is engaged in federally funded cooperative (multi-site) research with other sites, DMC must rely upon approval by an sIRB for that portion of the research that is conducted in the United States, by January 20, 2020.

In general, the Federal department or agency supporting or conducting a research project identifies the sIRB to oversee the research. A lead institution may propose the sIRB, subject to the acceptance of the Federal department or agency supporting the research.

**At present, the DMC IRB does not have the capacity to serve as a sIRB; therefore, when the research requires a sIRB, follow the process for using an External IRB. Contact the DMC IRB if seeking recommendations for another sIRB.**

**NOTE:** Investigators applying for an NIH grant requiring sIRB review, should include the sIRB fees in the budget. Be mindful that it is not known if other federal departments or agencies will allow for sIRB fees in the budget of their grants, which must be implemented by January 20, 2020. For additional information, please consult with the federal department or agency funding the research.

For certain research, more than single IRB review may be required by law (e.g., tribal law passed by the official governing body of a Native American or Alaska Native tribe, research for which any federal department or agency supporting or conducting the research determines and documents that the use of a single IRB is not appropriate).

**INVESTIGATOR QUALIFICATIONS**

The IRB needs information about the qualifications of the investigator(s) to conduct and supervise the proposed research. Depending upon the nature and risks of the proposed research and the relationship between the IRB and the investigator or the location of the research, this may be relatively simple and straightforward or it may entail a more involved assessment to evaluate the investigator’s qualifications.
Such steps may include, as appropriate (such as the case for external study team members, when the IRB is not familiar with the PI, or for clinical trials that follow GCP requirements):

- Reviewing the CV of the PI or other research staff,
- Verifying professional associations, references, or medical licensure, when applicable,
- Reviewing relevant and recent publications and the investigator's training in good clinical practice, as appropriate, and/or
- Assessing the investigator's training and experience specifically related to the proposed study, particularly if the proposed research involves extremely high risks, vulnerable research participants, or novel technologies.

For clinical trials overseen by a PI from an external site, other than NYC H+H, Kings County, the PI should provide a statement from an administrator of the external institution to confirm the PI qualifications. This should come from a Credentialing Office, IO, Department Chair, or Dean and include information about the clinical investigator's qualifications, his or her credentials and licensure, and whether there have been any institutional disciplinary actions brought against the PI.

If a PI does not have the appropriate privileges or credentials to carry out a research intervention in a research study, the applicable activities may be conducted by another appropriately qualified PI (multiple PIs are permitted), or Co-investigator, approved by the IRB.

The IRB may check lists posted on FDA's website, Clinical Investigator Status (Biologics), Inspection Classification Database Search, Clinical Investigators - Disqualification Proceedings, Inspections, Compliance, Enforcement, and Criminal Investigations to determine whether an investigator has been the subject of an inspection by the agency and the results of such inspections (e.g., Warning). The FDA also posts on its website a listing of all investigators who have been notified of the initiation of a disqualification proceeding or have been disqualified. The IRB may check FDA's Inspections, Compliance, Enforcement, and Criminal Investigations website for information related to clinical investigator inspections, warning letters, disqualification proceedings, and debarments.

### APPLICABLE CLINICAL TRIALS AND REGISTRATION ON CLINICALTRIALS.GOV

ClinicalTrials.gov is a public registry for publicly and privately supported research studies conducted in the United States and around the world. The FDA’s Final Rule regarding “Applicable Clinical Trials (ACT)” requires the responsible party to register the following ACTs at www.ClinicalTrials.gov:

- All NIH funded Clinical Trials
- Any ACT initiated after September 9, 2007, which meets the requirements of FDAA 801.
- An ACT initiated after January 18, 2017, defined by the Clinical Trials ACT Checklist.
- A clinical trial which meets the criteria of the VA, CMS, WHO, PCORI, or ICMJE journals.

For ACTs, the exact following language is included in the informed consent document:

A description of this clinical trial will be available on [http://www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), as required by U.S. Law. This Web site will not include information that can identify you. At
most, the Web site will include a summary of the results. You can search this Web site at any time.

Use the following criteria to determine the Responsible Party at Downstate:

1. The sponsor (funding agency) - either the holder of the IND or the IDE.
2. The Downstate PI that initiates the Clinical Trial when awarded a grant (i.e. the NIH grantee).
   \textit{NOTE: In the case of Cooperative Agreements, the PI and study team must agree ahead of time who will be the responsible party. It will not be the NIH.}
3. The funder of a procurement agreement (i.e. funding by a contract). However, determine in advance if NCI is the responsible party, which may be the case in certain instances.
4. The provider of the study drug (typically the industry or pharmaceutical company providing the funding). The contract should clearly outline the responsible party.
   \textit{NOTE: In the case of an investigator-initiated clinical trial, the Downstate PI is the responsible party, regardless of whether an IND is involved.}

If a Downstate PI is the “responsible party,” (s)he must contact the Director, Pre-Award Operations to establish a user name and password to register the ACT in the Protocol Registration and Results System (PRS). The responsible party must register the ACT 1) before enrolling the first research participant, when there are plans to publish results in an ICMJE journal, or 2) within 21 days after enrolling the first research participant. In addition, the responsible party must submit administrative and scientific information including adverse events and results of the research within the required reporting timelines.

\textbf{CAUTION:}

Failure to meet the FDA requirements of an ACT may lead to the following actions:
- Prohibition of Federal Agencies from releasing \textit{ANY} funding to Downstate!
- Fines of up to $250,000 to the responsible party or $10,000 per day to Downstate Department or College of the non-compliant investigator!
- Inability to publish in an ICMJE journal.
- The IRB may issue an enrollment hold, suspend or terminate a study, or make a finding of serious or continuing non-compliance. Such actions must be reported to federal authorities and funding entities.

\textbf{INVESTIGATORS AND RESEARCH TEAM}

\textbf{PRINCIPAL INVESTIGATOR}

The principal investigator (PI) oversees scientific, technical, and day-to-day management of the research. The PI must have appropriate qualifications and experience. The PI holds the lead responsibility for the research protocol, including oversight of its implementation and the activities of other investigators and research staff, and management of any funding associated with the protocol, and all compliance.
PIs should include one or more additional qualified co-investigator(s) if they need to incorporate additional skills beyond those held by the PI. In general, PIs should be on-site where the research takes place at least 50% of their time or include additional qualified co-investigator(s) or multiple PIs to address any safety and leadership concerns.

**PI STATUS**

For the purposes of this policy, the PI listed on an IRB application must be an investigator who meets at least one of the following eligibility criteria:

- Be a seasoned investigator with a field-specific terminal degree who is a Faculty Member at DMC,
- Meet the criteria for PI status by the NYC H + H, Kings County (e.g., Clinician with clinical privileges at NYC H + H, Kings County),
- Be a retired DMC faculty member with emeritus status, with approved to be a PI by a written memo or e-mail from the DMC Institutional Official and ancillary approval by a Department Chair (or Dean),
- Be a faculty member under recruitment to DMC approved to be a PI by a written memo or an e-mail from a Dean or Department Chair, or
- Qualify to be a PI at an external site (other than NYC H + H, Kings County), which includes an activity which makes DMC engaged in human research (see OHRP guidance: Engagement of Institutions in Human Subjects Research (2008)), including when federal funding or support is provided to DMC or when the research includes one of the following co-investigators or key personnel:
  - Employee of SUNY DMC
  - Employee of the Research Foundation for SUNY- DMC
  - Resident or Fellow trained under a GME program affiliated with DMC
  - Student in a DMC Academic Program

A PI who is an external employee to DMC and listed on a DMC IRB application agrees to abide by DMC policies for the duration of the study.

**MULTIPLE PRINCIPAL INVESTIGATORS**

In general, only one individual may serve as a PI for each IRB application; however, for the purposes of this policy, DMC permits multiple principal investigators on an IRB application when multidisciplinary efforts require more than one PI to be responsible for the scientific and technical direction of the project.

The rationale for choosing a multiple PI approach should be described in the IRB application materials and include a description of the roles, the responsibilities, and the working relationship of the identified PIs. Each PI must have the necessary qualifications for their role and must contribute towards the proposed goals of the research.

Unless otherwise noted, the first PI listed in the IRB application with an affiliation with the institution that is submitting the application will serve as the contact PI.
PI RESPONSIBILITIES

The PI must uphold professional and ethical standards and practices when conducting research. This policy, the IRB application, and the research protocol define investigator responsibilities. The sponsor or other agreements may define additional responsibilities.

As applicable to the research, the PI responsibilities include, but are not limited to, the following:
- Conduct ethical research and protect the rights and welfare of research participants;
- Develop a research plan that is scientifically sound and minimizes risk to the research participants;
- Comply with all Federal and State laws and regulations, contractual obligations, and DMC policies;
- Ensure that risks to research participants are minimized:
  - by using procedures which are consistent with sound research design and which do not unnecessarily expose research participants to risk, and
  - whenever appropriate, by using procedures already being performed on the research participants for diagnostic or treatment purposes;
- Ensure that all research involving research participants or information about them receives IRB review and approval in writing before commencement of the research;
- Comply with all IRB decisions, conditions, and requirements;
- Recruit research participants in a fair and equitable manner;
- **Ensure all investigators who obtain informed consent are approved by the IRB;**
- Obtain and document informed consent as required by the IRB and ensure that no research participant is involved in the research prior to obtaining their consent, unless waived;
- **Obtain all required signatures on the informed consent form and always provide a copy of the signed informed consent document to the research participant;**
- **Keep the entire original signed informed consent form (not just the signed pages) in a secure location;**
- Have plans to monitor the data collected for the safety of research participants;
- Protect the privacy of research participants and maintain the confidentiality of data;
- When some or all of the research participants are likely to be vulnerable to coercion or undue influence, include additional safeguards in the study to protect the rights and welfare of these research participants;
- Have a procedure to receive complaints or requests for additional information from research participants and respond appropriately;
- Submit accurate IRB application materials and conduct research according to all written approvals and applicable contractual obligations;
- Request amendments for all changes to previously IRB approved research (including changes that affect funding status or risks) on a timely basis and in accordance to IRB procedures, as required by this policy;
- Promptly obtain IRB review and approval of proposed changes before implementing a change, except when necessary to eliminate apparent immediate hazards or to protect the life or physical well-being of the research participant;
- Promptly review all IRB approved materials and request any administrative corrections (e.g., errors in IRB letters, stamps, approved documents, etc.), if needed;
- Report all required events or incidents to the IRB within the required deadlines;
• Report any apparent non-compliance to the IRB and when applicable include corrective action plans to prevent reoccurrence;
• Ensure protocols receive timely continuing IRB review and approval, by providing timely progress reports and associated materials for continuing review, when required;
• Provide timely check-in reports, when required;
• Ensure proper study closure;
• Oversee and ensure qualified research staff;
• Ensure all persons assisting with the research are adequately informed about the protocol and their research-related duties and functions;
• Ensure availability of medical or psychological resources that research participants might require as a consequence of the research;
• Assure all procedures in a study are performed with the appropriate level of supervision;
• When procedures require an investigator to have a specific license, be credentialed, or be otherwise qualified, ensure only appropriate individuals perform such procedures under applicable laws or DMC policies;
• Assure that all key personnel are educated in the regulatory requirements regarding the conduct of research and the ethical principles upon which they are based;
• As applicable to the study, prospectively obtain and document voluntary consent, parental permission, pediatric assent, and HIPAA research authorization using the IRB–approved, stamped form(s);
• Securely maintain complete research records, in accordance with regulatory time frames and DMC policies;
• Cooperate with any audit, sponsor site visit, or government investigation;
• Disclose conflicts of interest on a timely basis;
• Ensure appropriate use and review of laboratory reports;
• Follow correct billing practices, policies, and CMS regulations for research activities, including those for qualifying/deemed clinical trials;
• Follow policies for students and volunteers;
• Obtain appropriate approvals of the research budget and contracts related to the research;
• Ensure adequate resources necessary to protect research participants, including:
  o Access to a population that would allow recruitment of the required number of research participants,
  o Sufficient time to conduct and complete the research,
  o Adequate numbers of qualified staff, and
  o Adequate facilities;
• Supervise the administration of drugs, biologics, and devices, and ensure prescriptions (or medication orders) for study drugs and biologics are authorized;
• Ensure registration of all Applicable Clinical Trials at www.clinicaltrials.gov and maintenance of updates based on the required frequency, and complete Form FDA 3674, when applicable;
• Ensure the required language is provided in the consent document for Applicable Clinical Trials;
• Obtain a Certificate of Confidentiality, when applicable;
• Ensure multi-site studies have IRB approval;
• Notify the IRB of any relocation of research activities;
• Notify the IRB and Department Chair of any planned departures or an extended leave of absence;
• Ensure a Materials Transfer Agreement (MTA) is established, when required, and in consistency with IRB approved materials;

• Upon request, provide an enrollment list of research participants that were enrolled into a research study, only when permitted by this policy;

• Maintain a current list of study staff, CVs/Resumes, credentials, and their respective training certifications;

• Follow FDA regulations when conducting a clinical trial or device study;

• For FDA regulated clinical trials, complete the proper FDA forms and submit them to both the sponsor and the IRB, such as FDA Form 1571 (IND Application) and FDA Form 1572 (Statement of Investigator), for new submissions and when amended;

• Electronically sign the IRB application in the electronic IRB submission and reporting system, when required;

• Ensure that the Scientific Review Committee (SRC) approves the research, when required;

• Ensure Department Chair and other required ancillary reviewers electronically sign the IRB application in the electronic IRB submission and reporting system or provide an alternate form of signature approval (e.g., signed letter, memo, application, etc.);

• Ensure any require ancillary review is complete before the research begins;

• Before starting a study, where necessary obtain the specific required affiliate institutional approvals (e.g., STAR approval at NYC H+H, Kings County),

• Follow institutional policies for information security, and

• Back-up data to a secure network drive or alternative secure location approved by the Data Safety Officer.

CO-INVESTIGATORS AND KEY PERSONNEL

Co-investigators and key personnel assist the PI in fulfilling his/her responsibilities as outlined in the PI Responsibilities section of this document. For the purposes of this policy, the Downstate IRB follows the OHRP Investigator Responsibilities FAQs to determine who are investigators (or key personnel) for federally supported or conducted human research studies, whose involvement would include:

• Obtaining information about living individuals by intervening or interacting with them for research purposes;

• Obtaining identifiable private information and identifiable biospecimens about living individuals for research purposes;

• Obtaining the voluntary informed consent of individuals to be research participants in research; or

• Studying, interpreting, or analyzing identifiable private information or data for research purposes.

Co-investigators and key personnel are responsible for research protocols with research participants, and must have suitable qualifications, including: (1) familiarity with research methods and procedures; (2) familiarity with research regulations and other applicable regulatory requirements; and (3) certificates for required training courses.

The PI may wish to distinguish between co-investigators and key personnel on the IRB application, as it may be a preference of a sponsor or a publication; however, for the purpose of
this policy, they are treated the same, even if they are distinguished separately on the IRB application or related materials.

The IRB application must list Hospital staff, research coordinators and research assistants as a co-investigator or key personnel if they conduct human research including any of the activities described above; however, the FDA provides an exception for delegating clinical trial tasks to hospital staff and residents, as described in the section below.

Co-investigators and key personnel can include physicians, scientists, nurses, administrative staff, teachers, and students, among others.

DELEGATION OF CLINICAL TRIAL TASKS TO HOSPITAL STAFF AND RESIDENTS

For FDA regulated clinical trials (IND, IDE, NSR device studies), the PI may delegate certain responsibilities; however, the PI must provide adequate supervision of those who tasks are delegated. For more information on investigator responsibilities, see FDA Guidance for Investigator Responsibilities and the FDA FAQs for Form 1572.

The PI must ensure that any individual performing a delegated task is appropriately qualified, by education, training, experience, licensure, certification, or credentialing, to perform the delegated task. The IRB strongly encourages the PI to maintain a delegation log in the research record to describe the delegated tasks, qualifications, and training, to avoid any appearance of non-compliance. In all cases, a qualified clinician is responsible for all trial-related medical decisions and care.

Hospital staff (e.g., nurses, residents, fellows or office staff) who have only an occasional role in the conduct of the research by providing ancillary or intermittent care and do not make a direct and significant contribution to the clinical data do not need to be listed on the IRB application for FDA regulated clinical trials. This includes for example, an on-call physician who temporarily dealt with a possible adverse effect or a temporary substitute for any research staff. When it is difficult to identify rotational staff (e.g., residents, nurses) who might perform specified protocol procedures or collect clinical data, rather than listing the specific names of the rotational staff on an IRB application, please document the names of such individuals along with the procedures they may perform in the research records.

The decision about whether to list other hospital staff (e.g., pharmacist, nurse, medical technologist, x-ray technician, sonographer, research coordinator, statistician, etc.) as a co-investigator or key personnel on the IRB application is a matter of judgment, dependent upon the contribution that the individual makes to the study. For example, a pharmacist may prepare test articles and maintain drug accountability for many clinical studies that are ongoing concurrently at an institution. Because the pharmacist would not be making a direct and significant contribution to the data for a particular study, it would not be necessary to list the pharmacist as a co-investigator in the IRB application; however, the IRB recommends including the pharmacist name(s) in the investigator’s study records or listing them as non-research staff on the IRB application.

Generally, a research coordinator has a greater role in performing critical study functions and making direct and significant contributions to the data. For example, if a research coordinator is recruiting research participants, collecting or evaluating study data, and maintaining study
records, (s)he may be listed as a co-investigator or key personnel. Some PIs prefer to list research coordinators as research staff when they have more of an intellectual role or can defend the results of the study.

Delegated staff members are encouraged to take CITI training, but are not required to do so.

**NON-RESEARCH STAFF**

In general, individuals that carry out activities to support a research study who are doing something that would not make them an investigator as described above, are not investigators on an IRB application, and therefore would not need to complete the requirements (e.g., training and COI disclosures) of an investigator. The PI may list these individuals as non-research staff, if desired.

Non-research staff may perform routine clinical or administrative services to support research (e.g., perform a clinical lab test, take an x-ray, perform healthcare operations activities, etc.) provided these are part of their routine responsibilities without being listed as an investigator; however, they cannot collaborate as an investigator or conduct any research activities.

Some examples of non-research activities, may include, but are not limited to the following:
- Performing a commercial or other service (e.g., qualified laboratory services, transcription services, obtaining blood or urine, radiology services, nursing services) for investigators, provided all of the following conditions are met:
  - the services performed do not merit professional recognition or publication privileges;
  - the services performed are typically performed by those institutions for non-research purposes; and
  - the individual does not administer any study intervention being tested or evaluated under the protocol, or
- Releasing identifiable information, materials, or specimens to investigators,
- Releasing de-identified information, materials, or specimens to investigators (e.g., an employee who serves as an honest broker),
- Reviewing identifiable information for the purposes of auditing or other healthcare operations activities,
- Receiving de-identified specimens for the purposes of analytical testing, or
- Reviewing de-identified data for the purpose of authoring, describing, or presenting a research study.

Individuals performing operations activities relevant to the research (e.g., research audit, audit preparation, IRB review, protocol development, scientific review, consulting, or advising) are not considered research staff, if they do not perform or conduct any activities described under the above section regarding "Co-Investigators and Key Personnel."

Non-Research staff members are encouraged to take CITI training, but are not required to do so.
KEY CONTACT OR IRB LIAISON

The PI may list a Key Contact or an IRB liaison on the IRB application and registration form to have access to the IRB application materials, or a member of the study team can share access in the electronic IRB submission and reporting system. They may review these materials as a Healthcare Operations Activity. Examples of key contacts include administrative personnel that have a need to follow or assist in the research, but not conduct investigator activities.

External sites with an IRB Authorization Agreement may have a liaison who receives copies of communications from the IRB. The individuals may have access to the study files, regardless of whether the PI includes them on the IRB application.

ADEQUACY OF RESEARCH SITE

When the IRB is not familiar with the research site, the IRB may require additional assessment of the site’s adequacy. The IRB may need to assess the adequacy of the facility’s staff and medical equipment, including the adequacy of emergency or specialized care, if the need arises. If needed, the IRB may require a statement from the research site indicating the site is adequate or require a description from the PI that includes a description of the facility where the research will take place, including staffing and resources relevant to the research under review.

GENERAL CRITERIA FOR IRB APPROVAL

Before granting approval, the IRB must determine all of the criteria for IRB approval are satisfied, as specified in federal and state regulations. When the research does not meet the criteria for approval, the IRB requests revisions.

EXEMPT RESEARCH

Some human research activities are exempt from HHS or FDA federal regulations; however, the DMC still has oversight of these activities. In general, the IRB prospectively determines when the research is exempt. However, an independent determination by an investigator is acceptable solely for the purpose of making and documenting representations for reviews preparatory to research, as described elsewhere in this policy.

In order to approve exempt human research, except for Reviews Preparatory to Research, the IRB must determine that the research as described in the IRB application and associated materials meets the specific criteria for exempt research.

The HIPAA regulations apply to exempt research that involves PHI and, therefore, the IRB will confirm the appropriate and relevant HIPAA protections are in place (e.g., HIPAA authorization, HIPAA waiver, DUA, BAA, Certification for PHI of Decedents, Subject Recruitment Authorization, etc.) for such research.
The IRB will confirm the research meets all requirements and verify it meets the criteria for exempt research; however, it may require additional protections, particularly when vulnerable populations are involved.

When an exempt study requires limited IRB review, an IRB member must determine that there are adequate provisions to protect the privacy of research participants and to maintain the confidentiality of the data. Limited IRB review does not preclude an IRB member from requiring other reasonable protections outside of the context of privacy or confidentiality, as applicable to the research.

NON-EXEMPT HUMAN RESEARCH

In order to approve non-exempt human research or FDA regulated clinical investigations the IRB must determine all of the following requirements (as described in the Common Rule at 45 CFR 46.111 or FDA regulations at 21 CFR 56.111) are satisfied, based on review of IRB application materials.

- Risks to research participants are minimized:
  - by using procedures which are consistent with sound research design and which do not unnecessarily expose research participants to risk, and
  - whenever appropriate, by using procedures already being performed for diagnostic or treatment purposes.

  *Note: To evaluate the above for a clinical investigation involving an IND, the IRB may wish to obtain and review the following information, as applicable for the review:*
  - *Published literature about the chemistry, manufacturing, and control of the drug substance and product;*
  - *A summary of previous human experience with the drug product;*
  - *Sufficient information regarding the source, purity, quality, and method of preparation and delivery of the drug used in the research; and*
  - *Information regarding the pharmacology and toxicity of the drug product in animals.*

- Risks to research participants are reasonable in relation to anticipated benefits, if any, to research participants, and the importance of the knowledge that may reasonably be expected to result. In evaluating risks and benefits, the IRB considers only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies research participants would receive even if not participating in the research). The IRB does not consider possible long-range effects of applying knowledge gained in the research (e.g., the possible effects of the research on public policy) as among those research risks that fall within the purview of its responsibility.

- Selection of research participants is equitable. In making this assessment the IRB takes into account the purposes of the research, the adequacy of inclusion and exclusion criteria, and the setting in which the research will be conducted. The IRB is particularly cognizant of the special problems of research that involves a category of research participants who are vulnerable to coercion or undue influence, such as children,
prisoners, individuals with impaired decision-making capacity, or economically or educationally disadvantaged persons. For FDA regulated clinical trials, vulnerable populations also include pregnant women, mentally disabled persons, and handicapped individuals.

- Informed consent (and HIPAA research authorization, when applicable) will be sought from each prospective research participant or his/her LAR/surrogate, in accordance with, and to the extent required by the federal regulations and will be appropriately documented, unless waived.
  - The IRB members review the informed consent document to ensure all required elements and appropriate additional elements are provided to the research participant at the time of initial review.
  - At the time of continuing review, the IRB must also review the informed consent document to determine if any additional changes are required.
- Informed consent (and HIPAA research authorization, when applicable) will be appropriately documented or waived in accordance with this policy.
- When appropriate, the research plan must make adequate provision for monitoring the data collected to ensure the safety of research participants.
- When appropriate, there are adequate provisions to protect the privacy of research participants and to maintain the confidentiality of data.
- When some or all of the research participants are likely to be vulnerable to coercion or undue influence, such as children, prisoners, adults with impaired decision-making capacity, or economically or educationally disadvantaged persons, the IRB must evaluate whether additional safeguards have been included in the study to protect the rights and welfare of these research participants based on the IRB application materials. The IRB may require additional safeguards, if needed. For FDA regulated clinical trials, vulnerable populations also include pregnant women, mentally disabled persons, and handicapped individuals.
- In order to approve research involving some or all research participants that include vulnerable populations, the IRB must also ensure the research is in compliance with regulations to the extent required by 45 CFR 46, subpart B, C, and D. See next sections for more details.
- In order to approve FDA regulated clinical investigations involving some or all research participants that include children, the IRB must also ensure the research is in compliance with regulations to the extent required by 21 CFR 50, subpart D. See next sections for more details.
- FDA requires the sponsor or the sponsor-investigator to determine whether an IND or IDE is required for a particular study. The IRB may request the basis for the determination or request supporting documentation from the FDA. If the IRB is unable to resolve a controverted issue regarding the IND or IDE, it cannot approve the study until the matter is resolved.
- The IRB may make a determination that a device study is significant risk (SR) or non-significant risk (NSR) at a convened meeting; however, any experienced member can
make or confirm the determination. A SR device study must have an IDE from the FDA before the IRB can approve the investigation.

**RESEARCH REGULATED UNDER NYS ARTICLE 24A**

Certain research as defined by NYS Article 24A requires additional IRB approval requirements including approval by NYS Commissioner of Health, unless the research is subject to and in compliance with federal regulations. Downstate voluntarily applies the Common Rule to all research; therefore, NYS Article 24A does not apply to research at Downstate.

**RISK**

Risk means a potential harm (injury) associated with the research that a reasonable person in the position of research participants would be likely to consider significant in deciding whether to participate in the research. The concept of risk includes discomfort, burden, or inconvenience a research participant may experience because of the research procedures. Underlying the consideration of risk is the implicit moral guideline that all investigators have a duty not to harm their research participants and must minimize potential risk to the greatest extent possible.

The five major types of risk are:

- **physical risk** (e.g., pain, bruising and infection associated with venipuncture, adverse reactions to drugs, muscle soreness and pain as a consequence of exercise testing, heart attack induced by maximal exercise test);
- **psychological risk** (e.g., depression and confusion as a result of administration of drugs, feelings of guilt precipitated by a sensitive survey, feelings of coercion or undue influence during enrollment);
- **social risk** (e.g., invasion of privacy, loss of community standing, breach of confidentiality);
- **legal risk** (e.g., criminal prosecution or revocation of parole); and
- **economic risk** (e.g., loss of employment, loss of potential monetary gain).

**MINIMAL RISK**

IRB members must determine the level of risk for each non-exempt study. For more information, refer to the definitions below. One may also wish to refer to the Secretary’s Advisory Committee on Human research Protections (SACHRP) document on Understanding Minimal Risk.

**GENERAL DEFINITION**

**Minimal risk** in research involving individuals means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.
The IRB calibrates the interpretation of *minimal risk* to the life of normal, healthy individuals and to daily life of activities to which most individuals are exposed. However, the IRB may consider whether minimal risk procedures for normal healthy individuals constitute greater than minimal risk for populations that are vulnerable by virtue of their condition or circumstances.

**PRISONER RESEARCH**

*Minimal risk* in research involving prisoners is the probability and magnitude of physical or psychological harm that healthy persons normally encounter in their daily lives, or in their routine medical, dental, or psychological examinations.

**DEPARTMENT OF DEFENSE RESEARCH**

When following DoD regulations, the definition of minimal risk based on the phrase “ordinarily encountered in daily life or during the performance of routine physical or physiological examination or tests” shall not be interpreted to include the inherent risks certain categories of research participants’ face in their everyday life. For example, the risks imposed in research involving research participants focused on a special population should not be evaluated against the inherent risks encountered in their work environment (e.g., emergency responder, pilot, soldier in a combat zone) or having a medical condition (e.g., frequent medical tests or constant pain).

**RESEARCH INVOLVING VULNERABLE POPULATIONS**

**CHILDREN**

45 CFR Subpart D and 21 CFR 50 Subpart D (for FDA regulated clinical investigations) applies to all research involving children (including neonates).

The IRB must make the determinations necessary to approve the research found in this section of the regulations. The IRB Members may document their determinations in the electronic IRB submission and reporting system.

In general, assent of children over the age of seven (7) is expected and parental or legal guardian permission is sought, unless the IRB waives the requirement for such.

For the purposes of this policy, a *legal guardian* is an individual authorized under applicable law or by court order to provide consent on behalf of a child.

The IRB determines the placement of the approval in one of the following allowable categories, provided the research with children meets the criteria listed below:

- **Category 404**: Human research or a clinical investigation not involving greater than minimal risk (45 CFR 46.404 and 21 CFR 50.51)
- Requires assent of the child (unless waived); and
- The IRB may find that permission of one parent (or legal guardian) is sufficient.

**Category 405:** Human research or a clinical investigation involving greater than minimal risk but presenting the prospect of direct benefit to the individual research participants (45 CFR 46.405 and 21 CFR 50.52)
- Requires assent of the child, unless waived;
- The IRB may find that permission of one parent (or legal guardian) is sufficient (unless waived);
- The IRB must find that the intervention or procedure holds out the prospect of direct benefit for the individual participant, or by a monitoring procedure that is likely to contribute to the participants' well-being;
- The risk is justified by the anticipated benefit to the participants; and
- The relation of the anticipated benefit to the risk is at least as favorable to the participants as that presented by available alternative approaches.

**Category 406:** Human research or a clinical investigation involving greater than minimal risk (minor increase over minimal risk) but no prospect of direct benefit to the individual research participants but likely to yield generalizable knowledge about the research participants' disorder or condition. (45 CFR 46.406 and 21 CFR 50.53)
- Requires assent of the child, unless waived;
- The permission, unless waived, must be obtained by both parents (or legal guardians), unless one is deceased, unknown, incompetent or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child;
- The risk represents a minor increase over minimal risk;
- The intervention or procedure presents experiences to participants that are reasonably commensurate with those inherent in their actual or expected medical, dental, psychological, social, or educational situations;
- The intervention or procedure is likely to yield generalizable knowledge about the participants' disorder or condition which is of vital importance for the understanding or amelioration of the participants' disorder or condition; and
- If children who are wards of the state or any other agency, institution, or entity are included, the IRB requires additional requirements of 45 CFR 46.409 (or 21 CFR 50.56 for clinical investigations).

**Category 407:** Human research or a clinical investigation that is not otherwise in category 404, 405, or 406, which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children. (45 CFR 46.406 and 21 CFR 50.54)
- Requires assent of the child (unless waived)
- The permission (unless waived) must be obtained by both parents (or legal guardians), unless one is deceased, unknown, incompetent or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child;
- The research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children;
If children who are wards of the state or any other agency, institution, or entity are included, additional requirements outlined in 45 CFR 46.409 (or 21 CFR 50.56 for clinical investigations) must be met; and

- The OHRP (or by the FDA, if FDA regulated) must also approve the research.

**CHILDREN WHO ARE WARDS**

For the purpose of this policy, a child who is placed in the legal custody of the state or other agency, institution or entity, consistent with applicable federal, state or local law.

Investigators must describe research involving a child with a ward status in the IRB application at the time of initial review or through an amendment proposal. As applicable, additional protections must be provided for the Wards as described in 45 CFR 46.409 or 21 CFR 50.56.

**PREGNANT WOMEN, FETUSES, NEONATES, OR IN-VITRO FERTILIZATION**

When reviewing research that involves pregnant women, fetuses, neonates, or In-Vitro fertilization, the IRB must ensure it satisfies all of the conditions covered by Subpart B - Additional Protections for Pregnant Women, Human Fetuses and Neonates.

**PREGNANT WOMEN OR FETUSES**

Pregnant women or fetuses may be involved in research under the following conditions:

- Where scientifically appropriate, preclinical studies, including studies on pregnant animals, and clinical studies, including studies on non-pregnant women, have been conducted and provide data for assessing potential risks to pregnant women and fetuses;
- The risk to the fetus is caused solely by interventions or procedures that hold out the prospect of direct benefit for the woman or the fetus; or, if there is no such prospect of benefit, the risk to the fetus is not greater than minimal and the purpose of the research is the development of important biomedical knowledge which cannot be obtained by any other means;
- Any risk is the least possible for achieving the objectives of the research;
- If the research holds out the prospect of direct benefit to the pregnant woman, the prospect of a direct benefit both to the pregnant woman and the fetus, or no prospect of benefit for the woman nor the fetus when risk to the fetus is not greater than minimal and the purpose of the research is the development of important biomedical knowledge that cannot be obtained by any other means, her consent is obtained in accord with the informed consent provisions;
- If the research holds out the prospect of direct benefit solely to the fetus then the consent of the pregnant woman and the father is obtained in accord with the informed consent provisions, except that the father’s consent need not be obtained if he is unable to
consent because of unavailability, incompetence, or temporary incapacity or the pregnancy resulted from rape or incest.

- Each individual providing consent is fully informed regarding the reasonably foreseeable impact of the research on the fetus or neonate;
- For children who are pregnant, assent and parental/legal guardian permission are obtained in accord with the provisions of the IRB;
- No inducements, monetary or otherwise, will be offered to terminate a pregnancy;
- Individuals engaged in the research will have no part in any decisions as to the timing, method, or procedures used to terminate a pregnancy; and
- Individuals engaged in the research will have no part in determining the viability of a neonate.

NEONATES OF UNCERTAIN VIABILITY AND NONVIABLE NEONATES

Neonates of uncertain viability and nonviable neonates may be involved in research under the following conditions:

- Where scientifically appropriate, preclinical and clinical studies have been conducted and provide data for assessing potential risks to neonates.
- Individuals providing consent are fully informed regarding the reasonably foreseeable impact of the research on the neonate.
- Individuals engaged in the research will have no part in determining the viability of a neonate.

NEONATES OF UNCERTAIN VIABILITY.

Until it has been ascertained whether or not a neonate is viable, a neonate may not be involved in ANY research covered by this policy unless the following additional conditions have been met:

- The IRB determines that:
  - The research holds out the prospect of enhancing the probability of survival of the neonate to the point of viability, and any risk is the least possible for achieving that objective, or
  - The purpose of the research is the development of important biomedical knowledge which cannot be obtained by other means and there will be no added risk to the neonate resulting from the research; and
- The legally effective informed consent of either parent of the neonate or, if neither parent is able to consent because of unavailability, incompetence, or temporary incapacity, the legally effective informed consent of either parent's LAR/surrogate is obtained in accord with regulatory requirements, except that the consent of the father or his LAR/surrogate need not be obtained if the pregnancy resulted from rape or incest.

NONVIABLE NEONATES
After delivery, a nonviable neonate may not be involved in research covered by this policy unless all of the following additional conditions are met:

- Vital functions of the neonate will not be artificially maintained;
- The research will not terminate the heartbeat or respiration of the neonate;
- There will be no added risk to the neonate resulting from the research;
- The purpose of the research is the development of important biomedical knowledge that cannot be obtained by other means; and
- The legally effective informed consent of both parents of the neonate is obtained. Waivers and alteration provisions do not apply; however, if either parent is unable to consent because of unavailability, incompetence, or temporary incapacity, the informed consent of one parent of a nonviable neonate will suffice, except that the consent of the father need not be obtained if the pregnancy resulted from rape or incest.

**Viable Neonates**

A neonate, after delivery, that has been determined to be viable may be included in research only to the extent permitted by and in accord with the requirements for Children.

**Research Involving Placenta, Dead Fetus, or Fetal Material**

Research involving, after delivery, the placenta; the dead fetus; macerated fetal material; or cells, tissue, or organs excised from a dead fetus, shall be conducted only in accord with any applicable federal regulation and any state, or local laws and regulations regarding such activities.

*NOTE: At the time of this writing, the Downstate Office of General Counsel determined there are no additional regulatory requirements for the state of NY.*

If information associated with material described in this section is recorded for research purposes in a manner that living individuals can be identified, directly or through identifiers linked to those individuals, those individuals are research participants and all IRB requirements applicable.

**Research Not Otherwise Approvable Which Presents an Opportunity to Understand, Prevent, or Alleviate a Serious Problem Affecting the Health or Welfare of Pregnant Women, Fetuses, or Neonates.**

DMC may conduct research involving pregnant women fetuses, or neonates that the IRB does not believe meets the requirements of the above policy, only if:

- The IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of pregnant women, fetuses or neonates; and
- OHRP, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, ethics, law) and following opportunity for public review and comment, including a public meeting announced in the Federal Register, has determined either:
That the research in fact satisfies the conditions for research with pregnant women or fetuses, as applicable; or
The following:
- The research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of pregnant women, fetuses or neonates;
- The research will be conducted in accordance with sound ethical principles; and
- Informed consent will be obtained in accordance with the informed consent provisions.

IN-VITRO FERTILIZATION

Federal agencies prohibit funding for in-vitro fertilization (IVF) research. However, investigators involved in IVF research or the IRB may wish to consult the references below for historical perspectives, regulations, and ethical considerations.

- American College of Obstetrics and Gynecologists (ACOG)
- American Society for Reproductive Medicine (ASRM)

PRISONERS

When reviewing research involving prisoners the IRB must ensure it satisfies all of the conditions covered by Subpart C - Additional Protections Pertaining to Biomedical and Behavioral research Involving Prisoners as Research Participants.

The IRB Member who is the prisoner representative must review the research. OHRP must also approve the federally supported or conducted research. In order to approve research that involves prisoners, the IRB must find that the proposed research falls into one of the permissible categories of research, and make the following seven findings:

1. The research under review represents one of the permissible categories of research:
   - **Category #1**: Study of the possible causes, effects, and processes of incarceration, and of criminal behavior, provided that the study presents no more than minimal risk and no more than inconvenience to the research participants;
   - **Category #2**: Study of prisons as institutional structures or of prisoners as incarcerated persons, provided that the study presents no more than minimal risk and no more than inconvenience to the research participants;
   - **Category #3**: Research on conditions particularly affecting prisoners as a class (for example, vaccine trials and other research on hepatitis which is much more prevalent in prisons than elsewhere; and research on social and psychological problems such as alcoholism, drug addiction, and sexual assaults) provided that the study may proceed only after OHRP has consulted with appropriate experts including experts in penology, medicine, and ethics, and published notice, in the Federal Register, of his/her intent to approve such research; or
   - **Category #4**: Research on practices, both innovative and accepted, which have the intent and reasonable probability of improving the health or well-being of the
research participants. In cases in which those studies require the assignment of prisoners in a manner consistent with protocols approved by the IRB to control groups which may not benefit from the research, the study may proceed only after OHRP has consulted with appropriate experts, including experts in penology, medicine, and ethics, and published notice, in the Federal Register, of the intent to approve such research.

2. Any possible advantages accruing to the prisoner through his or her participation in the research, when compared to the general living conditions, medical care, quality of food, amenities and opportunity for earnings in the prison, are not of such a magnitude that his or her ability to weigh the risks of the research against the value of receiving such advantages in the limited-choice prison environment is impaired;

3. The risks involved in the research are commensurate with risks that would be accepted by non-prisoner volunteers;

4. Procedures for the selection of research participants within the prison are fair to all prisoners and immune from arbitrary intervention by prison authorities or prisoners. Unless the PI provides the IRB with written justification for following some other procedures, control research participants must be selected randomly from the group of available prisoners that meet the characteristics needed for that particular research proposal;

5. The information is presented in language that is understandable to the research participant population;

6. Adequate assurance exists that parole boards will not take into account a prisoner's participation in the research in making decisions regarding parole, and each prisoner is clearly informed in advance that participation in the research will have no effect on his or her parole; and

7. Where the IRB finds there may be a need for follow-up examination or care of participants after the end of their participation, the IRB ensures adequate provisions are in place for such examination or care, taking into account the varying lengths of individual prisoners' sentences, and for informing participants of this fact.

In order to make these findings, the IRB must be familiar with the specific conditions in the local prison(s) or jail site(s) that are pertinent to protections, before approving the proposal for the local site.

EPIDEMIOLOGIC RESEARCH INVOLVING PRISONERS

Note: See Section “Activities That Do Not Require IRB Review and Approval; Public Health Surveillance Activities” to determine whether IRB approval is required for such activities.

Health and Human Services has waived the applicability of 45 CFR 46.305(a) (l) and 46.306(a) (2) for certain research conducted or supported by HHS that involves epidemiological studies that meet the following criteria:

1. In which the sole purposes are:
   a. To describe the prevalence or incidence of a disease by identifying all cases, or
   b. To study potential risk factor associations for a disease, and
2. Where the IRB has approved the research and has fulfilled its duties under 45 CFR 46.305(a)(2)–(7) and determined and documented that the following conditions are met:
   a. The research presents no more than minimal risk and no more than inconvenience to the research participants, and
   b. Prisoners are not a particular focus of the research.
3. The specific type of epidemiological research subject to the waiver involves no more than minimal risk and no more than inconvenience to the research participants. The waiver would allow the conduct of minimal risk research that does not now fall within the categories set out in 45 CFR 46.306(a) (2).
4. The range of studies to which the waiver would apply includes epidemiological research related to chronic diseases, injuries, and environmental health. This type of research uses epidemiologic methods (such as interviews and collection of biologic specimens) that generally entail no more than minimal risk to the research participants.
5. In order for the IRB to approve a study under this waiver, the IRB would need to ensure that, among other things, there are adequate provisions to protect the privacy of research participants and to maintain the confidentiality of the data.

OTHER POTENTIALLY VULNERABLE POPULATIONS

When some or all of the research participants are students, residents, fellows or volunteers, please refer to the IRB guidance on this topic.

When some or all of the research participants are patients of the investigators, consult the IRB guidance within the IRB applications.

NEWBORN SCREENING SPOTS

The IRB considers all HHS supported or conducted research using newborn dried blood spots to be human research regardless of whether the specimens are identifiable.

The IRB may NOT waive informed consent under for research involving newborn dried blood spots for HHS supported or conducted research.

For more information, please see The Newborn Screening Saves Lives Reauthorization Act of 2014.

CERTIFICATES OF CONFIDENTIALITY

Effective October 1, 2017, all research commencing or ongoing on or after December 13, 2016 and is within the scope of NIH Policy for Issuing Certificates of Confidentiality (NOT-OD-17-109), is deemed to be issued a Certificate of Confidentiality (CoC). The CoC is required to protect the privacy of individuals who are participants of such research in accordance with subsection 301(d) of the Public Health Service Act. Include the disclosures regarding the CoC as outlined in the IRB Informed consent template.
The intent of CoCs is to prohibit disclosure of sensitive, identifiable information in response to legal demands. The CoC does not prohibit disclosure of state mandated reporting requirements (e.g., child abuse or neglect, certain communicable diseases, possible threat or harm to the research participant or others).

The CoC broadly applies automatically to any of the following types of NIH funded research:
- All human research (including exempt research) when individuals can be readily identified.
- Research involving identifiable biospecimens data sources when it may be possible to deduce the identity of an individual’s biospecimens.
- Research that generates individual-level human genomic data from biospecimens, or the use of such data.
- Any other research that involves information about an individual when it may be possible to deduce the identity of an individual.

For NIH funded studies, NIH will no longer provide a paper certificate. The award itself is confirmation that CoC protections are in place. Additional information is available on the NIH CoC website, which includes FAQs on this topic.

Upon request, the NIH will issue CoCs for non-NIH funded studies. For more information, visit the NIH Certificate of Confidentiality (CoC) Kiosk. Any documents related to processing of the CoC that require the IO signature should go to the Executive Director for review and processing, before they are sent to the IO. The Executive Director will confirm all information is correct, before sending to the IO.

IMPORTANT: A copy of the signed informed consent document which includes the CoC disclosure language must be filed in the medical record to prevent unintentional disclosure by HIM pursuant to a request that does not require patient authorization (e.g. court subpoena).

DEVICE STUDIES

The PI must provide information in the IRB application to assess whether the investigator or sponsor determined that an IDE is required for a device study, if applicable. Additional supportive documentation is required in the application submission (e.g., letters from the FDA or sponsor).

The IDE regulations (21 CFR 812) apply to all clinical investigations to determine the safety and effectiveness of a medical device; unless the investigation meets the criteria for an IDE exemption (see IDE exempted investigations).

A medical device is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part or accessory that is:
- Listed in the online FDA database,
- Intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, in man or other animals, or
- Intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or
on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes [21 U.S.C. 321(h)].

A device that is substantially equivalent to a FDA approved device may have a 510(k) approval to demonstrate the device is safe and effective. Search the FDA 510(k) Database to determine the status of a device in the system.

Studies that involve devices, but do not evaluate the safety and effectiveness of the device, do not fall under the IDE regulations. However, the IRB still needs to ensure the risks are minimized by using procedures which are consistent with sound research methods or practice and which do not unnecessarily expose participants to risk, and whenever appropriate, by using procedures already being performed on the research participants for diagnostic or treatment purposes. If a device or scientific equipment is not FDA approved for the indicated use in the research, the IRB needs to assess whether it is safe to use in the study.

### IDE EXEMPTED INVESTIGATIONS

The IDE regulations (21 CFR 812) do not apply to investigations of the following categories of devices:

- A device, other than a transitional device, in commercial distribution immediately before May 28, 1976, when used or investigated in accordance with the indications in labeling in effect at that time.
- A device, other than a transitional device, introduced into commercial distribution on or after May 28, 1976, that FDA has determined to be substantially equivalent to a device in commercial distribution immediately before May 28, 1976, and that is used or investigated in accordance with the indications in the labeling FDA reviewed under subpart E of part 807 in determining substantial equivalence.
- A diagnostic device, if the sponsor complies with applicable requirements in 809.10(c) and if the testing:
  - Is noninvasive,
  - Does not require an invasive sampling procedure that presents significant risk,
  - Does not by design or intention introduce energy into the research participant,
  - Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure.
- A device undergoing consumer preference testing, testing of a modification, or testing of a combination of two or more devices in commercial distribution, if the testing is not for the purpose of determining safety or effectiveness and does not put the research participants at risk.
- A device intended solely for veterinary use.
- A device shipped solely for research on or with laboratory animals and labeled in accordance with 812.5(c).
- A custom device as defined in 812.3(b), unless the device is being used to determine safety or effectiveness for commercial distribution.

An exempted device study does not require an IND from the FDA, but requires IRB review.
DETERMINING WHICH DEVICE STUDIES POSE A SIGNIFICANT RISK OR NON-SIGNIFICANT RISK

The sponsor determines whether the investigation is a significant risk (SR) or non-significant risk (NSR). However, the IRB must concur with the determination before approving a study. A medical device study requires an IDE when:

- The investigation is designed to evaluate the safety and effectiveness of a medical device,
- An IDE has not been issued by the FDA, and
- The study is not IDE exempted.

FDA requires an IDE for a SR device study; however, an IRB can review a study that qualifies as a NSR device study (under abbreviated IDE requirements), provided the following:

- The device is not a banned device
- The FDA has NOT notified the sponsor that an IDE is required
- PI maintains the required records and reporting responsibilities to the FDA, 21 CFR 812, Subpart G and complies with the prohibitions against promotion and other practices described in 21 CFR 812.7.

The definition of a SR device is one that is:

- Intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a research participant;
- Purported or represented for supporting or sustaining human life and presents a potential for serious risk to the health, safety, and welfare of a research participant;
- For a use of substantial importance in diagnosing, curing, mitigating, or treating disease and presents a potential for serious risk to the health, safety, or welfare of a research participant; or
- Otherwise presents a potential for serious risk to the health, safety, or welfare of a research participant.

Examples of SR devices are dental lasers for hard tissue applications, vascular hemostasis devices, biliary stents, and collagen and bone replacements.

NSR devices are devices that do not pose a significant risk to human subjects. FDA does not have a specific definition for a NSR device.

**NOTE:** Do not confuse a NSR with minimal risk; a term used to identify certain studies that IRBs may approve through an expedited review procedure.

Sponsors are responsible for making the initial risk determination and presenting it to the IRB. The FDA is also available to help the sponsor, PI, and IRB in making the risk determination. Unless the FDA has already made a risk determination for the study, the IRB must review the sponsor’s SR or NSR determination for every investigational medical device study reviewed and modifies the determination if the IRB disagrees with the sponsor. If the FDA has already made the SR or NSR determination for the study, the FDA’s determination is final. For more information, see FDA guidance on SR and NSR Medical Device Studies.

RESPONSIBILITIES FOR DEVICE STUDIES
Consult the FDA website on IDE Responsibilities to understand the requirements of Sponsors, Investigators, and Monitors.

DRUGS AND BIOLOGICALS

The following applies to all research involving drugs and biologics:
- Conduct the research according to all regulatory guidelines and DMC’s policies and procedures.
- Obtain approval from the IRB before initiating any research activities.
- Comply with DMC’s Investigational Drug/Dispensing and Utilization policy (PHA-11).

INVESTIGATIONAL NEW DRUG (IND) REQUIREMENTS

When the principle intent of the investigational use of a test article is to develop information about the product’s safety or efficacy, an Investigational New Drug (IND) may be required. An IND goes into effect 30 days after the FDA receives the IND request, unless the sponsor receives earlier notice from the FDA.

The PI must provide information in the IRB application to assess whether the investigator or sponsor determined that an IND is required for a proposed study, if applicable. Additional supportive documentation is required in the application submission (e.g., letters from the FDA or sponsor).

Investigators must indicate on the IRB application whether the research involves drugs. If so, they must indicate whether an IND is required for the research. If so, they must provide evidence of the IND, which could be an:
- Industry sponsored protocol with IND.
- Letter from FDA.
- Letter from industry sponsor.
- Other document and/or communication verifying the IND.

The IRB reviewer verifies the IND number is consistent across documents. The IRB is not required to monitor the PI’s performance of required FDA paperwork.

If the research involves drugs and there is no IND, the PI must provide a rationale why it is not required, upon request from the IRB. The IRB may include a determination as to whether the research requires an IND and the IRB should document this determination in the IRB Minutes. The IRB may ask the PI to request a consultation from the FDA as to whether or not there is a need for an IND.

If the IRB requires an IND, it cannot grant approval until the PI provides one of the following:
- Documentation to confirm an IND number, or
- Documentation from the FDA indicating that the FDA does not require an IND.
IND EXEMPTION

The clinical investigation of a drug product lawfully marketed in the United States is exempt from the IND requirements if all the following apply:

- The investigation is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug;
- If the drug that is undergoing investigation is lawfully marketed as a prescription drug product, the investigation is not intended to support a significant change in the advertising for the product;
- The investigation does not involve a route of administration or dosage level or use in a patient population or other factor that significantly increases the risks (or decreases the acceptability of the risks) associated with the use of the drug product;
- The investigation is conducted in compliance with the requirements for institutional review and with the requirements for informed consent set forth 21 CFR parts 56 and 50, respectively; and
- The PI conducts the investigation in compliance with the requirements concerning the promotion and sale of drugs (21 CFR 312.7).

NOTE: The FDA does not require an IND for a placebo drug or for in vitro testing of a drug.

RESPONSIBILITIES ASSOCIATED WITH AN IND

- The PI must comply with the FDA Investigator’s Responsibilities for INDs;
- For investigator-initiated IND studies, the PI must comply with FDA Investigator Responsibilities for Investigator-Initiated IND Applications;
- If the sponsor terminates an investigation with an IND, inform the IRB and the Research Pharmacist;
- The PI will report to the sponsor any adverse effect that may reasonably be regarded as caused by, or probably caused by, the drug (21 CFR 312 (b)) according to the procedures in the protocol.

BIOAVAILABILITY AND BIOEQUIVALENCE RESEARCH

Clinical investigations for measuring bioavailability or demonstrating bioequivalence shall be subject to principles and requirements of 21 CFR 320.

RESEARCH INVOLVING ENDOGENOUS COMPOUNDS, LIVE ORGANISMS, COSMETICS, DIETARY SUPPLEMENTS, FOOD, FOOD-DERIVED PRODUCTS, SPICES, HERBS, OR ELECTRONIC CIGARETTES

Research using endogenous compounds (e.g., bradykinin, histamine, angiotensin), live organisms (e.g., virus, bacteria, or fungi, whether modified or wild-type), cosmetics dietary supplements, food, food-derived products, spices, herbs, or electronic cigarettes may be an important area of study, particularly, for better understanding, through rigorous scientific
investigation, of their mechanisms of actions, pharmacokinetic and clinical effects. Any DMC IRB application involving these materials must include either proof of an approved IND from the FDA, or a written statement, preferably from the FDA, certifying that FDA does not require an IND for the investigation.

For more information, see the following
- FDA Guidance for Clinical Investigators, Sponsors, and IRBS: INDS – Determining Whether Human research Studies Can Be Conducted Without an IND
- FAQs - Clinical Studies Involving Electronic Cigarettes and INDS

**GENE TRANSFER RESEARCH**

Gene transfer involves the administration of genetic material to alter the biological properties of living cells for therapeutic use. Gene transfer activities in humans are investigational and must meet the regulatory requirements of both FDA and the National Institutes of Health (NIH) Office of Biotechnology Activities (OBA). Prior to IRB approval of a research application and an informed consent involving gene transfer, obtain the following to submit to the IRB:
- IND for human gene transfer from the FDA,
- Approval of the U.S. Department of Health and Human Services (DHHS), NIH Recombinant DNA Advisory Committee (RAC), and
- Approval by the DMC Institutional Biosafety Committee (IBC).

**RESEARCH INVOLVING MARIJUANA (CANNABIS)**

In addition to obtaining IRB approval, conducting clinical research using marijuana (cannabis) involves interactions with three federal agencies, and the NYS DOH, including:
- Obtaining the marijuana for research from the National Institute on Drug Abuse (NIDA) within the National Institutes of Health;
- Review of an investigational new drug (IND) application and the research protocol by the Food and Drug Administration (FDA),
- An investigator registration and site licensure by the Drug Enforcement Administration (DEA),
- Obtaining a Class 7 Researcher (Individual) License from the NYSDOH Bureau of Narcotics Enforcement (BNE),
- Obtaining a Certificate of Confidentiality from the NIH, if the research is not NIH funded.

For more information, see the FDA Guidance on Marijuana research with Research Participants.

**PLANNED EMERGENCY HUMAN RESEARCH OR CLINICAL TRIALS**

Emergency research refers to the study of acute, life-threatening clinical situations that necessitates urgent intervention. Often, informed consent from the participants is not feasible because the participant lacks the capacity to provide their own consent (e.g., unconscious) and/or there is insufficient time because treatment must be promptly administered. The conduct of planned emergency human research or clinical trials in life-threatening emergent situations requires special consideration by the IRB, including consideration of whether to grant an exception from informed consent requirements for emergency research.
EXCEPTION FORM INFORMED CONSENT REQUIREMENTS FOR EMERGENCY RESEARCH

The IRB may review and approve a clinical investigation without requiring informed consent of all research participants, if the IRB (with the concurrence of a licensed physician who is a member of or consultant to the IRB and who is not otherwise participating in the clinical investigation) finds and documents each of the following:

(1) The research participants are in a life-threatening situation, available treatments are unproven or unsatisfactory, and the collection of valid scientific evidence, which may include evidence obtained through randomized placebo-controlled investigations, is necessary to determine the safety and effectiveness of particular interventions.

(2) Obtaining informed consent is not feasible because:

   (i) The research participants will not be able to give their informed consent as a result of their medical condition;

   (ii) The intervention under investigation must be administered before consent from the research participants’ legally authorized representatives is feasible; and

   (iii) There is no reasonable way to identify prospectively the individuals likely to become eligible for participation in the clinical investigation.

(3) Participation in the research holds out the prospect of direct benefit to the research participants because:

   (i) Research participants are facing a life-threatening situation that necessitates intervention;

   (ii) Appropriate animal and other preclinical studies have been conducted, and the information derived from those studies and related evidence support the potential for the intervention to provide a direct benefit to the individual research participants; and

   (iii) Risks associated with the investigation are reasonable in relation to what is known about the medical condition of the potential class of research participants, the risks and benefits of standard therapy, if any, and what is known about the risks and benefits of the proposed intervention or activity.

(4) The clinical investigation could not practicably be carried out without the waiver.

(5) The proposed investigational plan defines the length of the potential therapeutic window based on scientific evidence, and the investigator has committed to attempting to contact a legally authorized representative for each research participant within that window of time and, if feasible, to asking the legally authorized representative contacted for consent within that window rather than proceeding without consent. The investigator will summarize efforts made to contact
legally authorized representatives and make this information available to the IRB at the time of continuing review.

(6) The IRB has reviewed and approved informed consent procedures and an informed consent document consistent with 50.25. These procedures and the informed consent document are to be used with research participants or their legally authorized representatives in situations where use of such procedures and documents is feasible. The IRB has reviewed and approved procedures and information to be used when providing an opportunity for a family member to object to a research participant’s participation in the clinical investigation consistent with paragraph (7)(v) below.

(7) Additional protections of the rights and welfare of the research participants will be provided, including, at least:

(i) Consultation (including, where appropriate, consultation carried out by the IRB) with representatives of the communities in which the clinical investigation will be conducted and from which the research participants will be drawn;

(ii) Public disclosure to the communities in which the clinical investigation will be conducted and from which the research participants will be drawn, prior to initiation of the clinical investigation, of plans for the investigation and its risks and expected benefits;

(iii) Public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study, including the demographic characteristics of the research population, and its results;

(iv) Establishment of an independent data monitoring committee to exercise oversight of the clinical investigation; and

(v) If obtaining informed consent is not feasible and a legally authorized representative is not reasonably available, the investigator has committed, if feasible, to attempting to contact within the therapeutic window the research participant’s family member who is not a legally authorized representative, and asking whether he or she objects to the research participant’s participation in the clinical investigation. The investigator will summarize efforts made to contact family members and make this information available to the IRB at the time of continuing review.

The IRB is responsible for ensuring that procedures are in place to inform, at the earliest feasible opportunity, each participant, or if the participant remains incapacitated, a legally authorized representative of the participant, or if such a representative is not reasonably available, a family member, of the participant's inclusion in the clinical investigation, the details of the investigation and other information contained in the informed consent document. The IRB shall also ensure that there is a procedure to inform the participant, or if the participant remains incapacitated, a legally authorized representative of the participant, or if such a representative is not reasonably available, a family member, that he or she may discontinue the participant's participation at any time without penalty or loss of benefits to which the participant is otherwise entitled. If a legally authorized representative or family member is told about the clinical investigation and the participant's condition improves, the participant is also to be informed as soon as feasible. If a participant is entered into a clinical investigation with waived consent and the participant dies before a legally authorized representative or family member can be contacted, information about
the clinical investigation is to be provided to the participant's legally authorized representative or family member, if feasible.

The IRB determinations required by paragraph (a) of this section and the documentation required by paragraph (e) of this section are to be retained by the IRB for at least 3 years after completion of the clinical investigation, and the records shall be accessible for inspection and copying by FDA in accordance with 56.115(b) of this chapter.

Protocols involving an exception to the informed consent requirement under this section must be performed under a separate investigational new drug application (IND) or investigational device exemption (IDE) that clearly identifies such protocols as protocols that may include participants who are unable to consent. The submission of those protocols in a separate IND/IDE is required even if an IND for the same drug product or an IDE for the same device already exists. Applications for investigations under this section may not be submitted as amendments under 312.30 or 812.35.

If an IRB determines that it cannot approve a clinical investigation because the investigation does not meet the criteria in the exception provided under paragraph (a) of this section or because of other relevant ethical concerns, the IRB must document its findings and provide these findings promptly in writing to the clinical investigator and to the sponsor of the clinical investigation. The sponsor of the clinical investigation must promptly disclose this information to FDA and to the sponsor's clinical investigators who are participating or are asked to participate in this or a substantially equivalent clinical investigation of the sponsor, and to other IRB's that have been, or are, asked to review this or a substantially equivalent investigation by that sponsor.

For additional guidance, see:

- FDA 21 CFR 50.24: Exception from Informed Consent (EFIC) Requirements for Emergency research
- FDA Website: Protection of Research Participants; Informed Consent and Waiver of Informed Consent Requirements in Certain Emergency research
- FDA Guidance on Exception from Informed Consent Requirements for Emergency research
- OHRP Guidance: Informed Consent Requirements in Emergency research, for research not subject to FDA regulations

**ENROLLMENT LIST**

Upon request, provide an enrollment list to the IRB, DMC Leadership, auditors, or government inspectors, unless the IRB waived documentation of informed consent under the condition that the only record linking the participant to the research is the informed consent form and the primary risk would be potential harm resulting from a breach of confidentiality.

At a minimum, this list should include the names of participants and their medical record number, if the research participants are also patients. The enrollment list should not be provided to anyone that is not otherwise listed above or in an IRB approved HIPAA instrument. The IRB,
Privacy Officer, or Data Security Officer may use the enrolment list to notify research participants of possible breaches or concerns that might occur in the research.

TIP: If the IRB waives documentation of informed consent, the investigator signature and a witness signature may be included on an enrollment list, when there is IRB approval to enroll cognitively impaired adults or those with limited English proficiency.

MEDICAL RECORD RESEARCH NOTE FOR CLINICAL TRIALS

The research team must place a research note in the electronic medical record (EMR) when enrolling a research participant into a clinical trial involving an IND or IDE at DMC who is also a patient. This helps ensure clinicians and the pharmacy aware of contraindications.

When a standard research note is not part of the programing within the EMR, the research team must enter the following information manually:

- IRB study number
- Study name
- Sponsor
- Principal Investigator
- Main contact information for the study
- Date the patient was enrolled
- Known contraindications
- Anticipated length of study period (years)

For areas that do not use an EMR, the research team must place the above information in the beginning of the paper medical records.

External institutions may have their own requirements about research notes.

LEGALLY EFFECTIVE INFORMED CONSENT AND HIPAA RESEARCH AUTHORIZATION

REQUIREMENTS

Investigators conducting non-exempt human research under the auspices of DMC may involve participants after (s)he or his/her LAR/surrogate, or parent/guardian provides prospective legally effective informed consent/permission (and HIPAA Authorization, when PHI is involved), unless the waiver of such requirements has been approved by IRB.

Assent and (or documentation of assent, when required) of a child or a cognitively impaired adult must also be obtained, unless waived by the IRB.
The IRB will evaluate both the consent process and the procedures for documenting informed consent to ensure that both are adequate.

The following procedures describe the requirements for obtaining consent from participants in research conducted at DMC.

**LEGALLY AUTHORIZED REPRESENTATIVE (LAR) OR SURROGATE**

For the purposes of this policy, a *legally authorized representative (LAR, personal representative or legally empowered representative or surrogate)* is an individual, judicial, or other body authorized under applicable law to provide consent on behalf of an adult prospective research participant for the research participation of an adult who is cognitively impaired and unable to provide consent. A LAR is an individual authorized to provide permission on behalf of a prospective research participant to be involved in the research.

Base the designation of a LAR in individual cases on the presence or absence of a power of attorney, living will, or health care proxy (as above).

The informed consent process must comply with institutional policy. For research at Downstate, this includes Policy CONS-01. Only one person from the list below, from the class of highest in priority may authorize the research when persons in prior classes are not reasonably available. The surrogate must be willing and competent to act. The person who is designated may designate another person on the list to be surrogate, as long as no one in the class higher in priority objects. However, if one surrogate does not provide consent, the investigator must honor that decision and not seek consent from another surrogate on the list.

- Healthcare Agent (legal guardian) with authority to provide consent to healthcare decisions (highest priority)
- Guardian authorized to decide about health care, pursuant to Article 81 of the NYS Mental Hygiene law
- Spouse or domestic partner (provided there is no legal separation)
- Adult child (son or daughter)
- Parent
- Adult sibling (brother or sister)
- Close adult friend (must be 18 years or older and present a signed statement of relationship to a patient/participant) (lowest priority)

**FORM REQUIREMENTS FOR INFORMED CONSENT AND HIPAA RESEARCH AUTHORIZATION**

**TIP:** Informed consent is a “PROCESS,” not just a FORM!!!

This section focuses on the regulatory requirements for the “form”.
Please review additional IRB Guidance on the “process” for obtaining legally effective informed consent and HIPAA Authorization.

INFORMED CONSENT REQUIREMENTS

Please refer to IRB templates to ensure all required components are included in the document for submission to the IRB.

Except as provided elsewhere in this policy, an investigator may not involve a participant in research covered by this policy, unless the investigator has obtained the legally effective informed consent of the research participant or his/her LAR/surrogate. An investigator shall seek such consent only under circumstances that provide the prospective participant or the LAR/surrogate sufficient opportunity to discuss and consider whether to participate and that minimize the possibility of coercion or undue influence. The investigator must provide the prospective research participant or LAR/surrogate with the information that a reasonable person would want to have in order to make an informed decision about whether to participate, and an opportunity to discuss that information. The investigator must provide the information to the participant or the LAR/surrogate in a language understandable to the participant or the representative. No informed consent may include any exculpatory language through which the participant or the LAR/surrogate is made to waive or appear to waive any of the participant’s legal rights, or releases or appears to release the investigator, the sponsor, the institution or its agents from liability for negligence.

The following applies to research initially approved under this policy and to any research that transitions to this policy:

- Informed consent must begin with a concise and focused presentation of the key information that is most likely to assist a prospective research participant or LAR/surrogate in understanding the reasons why one might or might not want to participate in the research. This part of the informed consent must be organized and presented in a way that facilitates comprehension.

- Informed consent as a whole must present information in sufficient detail related to the research, and must be organized and presented in a way that does not merely provide lists of isolated facts, but rather facilitates the prospective research participant’s or LAR/surrogate’s understanding of the reasons why one might or might not want to participate.

BASIC ELEMENTS OF INFORMED CONSENT

When seeking informed consent, include the following basic elements to each prospective participant (unless waived by the IRB):

- A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the participant’s participation, a description of the procedures to be followed, and identification of any procedures that are experimental;

- A description of any reasonably foreseeable risks or discomforts to the participant;
• A description of any benefits to the research participants or to others that may reasonably be expected from the research;
• A disclosure of appropriate alternative procedures or courses of treatment, if any alternatives are available, that might be advantageous to the research participant;
• A statement describing the extent, if any, to which confidentiality of records identifying the participant will be maintained and that notes the possibility that the Food and Drug Administration may inspect the records (if the research is FDA regulated);
• For research involving more than minimal risk, an explanation as to whether there is any compensation for potential study-related injury and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained;
• An explanation of whom to contact for answers to pertinent questions about the research and research participants’ rights, and whom to contact in the event of a research related injury to the participant;
• A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the participant is otherwise entitled, and that the participant may discontinue participation at any time without penalty or loss of benefits to which the participant is otherwise entitled.
• Include either of the following statements for research that involves the collection of identifiable private information or identifiable biospecimens:
  o A statement that identifiers might be removed from the identifiable private information or identifiable biospecimens and that, after such removal, the information could be used for future research studies or distributed to another investigator for future research studies without additional informed consent from the research participant or LAR/surrogate, if this might be a possibility; or
  o A statement that the research participant’s information or biospecimens collected as part of the research, even if identifiers are removed, will not be used or distributed for future research studies.
• When seeking informed consent for an “Applicable Clinical Trial”, as defined FDA Amendments Act of 2007 (FDAAA); the following statement must be included in the informed consent documents and should be included in the information sheet, when documentation of informed consent is waived by the IRB: “A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”

HIPAA AUTHORIZATION

Include HIPAA authorization language with the informed consent to cover the uses and disclosures of Protected Healthcare Information (PHI) or Individual Identifiable Healthcare Information (IIHI), including when such information is about specimens.

The following core elements must be present in plain language for a research authorization to be valid:
• A specific and meaningful description of the PHI to be used or disclosed
  Note: The minimum necessary rule does not apply to Authorizations; however, Downstate encourages the investigators to limit the PHI to the minimal necessary PHI that is reasonably necessary to accomplish the purpose of the research.
The name or identification of the person(s) or class of person(s) authorized to make the use or disclosure of PHI. For example, who will disclose the PHI? (e.g., UHB, NYC H+H, Kings County, other hospitals, practice groups, etc.)

The identification of the persons or class of persons to whom the covered entity is authorized to make the disclosure. For example, what internal or external persons or entities will be receiving PHI?

Description of each purpose for which the specific PHI identified earlier is to be used or disclosed

An expiration date or event (this must be a certain date or an event tied to the individual). For example, a statement providing that the authorization will expire on a specific date, after a specific amount of time, or upon occurrence of some event related to the research participant. (e.g., “at the completion of the research”)

The individual’s signature and date, and if signed by a personal representative, a description of his or her authority to act for the individual (e.g., required when recruiting children or cognitively impaired adults).

The following statements must be included:

A statement that the individual may revoke the authorization in writing at any time (except to the extent that a provider has taken action in reliance of the authorization), and instructions on how to exercise such right (who does the individual need to write, name and address)

A statement that treatment, payment, enrollment, or eligibility for benefits may not be conditioned on obtaining the authorization if such conditioning is prohibited by the Privacy Rule or, if conditioning is permitted, a statement about the consequences of refusing to sign the authorization.

Note: The PI may condition healthcare on the provision of the authorization for research related treatment (e.g., clinical trial), in which case the provider may refuse to provide the research related healthcare if the research participant refuses to execute the authorization.

A statement about the potential for the PHI to be re-disclosed by the research team (e.g., to another organization) and no longer protected by the Privacy Rule

Suggested language is included in the informed consent template posted on the IRB website. There are additional requirements for authorizations for using PHI for marketing purposes, sale of PHI, or for the use or disclosure of psychotherapy notes. Contact the IRB or Privacy Officer for additional information or refer to SUNY Downstate HIPAA (Health Insurance Portability and Accountability Act) Policies and Forms.

For additional information see:

- DMC HIPAA-28 Policy: Uses and Disclosures for Research Purposes

EU GENERAL DATA PROTECTION REGULATION (GDPR) REQUIREMENTS

The European Union General Data Protection Regulation (EU GDPR), effective May 25, 2018, is a data privacy regulation that may apply to some DMC research including research conducted in the European Union (EU), research sponsored by an EU entity, or research involving transmission of protected data within the EU.
The U.S. Office of Human Research Protections (OHRP) released a completion of guidance on EU GDPR and the Secretary’s Advisory Committee on Human Research Protections (SACHRP) released recommendations related to the GDPR.

For assistance with determining whether the GDPR regulations apply to a study, please contact the Sponsor of the study, the IRB Office, OCAS, or the Downstate Privacy Officer. The investigator should work with the sponsor of the study to include the appropriate GDPR disclosures within an informed consent document. Before approval, the IRB will generally consult with OCAS or the Privacy Officer to ensure the required disclosures are appropriately included in the informed consent document (or an addendum) for the study.

**ADDITIONAL ELEMENTS OF INFORMED CONSENT**

When appropriate, include one or more of the following additional elements in the informed consent document:

- A statement that the particular treatment or procedure may involve risks that are currently unforeseeable to the participant (or to the embryo or fetus, if the participant is or may become pregnant);
- Anticipated circumstances under which participation in the research may be terminated by the investigator without regard to the research participant’s or LAR/surrogate’s consent;
- Any additional costs to the participant that may result from participation in the research;
- The consequences of a participant’s decision to withdraw from the research and procedures for orderly termination of participation;
- A statement that significant new findings developed during the course of the research that may relate to the participant’s willingness to continue participation will be provided to the participant;
- The number of participants (approved by the IRB) to be involved in the study. For multi-site studies, it is best to indicate both the number that will be enrolled at the local site and all sites.

- **When applicable to the research include the following:**
  - A statement that the research participant’s biospecimens (even if identifiers are removed) may be used for commercial profit and whether the research participant will or will not share in this commercial profit;
  - A statement regarding whether clinically relevant research results, including individual research results, will be disclosed to research participants, and if so, under what conditions; or
  - For research involving biospecimens, whether the research will (if known) or might include whole genome sequencing (i.e., sequencing of a human germline or somatic specimen with the intent to generate the genome or exome sequence of that specimen).
  - Any requirements of any applicable federal, state, or local law.
  - Any requirements of any applicable tribal law passed by the official governing body of an American Indian or Alaska Native tribe.

**ELEMENTS OF INFORMED CONSENT FOR DIAGNOSTIC GENETIC TESTS**
The IRB recommends using a tiered consent option for diagnostic genetics test that is part of the informed consent template.

For studies involving genetic testing (or possible genetic testing) for diagnostic purposes (e.g., any laboratory test of human DNA, chromosomes, genes, gene products, or DNA profile analysis to diagnose the presence of a genetic variation linked to a predisposition to a genetic disease or disability in the individual or the individual’s offspring), include the elements of informed consent described below.

- A general description of the test;
- A statement of the purpose of the test;
- A statement indicating that the individual may wish to obtain professional genetic counseling prior to signing the informed consent;  
  \textit{NOTE: Information about specific genetic test results on stored specimens cannot be disclosed to the individual or others without obtaining informed consent for the disclosure.}
- The name of the person or categories of persons or organizations to whom the test results may be disclosed;
- A statement the only tests authorized on the specimen are performed and the specimen is destroyed at the end of the testing process or not more than sixty (60) days after the sample was taken, unless a longer period of retention is expressly authorized in the consent.

If the research permits such degree of specificity, include the following:

- A statement that a positive test result is an indication that the individual may be predisposed to or have the specific disease or condition tested for and may wish to consider further independent testing, consult their physician or pursue genetic counseling;
- A general description of each specific disease or condition tested for;
- The level of certainty that a positive test result for that disease or condition serves as a predictor of such disease.
- A description of the policies and procedures to protect patient confidentiality;
- A statement of the right to withdraw consent to use of the specimen for future use at any time and the name of the organization that should be contacted to withdraw consent;
- A statement allowing individuals to consent to future contact for any or all purposes, including the following:
  - research purposes;
  - provision of general information about research findings; and
  - information about the test on their sample that may benefit them or their family members in relation to their choices regarding preventive or clinical care; and
  - a statement explaining the benefits and risks of consenting to future contact.

\begin{table}[h]
\centering
\begin{tabular}{|l|}
\hline
FUTURE USE OF SPECIMENS OR INFORMATION \hline
\end{tabular}
\end{table}

Specify whether specimens or information will be stored for future studies. See Informed Consent template for suggested language.

In general, the IRB does not permit “unspecified future use.” Present the use or disclosure of identifiable (or coded) information/specimens for future either as an optional provision (e.g., tiered consent) or as a separate optional consent form. Provide an
adequate description of the future indications or purposes so that it would be reasonable for the research participant to expect the use or disclosure of his/her Protected Health Information (PHI) for such future research.

Note: Unless legally permissible or authorized, additional IRB approval of future research may be required, at which time the IRB can determine if a new consent or HIPAA Authorization, waivers, or Data Use Agreement is be required for future research.

If applicable, include an option for future contact to invite participates to consider other research.

**CONSENT ADDENDUM FOR SUNY RF PAYMENT**

Include the Consent Addendum for SUNY RF Payment with an IRB submission when providing compensation (not including travel reimbursements) to research participants of $600 or more per calendar year, when the SUNY RF processes payments to the participants. The IRB stamps the form specific to a study, once approved.

Note: This form is not required when using a commercial vendor (e.g., credit card payment vendor) for processing payments and reporting income to the Internal Revenue Service.

**POSTING CONSENT FORMS FOR A FEDERALLY CONDUCTED OR FUNDED CLINICAL TRIAL TO A FEDERAL WEBSITE**

The Common Rule defines a Clinical Trial as a research study in which one or more research participants are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

For each clinical trial, as defined (see paragraph above) by the Common Rule, conducted or supported by a Federal department or agency, the awardee or the Federal department or agency component conducting the trial must post one IRB-approved informed consent form used to enroll research participants on a publicly available Federal Web site established as a repository for such informed consent forms. This posting must take place after the clinical trial is closed to recruitment and no later than 60 days after the last study visit by any research participant, as required by the protocol.

A Federal department or agency supporting or conducting the clinical trial may determine that certain information should not be made publicly available on a Federal Web site (e.g. confidential commercial information), and may permit or require redactions to the information posted.

The following websites are available for posting the consent form:

- [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), or
BROAD CONSENT FOR STORAGE, MAINTENANCE, AND SECONDARY RESEARCH OF IDENTIFIABLE PRIVATE INFORMATION OR IDENTIFIABLE BIOSPECIMENS

The DMC IRB will not approve research under exemption categories 7 or 8, as this time.

Please follow the current requirements for obtaining consent or waivers to store, maintain or use such identifiable private information or identifiable specimens for research purposes. Contact the IRB for additional information, when needed.

OBTAINING INFORMED CONSENT FROM INDIVIDUALS WITH LIMITED ENGLISH-SPEAKING PROFICIENCY (LEP)

The information given to the research participant or the representative shall be in language understandable to the research participant or the representative.

Unless waived by the IRB, the consent form may be either of the following, as approved by the IRB:

- A written informed consent document that meets all the requirements outlined above. The investigator shall give either the participant or the LAR/surrogate adequate opportunity to read the informed consent form before it is signed; alternatively, this form may be read to the research participant or the LAR/surrogate.
- A short (written informed consent) form stating that the elements of informed consent required above have been presented orally to the participant or the participant’s LAR/surrogate and that key information that is most likely to assist a prospective research participant or LAR/surrogate in understanding the reasons why one might or might not want to participate in the research was presented first to the research participant, before other information, if any, was provided.
- When this method is used, there shall be a witness to the oral presentation.
- Also, the IRB shall approve a written summary, if the entire consent is not read, of what is to be said to the research participant or the representative.
- The short form itself is to be signed by the participant or the representative.
- The witness shall sign both the short form and a copy of the summary (or consent form), and the person obtaining consent shall sign a copy of the summary (or consent form).
- A copy of the summary (if used) and the consent form shall be given to the participant or the representative, in addition to a copy of the short form.

For additional guidance, including how to obtain translations, please refer to the IRB Guidance document on Obtaining Legally Effective Informed Consent and HIPAA Research Authorizations.

INFORMED CONSENT PROCESS

The IRB evaluates and ensures the informed consent process is adequate and determines whether informed consent is documented and sought in accordance with regulations and policies.
based on information provided in the IRB application materials, including the IRB application and protocol.

**WAIVING THE REQUIREMENTS OF INFORMED CONSENT OR HIPAA AUTHORIZATION**

Most prospective human research requires a legally effective informed consent process, including the documentation of a signed (including in an electronic format) consent from the participants (or LAR/surrogate); however, when certain criteria are met, the IRB may grant a waiver of the informed consent or pediatric assent requirements. The PI must provide written justification for how the criteria can be met or the IRB can make this determination based on the information available in the protocol or IRB application materials. Requests for waivers of informed consent/assent requirements are not required if the research is considered exempt; however, a HIPAA waiver or HIPAA Authorization may still be required, for research involving PHI.

There are several types of waiver requests, as outlined below.

**WAIVER OF THE PROCESS FOR INFORMED CONSENT**

The PI may request to waive the entire process of consent (including documentation) for example, when the research involves review of retrospective data (i.e., medical charts).

For research, including FDA regulated clinical investigations, the criteria for waiving informed consent or elements of informed consent are as follows:

1. The research involves no more than minimal risk to the research participants;
2. The research could not practicably be carried out without the requested waiver or alteration;
3. **If the research involves using identifiable private information or identifiable biospecimens, the research could not practicably be carried out without using such information or biospecimens in an identifiable format**;
4. The waiver or alteration will not adversely affect the rights and welfare of the participants;
5. Whenever appropriate, the research participants or LARs/surrogates will be provided with additional pertinent information after participation (e.g., debriefing research participants involved in deception research).

The IRB cannot waive the requirement to obtain informed consent for research under which broad consent is required to be obtained.

For federally supported or conducted research or demonstration projects to be conducted by or subject to the approval of state or local government officials (e.g., research approved by the HHS Secretary, NYS DOH, etc.), the criteria for waiving informed consent or elements of informed consent are as follows:
1. The research or demonstration project is to be conducted by or subject to approval of state or local government officials and is designed to study, evaluate, or otherwise examine:
   a. public benefit or service programs;
   b. procedures for obtaining benefits or services under those programs;
   c. possible changes in or alternatives to those programs or procedures; or
   d. possible changes in methods or levels of payment for benefits or services under those programs; and
2. The research could not practicably be carried out without the waiver or alteration.

**WAIVER OF PARENTAL PERMISSION**

If the IRB determines that a research protocol is designed for conditions or for a population for which parental or guardian permission is not a reasonable requirement to protect the research participants (for example, neglected or abused children), it may waive the consent requirements, provided an appropriate mechanism for protecting the children participating in the research is substituted, and provided further that the waiver is not inconsistent with federal, state, or local law. The choice of an appropriate mechanism would depend upon the nature and purpose of the activities described in the protocol, the risk and anticipated benefit to the research participants, and their age, maturity, status, and condition.

**WAIVERS OF CHILD ASSENT**

Request a waiver of child assent when the capability of some or all of the children is so limited that it is not reasonable to consult the child regarding consent. The PI must provide justification for this type of waiver.

A request to waive child assent may be made when the intervention or procedure involved in the research holds out a prospect of direct benefit that is important for the health and well-being of the children, and is only available in the context of an FDA regulated clinical investigation (even if the IRB determines the children are capable of assenting). The IRB can approve a waiver when the PI provide justifications to meet the following criteria:

- The clinical investigation involves no more than minimal risk to the research participants;
- The waiver or alteration will not adversely affect the rights and welfare of the participants;
- The clinical investigation could not practicably be carried out without the waiver or alteration; and
- Whenever appropriate, the research participants will be provided with additional pertinent information after participation.
- The permission of the parent(s)/guardian(s) will be documented in accordance with informed consent requirements.

**WAIVER OF DOCUMENTATION OF INFORMED CONSENT**

Request a waiver of documentation of informed consent to obtain (verbal) informed consent without documentation (e.g., signed informed consent). When requesting this type of waiver, the IRB generally requires the investigator to provide an information sheet to the research participant.
The IRB may approve a request to waive documentation of informed consent when it meets the one of the following criteria:

- The research is no greater than minimal risk and involves no procedures for which written consent is normally required outside of the research context, OR
- The only record linking the participant to the research is the informed consent form and the primary risk would be potential harm resulting from a breach of confidentiality. Under this condition, each participant (or LAR/surrogate) must be asked whether (s)he wants to sign documentation linking her/him to the research and her/his wishes will govern, OR
- For research which is not regulated by FDA or DOJ, the IRB may waive documentation of informed consent, if the research participant (or LAR/surrogate) are members of a distinct cultural group or community in which signing forms is not the norm, that the research presents no more than minimal risk of harm to participants and provided there is an appropriate alternative mechanism for documenting that informed consent was obtained.

If the study involves PHI, a HIPAA Authorization with a signature must be included, unless the IRB approves a HIPAA alteration (see below). It is permissible to combine a HIPAA Authorization with the Information Sheet.

**WAIVER OF REQUIRED ELEMENTS OF INFORMED CONSENT**

Request a waiver when the research cannot include all of the required elements of informed consent; however, when broad consent is used, none of the required elements of broad consent may be waived. This is requested when the PI does not wish to include all the required elements in the informed consent document (i.e., cannot disclose purpose of the research, for a project involving deception). The waiver must meet the criteria listed on the waiver request form.

**HIPAA WAIVERS**

The IRB may approve the uses and disclosures of PHI for research purposes when the investigator submits a HIPAA Waiver (of the HIPAA research authorization requirement). If the IRB approves a partial HIPAA waiver (e.g., for recruitment purposes), the IRB conditions the use or disclosure upon compliance with any HIPAA research authorization requirements not waived (e.g., obtaining a HIPAA authorization once consent is obtained).

The requested waiver must satisfy all of the following criteria:

- The use or disclosure involves no more than a minimal risk to the privacy of the research participants because:
  - There is an adequate plan to protect the “identifiers” from improper use or disclosure. Refer to DMC Policy on De-Identification of Information (HIPAA-6) for the types of information considered to be identifiers;
  - There is an adequate plan to destroy the identifiers at the earliest opportunity, unless there is a health or research justification for retaining the identifiers or their retention is required by law; and
  - There are adequate written assurances that the protected health information (PHI) will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research study or for other research for which the use or disclosure of PHI is otherwise permitted.
• The research could not practicably be conducted without the waiver—research involving
treatment will almost never be eligible since most clinical trials could practicably be
carried out without a waiver; and
• The research could not practicably be conducted without access to and use of the PHI—If
de-identified information or a limited data set can practicably be used, a waiver of
authorization should not be granted.

The PI should submit the request for waiver using the HIPAA Waiver of Authorization Form. The
IRB will review and approve the waiver, if appropriate, under either normal or expedited review
procedures. Refer to DMC Policy Uses and Disclosures for Research Purposes (HIPAA-28) for
more information.

The section below described the three types of HIPAA Waivers (full, partial, and alteration).

FULL HIPAA WAIVER

A Full HIPAA Waiver removes the requirement to obtain a HIPAA research authorization from
research participants for the use and disclosure of their PHI to conduct a study. Examples where
this is appropriate include:
• Retrospective chart reviews, or
• Exempt research involving PHI, when it is impracticable to obtain a HIPAA research
authorization

When applicable, the IRB may use the information in the HIPAA waiver to grant a waiver of
informed consent.

PARTIAL HIPAA WAIVER

Request a Partial HIPAA Waiver to review PHI for recruitment purposes; however, include the
HIPAA research authorization language within an informed consent document that uses
subsequent PHI.

HIPAA ALTERATION

A HIPAA Alteration is a type of HIPAA waiver that when approved permits the use of a research
authorization that does not contain all of the required elements or statements (e.g., signature or
another element), or that otherwise deviates from the format or process prescribed by the HIPAA
regulations. This may be useful, for example, when a PI is also seeking waiver of documentation
of informed consent, when the only link of a participant to a study is their signature on a consent
form and HIPAA research authorization, if it can be considered impracticable to the study’s
completion to obtain a signed research authorization form as such a requirement might prevent
study completion.

There also may be other circumstances where a simplified consent and authorization document
are appropriate given the nature of the population enrolling in the research and in these cases a
request to waive certain but not all elements or required statements of the authorization would be
made.
SCREENING, RECRUITING, OR DETERMINING ELIGIBILITY

CAUTION: This section does not apply to FDA or DOJ regulated research.

The DMC IRB may approve a research protocol in which an investigator will obtain information or biospecimens for screening, recruiting, or determining the eligibility of prospective research participants or the LAR/surrogate, when one of the following conditions are met; however, a HIPAA waiver may still be required, as noted above:
- The investigator will obtain information through oral or written communication with the prospective research participant or the LAR/surrogate, OR
- The investigator will obtain identifiable private information or identifiable biospecimens by accessing records or stored identifiable biospecimens.

DISTRIBUTION OF COPIES OF SIGNED INFORMED CONSENT MATERIALS

The following is a summary of the distribution requirements for informed consent materials:
- Signed Original: research file, secure and readily retrievable
- Copies to:
  - Person authorizing the research
  - Medical Record, if clinical trial (unless the IRB determines that it is not in the best interest of the patient or when a Certificate of Confidentiality is obtained)

ANCILLARY REVIEWS

Ancillary reviews by various departments or committees may be required as an administrative process for Downstate policy or at the discretion of the IRB for any human research protection concern. Examples of Ancillary Reviews may include Scientific Review Committee (SRC), Institutional Biosafety Committee (IBC), Radiation Safety, Radiology, Pharmacy, and UHB Pathology.

To determine if an ancillary review is required prior to IRB approval of a specific project, other than noted below, please consult the IRB website, contact the IRB, or refer to the policies of the above committees or departments. The IRB requires the following ancillary reviews in advance of granting IRB approval for the specific conditions noted below:

- **Downstate Department Chair or Dean Review:**
  - The Downstate Department Chair of Dean must review the following types of applications, prior to IRB approval:
    - IRB Applications for Exempt review, Expedited review, Full Board review, or External IRB Oversight
    - Application for a HUD for Clinical Purposes
    - Application for Expanded Access to Investigational Drug/Biologic for treatment
  - The IRB will ensure notification of the Downstate Department Chair or Dean of approvals when an IRB Decision Aid (Application for Determination Letter to
State IRB Approval is NOT required, if (s)he did not previously perform an ancillary review of the application.

- **Scientific (or Scholarly) Review** is required prior to IRB approval of the following types of research projects:
  - The following types of studies must undergo SR by the SUNY Downstate Cancer Program/Institute SRC, regardless of level of IRB review (e.g., full board, expedited, exempt, external IRB review):
    - Any cancer-related study involving the prospective enrollment of research participants at SUNY Downstate.
    - Prospective studies of tissue and/or body fluids with a scientific hypothesis related to cancer.
    - Studies in which the eligibility criteria requires a cancer diagnosis regardless if the study’s focus is cancer or not.
    - All interventional studies involving cancer prevention.
    - Research that includes individuals with cancer, individuals at risk for cancer, or individuals in a study involving a specific cancer focus (e.g., program evaluations, quality of life, and health education).
  - Unless otherwise noted above, the following IRB applications must undergo SR review, by a Downstate SRC:
    - Full Board Applications
    - Expedited Review Applications that qualify for research reviewed under categories (1A) or (1B) (e.g., studies involving a drug, biologic, or medical device).

**Note:** Unless otherwise required by the Department Chair or Dean, the IRB does NOT require Downstate SR review on the following activities, (except SR is required for all cancer studies):

- Application for Exempt Review;
- Application for Expedited Review, unless the research reviewed under categories (1A) or (1B) (e.g., studies involving a drug, biologic, or medical device);
- IRB Decision Aid – Application for a Determination Letter to State IRB Approval is NOT Required;
- Application for Humanitarian Use Device (HUD) for Clinical Purposes;
- Application for Expanded Access to Investigational Drug/Biologic for Treatment Use; or
- Application for External IRB Oversight, unless local SR is required by the external IRB.

- **Downstate Institutional Biosafety Committee (IBC) review and the NIH Recombinant DNA Advisory Committee (RAC) review** is required prior to IRB approval for any study that involves human gene therapy or any deliberate transfer of recombinant or synthetic nucleic acid molecules, or DNA or RNA derived from recombinant or synthetic nucleic acid molecules into one or more human research participants.

**Note:** IBC approval may be required for other activities, prior to starting the research. Refer to IBC policy or IRB guidance on the IRB application or IRB website for additional details.
**UHB pathology review** is required *prior to IRB approval* when patient material obtained for research will affect the clinical care of a patient (e.g., if the research proposes a surgical sample is divided for research and clinical purposes), as determined on a case by case basis by either the IRB or UHB Pathology.

*Note: UHB pathology approval may be required for other activities, prior to starting the research. Refer to UHB policy or IRB guidance on the IRB application or IRB website for additional details.*

- **Downstate Pharmacy Review** is required *prior to IRB approval* for clinical investigations at Downstate that involves an IND.

*Note: Downstate Pharmacy reviews for other studies involving a drug, including biologic can take place after IRB approval. Refer to Downstate Pharmacy policy or IRB guidance on the IRB application or IRB website for additional details.*

- **Any ancillary review required by the IRB not otherwise noted above** when the IRB determines there is a human research protection concern that requires the ancillary review. Examples may include the following:
  - The IRB may request Radiology review or Radiation Safety review for concerns with the risk or level of radiation exposure of a research participant.
  - The IRB may request a Biostatistical review for a study with possible design flaws or concerns with the data analysis plan.
  - The IRB may request a consultant review the study when there is not sufficient expertise on the IRB to evaluate the study.
  - The IRB may request review by the Privacy Officer or Data Security Officer to address any concerns with HIPAA regulations, GDPR regulations, privacy, confidentiality, or information security.
  - The IRB may request an ethics consult regarding the research proposal.
  - The IRB may request IBC review for any biosafety concern.
  - The IRB may request biomedical engineering review for any equipment used in the research, if there is a safety concern or unknown risk of using the equipment.

In general, when an ancillary review is required in advance of IRB approval and still pending, the IRB issues a conditional approval letter. The IRB grants final approval after receiving documentation of ancillary approval. However, any changes required by the ancillary review must also undergo IRB amendment review and approval.

When an ancillary review is *NOT* required prior to IRB approval, the investigator must document approval of any pending required ancillary review within the research record prior to starting the research or enrolling any research participants, as applicable. The IRB will provide a copy of the approval letter to the corresponding department or committee that should complete the ancillary review. If an ancillary reviewer requires or recommends any modifications to the previously IRB approved research, any such modification must be subsequently approved through an IRB amendment, prior to implementation of changes. If desired, by the PI or sponsor, the PI may submit a copy of the documentation of ancillary approval not requiring any modifications to the IRB for the IRB to acknowledge; however, this is not a requirement of this policy.
The DMC Institutional Review Board (IRB) is a committee established to review and approve human research. The purpose of the IRB is to ensure the ethical conduct of all human research in accordance with all applicable regulations and policy.

The IRB must ensure compliance of clinical trials involving investigational or unlicensed test articles (drugs, biologics, and devices), including when necessary ensuring appropriate exemptions.

Duties and responsibilities of DMC IRB include, but are not limited to the following:

- Conducting prospective review of human research activities carried out by a DMC faculty member that result in DMC being engaged in human research, regardless of whether the activity is considered a clinical trial, human research, or exempt human research;
- Confirming the competency of the PI;
- Reviewing protocols, investigator brochures, consent forms, advertisements and all other study-related materials submitted to the DMC IRB;
- Reviewing reportable events, as submitted;
- Acting as Privacy Board under 45 CFR Part 164 for research reviewed by DMC IRB and consulting with the DMC Privacy Officer or DMC Data Security Officer, as needed to address relevant matters;
- Maintaining and retaining all records of IRB proceedings required by applicable laws and regulations, for at least three (3) years, and up to ten (10) years, when practicable, including the following:
  - Research proposals reviewed,
  - Scientific evaluations, if any (e.g., SRC reviews),
  - Approved sample consent forms,
  - Progress reports submitted by investigators,
  - Reports of injuries of research participants,
  - Minutes,
  - Records of continuing review activities, including the rationale for conducting continuing review of research that does not require continuing review as described in this policy,
  - Copies of all correspondence between the IRB and investigators;
  - IRB rosters,
  - Written policies and procedures,
  - Statements of significant findings provided to research participants,
  - The rationale for an expedited reviewer’s determination that research appearing on the expedited review list is more than minimal risk, and
  - Documentation specifying the responsibilities that the Downstate Medical Center undertakes to ensure compliance of this policy (e.g., this policy, OCAS policies, IRB guidance, etc.);
- Conducting continuing review of approved studies;
- Reviewing data safety monitoring board reports and taking appropriate actions when needed;
- Reviewing any alleged or suspected incident of noncompliance and making determinations regarding these events;
• Auditing human research, as necessary;
• Providing written standard operating procedures to investigators regarding the process and requirements for IRB application and necessary reporting;
• Making IRB determinations as to whether a DMC activity must be approved by the DMC IRB;
• Providing copies of all IRB approved minutes to the IO, Medical Executive Committee, and the Executive Director, Human Research Protections and Quality Improvement; and,
• Providing relevant approved IRB Minutes (may be redacted) to an external institution, upon request.

The IRB approves each research protocol or plan according to criteria based on policy, applicable laws, regulations, codes, guidance, and best practices.

IRB CHAIR

The IRB Chair is responsible for seeing that the IRB discharges its functions in an appropriate and regulatory-compliant manner. (S)he holds ultimate responsibility for convening the Board and facilitating meetings, providing to the Institutional Official (IO) recommendations for IRB Membership (including recommendations for pairing primary members with alternates on the IRB roster), and ensuring the IRB operations are in compliance with applicable federal and state statute and regulations. (S)he may delegate some responsibilities to the Vice-Chairs or other experienced IRB Members.

The IRB Chair or designate will make determinations regarding events reported to the IRB, or consult with the IRB, IO, Privacy Officer, Information Security Officer, or General Counsel as needed.

IRB VICE-CHAIRS

The Vice-Chairs assist the IRB Chair in carrying out the responsibilities noted in the IRB Chair section and are primarily responsible for the oversight of their designated Full Board meeting. When a Vice-Chair plans to be absent from a full board meeting, the Vice-Chair or IRB Chair may designate an experienced IRB member to run the meeting, or the IRB Chair will fulfill this duty.

IRB MEMBERS

Downstate establishes an IRB & Privacy Board Roster in accordance with requirements of the Common Rule, FDA, NYS Article 24A, and HIPAA regulations. For more details on IRB membership and goals, please see the IRB Guidance: IRB Member Roles and Goals.

Experienced IRB Members may determine whether an activity requires review and approval by the IRB and whether reviews may take place via exempt, expedited, or a full board review process.
IRB REVIEW PROCESS

Below is an overview of the IRB review process.

REVIEW AND REVIEWER ASSIGNMENT

The IRB administrative staff performs a preliminary review of all protocol materials for determination of completeness, accuracy, and required ancillary reviews and accepts complete submissions. The IRB administrative staff informs the PI through an email or via the electronic application and reporting system of any missing materials or requirements and applicable response deadlines.

Experienced IRB administrative staff determine whether an activity requires review and approval by the IRB and whether reviews may take place via exempt, expedited, or a full board review process. The IRB administrative staff will assign protocols for review, based on the scientific content of the protocol and the potential reviewer’s area of expertise. If there are any questions, the IRB staff will consult with the Executive Director, Vice-Chair, or IRB Chair for guidance for a determination.

The IRB may use a primary and secondary reviewer process (e.g., two reviewers), or assign reviews based on special knowledge and expertise of the members (e.g., clinical expertise, informed consent reviewer, research design, statistics, regulatory and policy, ethics) or a combination thereof. The IRB will seek out the review of a consultant when the IRB receives a protocol that may be outside of the knowledge base of any of the IRB. **When a consultant reviews the research, the consultant must be given at a minimum the protocol (or a summary) and the informed consent document, if applicable for the research, for review.** The IRB must defer the review of research to either another meeting or an external IRB when appropriate expertise is not available among the IRB members or consultants to determine the research meets all of the criteria to approve the research.

The IRB administrative staff assign at least one IRB Member to review a study that qualifies for an exemption or expedited review. They assign at least two reviewers to each full board protocol. They may assign several protocols or other research items for review. Reviewers are assigned to all protocols requiring initial review, continuing review, and modifications. In general, the reviewers are responsible for the following:

- Having a thorough knowledge of all of the details of the proposed research;
- Performing an in-depth review of the proposed research and all uploaded documents;
- Leading the discussion of the proposed research at the convened meeting, presenting both positive and negative aspects of the research, and leading the IRB through the regulatory criteria for approval;
- Making suggestions for changes to the proposed research, where applicable;
- Completing all applicable IRB reviewer forms or placing comments in the electronic IRB submission and reporting system.

IRB members should complete their written reviews in advance of the IRB meetings within the electronic IRB submission and reporting system, including IRB determinations; however, the
reviews are not the final work product of full board studies. The IRB minutes and IRB approval/notification letters capture the final work product of the review including information discussed at the meeting and any required determinations.

**RECUSALS**

**FULL BOARD MEETINGS**

A recused IRB Member is someone with a potential or real conflict of interest and must not vote on any action related to the project during a full board review. The conflicted member will leave the room during discussion and voting, if required by the IRB Chair or Vice Chair. The IRB documents the abstention and absence, if applicable, in the IRB meeting IRB Minutes.

If an IRB member is conflicted at a convened meeting, (s)he must verbally notify the IRB and document the conflict on the attendance sheet.

**OTHER REVIEW ACTIVITIES**

An IRB Member or IRB Staff member with a potential or real conflict of interest will be considered recused and cannot approve any IRB submission, including those not requiring full board review (e.g., expedited review, exempt review, IRB determination, administrative review, consulting review, etc.).

Conflicted individuals must notify the IRB office staff or IRB Chair or an IRB Vice-Chair so that the review assignment can go to another individual.

**PROCESS FOR IRB DETERMINATIONS**

An experienced IRB Member or an experience IRB Administrator who is not an IRB Member may review IRB Determinations or IRB Decision Aid requests. When it is necessary for the reviewers to consult with General Counsel, OCAS, or the Privacy Officer, when making a determination, the reviewer should document such communications in the IRB records.

**PROCESS FOR EXEMPT, EXPEDITED, OR FULL IRB REVIEW**

All human research requires, based on the criteria set forth below, either full review, expedited review, or exempt review. An investigator may propose the type of review; however, the IRB makes the final determination.

If a project does not need IRB review and approval, the IRB will issue a determination letter to this effect.

**EXEMPT RESEARCH REVIEW PROCESS**

The IRB reviews exemption requests upon submission. There are no scheduled deadlines for submission, as the review process will start immediately.
The IRB office staff will conduct an administrative review of the research to determine whether the submission is complete and verify the study meets the criteria for an exempt review. If the IRB office staff member is also an experienced IRB Member and has the expertise necessary to conduct the review, (s)he may review and approve the research; otherwise, it will be assigned to another IRB Member.

The IRB Member may require additional changes or make recommendations before approving the study. The IRB Member can refer the study to the IRB Chair or another IRB Member, if the topic is out of his/her area of expertise. An IRB Member cannot disapprove exempt research, but may refer it to the full board review.

An experienced IRB Administrator who is not an IRB Member may review exempt research or IRB Decision Aid requests; however, only an IRB Member may approve exempt research requiring limited IRB review.

LIMITED IRB REVIEW PROCESS

If an exempt review requires limited IRB review, the IRB member reviewers ensure there are adequate provisions to protect the privacy of research participants and to maintain the confidentiality of data.

EXPEDITED REVIEW PROCESS

Expeditied review of a new study or continuing review of a previously IRB approved study entails designated review by the IRB Chair and/or a designated IRB Member(s) in lieu of a convened (full) IRB review and thus may shorten the time to approval; however, the project must still meet all requirements. There are no scheduled deadlines for submission, as the review process will start immediately.

An experienced IRB Member will review and may approve the research package. The IRB Member may require additional changes or make recommendations before approving the study. The IRB Member can refer the study to the IRB Chair, Vice-Chair or another experienced IRB Member, if the topic is out of their area of expertise. An IRB Member cannot disapprove the research under an expedited review process, but(s)he can defer it to full board review.

If an expedited reviewer determines that research appearing on the expedited review list is more than minimal risk, and therefore no longer qualifies for expedited review, the reviewer must document the rationale for making this determination. The IRB should document this in the IRBNet or within the approval or determination letter to the investigator.

The IRB Chair has final approval authority, if there are any concerns. The IRB Chair cannot disapprove a project under the expedited review process, but may defer it to the convened IRB for a final decision.
EXPEDITED REVIEW OF CONTINUING REVIEW (PROGRESS REPORTS), AMENDMENTS, REPORTABLE EVENTS, AND OTHER CONSIDERATIONS

Review of amendments, reportable events, and other considerations, shall be done via expedited review whenever permissible under the regulations. An experienced IRB Member conducting the review may approve the research submission. An IRB Member reviews the submissions for amendments, continuing review, reportable events, and all associated materials to determine whether the study requires amendments, termination, or continues as originally approved or as amended.

The IRB may require additional changes or make recommendations before approving the submission. The IRB Member can refer the study to the IRB Chair, Vice-Chair or another experienced IRB Member, if the topic is out of his/her area of expertise. An IRB Member cannot disapprove the research, but they can defer it to full board review for approval or acknowledgement.

SERIOUS ADVERSE EVENT (SAE) REVIEW PROCESS

An experienced IRB Member will review and may approve the SAEs or reportable event by expedited review. The IRB Member may require additional information, request changes to the research or make recommendations before approving the SAE. The IRB Member can refer the study to the IRB Chair, Vice-Chair, another experienced IRB Member, of the Full Board if the topic is out of their area of expertise.

FULL (CONVENED) IRB REVIEW PROCESS

It is the responsibility of the PI to submit all required materials and signatures according to the posted schedule on the IRB website prior to a scheduled IRB meeting, unless special extenuating circumstances are approved by the Executive Director, Vice-Chair, or IRB Chair.

SUBMISSION EVENTS WHICH REQUIRE FULL IRB REVIEW

Other than the initial or continuing review submissions that require full board review (described elsewhere in this policy), the IRB must review the following submission events by the full IRB:

- Amendments changing the level of risk of the study to greater than minimal risk.
- When an IRB member determines and requires full board and documents the reason for such referral.
- When determining or confirming serious or continuing noncompliance.

PRE-MEETING DISTRIBUTION OF DOCUMENTS

The IRB administrative staff prepare the meeting agenda and make it available to the IRB Members prior to the meeting. All IRB Members receive access to agenda and all submission materials, approximately five (5) business days before the scheduled meeting to allow sufficient time for the review process. Prior meeting IRB Minutes, applicable business items and audits,
and appropriate continuing education materials will be made available approximately five (5) business days before the scheduled meeting, if feasible; however, late submissions may be approved by the IRB Chair, Vice Chair, or Executive Director. All IRB Members should review all studies requiring full IRB review.

INVESTIGATOR ATTENDANCE

To improve efficiencies and communication regarding any new study undergoing initial review by the full committee, the IRB invites the PI to attend to present the study and answer any questions of the IRB. It is in the best interest of the PI to attend or call into the meeting. Study team members may also attend with or on behalf of the PI; however, if they cannot answer IRB questions, the IRB may need to disapprove the study or require additional modifications or clarifications in order to grant final approval.

The PI may attend via teleconference if they cannot physically be present at the meeting.

IRB ATTENDANCE, QUORUM, AND VOTING

By regulation, final actions on protocols that require full IRB review only occur at a convened meeting. The IRB posts the meeting schedule on the IRB website. The IRB Chair or Vice-Chair may call for additional meetings for administrative, educational purposes, for an emergency or otherwise critical review.

A necessary quorum for the IRB to consider a proposal is a majority of the total number of primary members for the Committee, including a member whose primary concern is in a nonscientific area, before taking regulatory actions at these meetings. See section on IRB Minutes for additional information. If research involving an FDA-regulated article is involved, a licensed physician must be included in the quorum. A quorum must be present before a vote can take place. Members must be present in person or via teleconference or video conference.

When there is an even number of Primary Members on the IRB Roster, calculate the majority using the "half-plus-one" technique. For example, if the total number of Primary Members is 14, then majority is 8 (half of 14 is 7, 7+1 =8). However, when the IRB has an odd number of Primary Members on the Roster, the majority is calculated by taking half of the number of Primary Members on the Roster, then rounding up to the next whole number. For example, if the total number of Primary Members is 15, then the majority is 8 (half of 15 is 7.5, and rounding up to the next whole number is 8).

All members receive all pertinent material prior to the meeting and the IRB considers them present when they actively and equally participate in all discussions through teleconferencing or videoconferencing.

The IRB does not permit advanced (proxy) votes for voting on regulatory actions that are required during a convened IRB meeting; however, an IRB Member may record their recommendations in the electronic IRB submission and reporting system in advance of the
meeting. Voting for non-regulatory required actions (e.g., approval of IRB Minutes or other business related decisions), may take place via e-mail or phone.

No IRB may have a member participate in the board's initial or continuing review of any project in which the member has a conflicting interest, except to provide information requested by the IRB.

An IRB member who is listed as PI, Co-investigator, or key personnel is conflicted and therefore is automatically recused from participation and voting, except (s)he can provide any information that is requested by the IRB.

A discussion takes place for each submission at the convened meeting, prior to making a motion and taking the vote. The primary member for the month will vote at the meeting. However, if the primary member is absent or recused, the vote will go to the alternate member, if present. When only the alternate member within a voting group receives a review assignment for an agenda item and when he/she is present for the convened meeting, his/her vote will count towards the motion of that item, rather than the primary member.

The IRB approves a submission when it receives the approval of the majority of the eligible voting members at the meeting. If there is an even number of eligible voting members present, calculate the majority using the “half-plus-one” technique. For example, if the total number of eligible voting members is 10, then majority is 6 (half of 10 is 5, 5+1 =6). However, there is an odd number of eligible voting members present, the majority is calculated by taking half of the number of eligible voting members present, then rounding up to the next whole number. For example, if the number of eligible voting members is 11, then the majority is 6 (half of 11 is 5.5, and rounding up to the next whole number is 6).

If an IRB Chair or Vice-Chair entertains a motion under which the IRB votes on groups of studies (sometimes called “block voting”), IRB Members have the ability to voice their vote “for” on some studies, “against” on others, and “abstain” on others.

If all of the reviewers are absent from the meeting, the IRB Vice Chair will determine if the study in question must be tabled for a review at a future meeting. If the present members have sufficient information and expertise, the IRB Vice Chair may determine the review may proceed.

**RISK ASSESSMENT AND MINIMIZATION**

At the time of initial and continuing review, the IRB will make a determination regarding the risks associated with the research protocols and whether risks can be minimized through appropriate measures. Risks associated with the research will be classified as either “minimal” (no greater than minimal risk) or “greater than minimal” based on the regulatory definitions of minimal risk. The level of risk is entered in the electronic IRB submission and reporting system.

In order for research involving children to meet the criteria for approval under category 406 (45 CFR 46.406 or 21 CFR 50.53), the IRB must determine that the research risk represents only a minor increase over minimal risk.
IRBs should verify or make the SR or NSR determination of an investigation involving the safety and effectiveness of a medical device by reviewing relevant information at a convened meeting.

**ASSESSMENT OF BENEFITS**

The IRB assesses the potential benefits of the research to the research participants and society, based on the IRB application materials and experience of the IRB. The IRB considers whether the benefits that may be reasonably expected to result provide a reasonable basis for assuming the risks of the research.

Compensation and reimbursement is NOT considered a benefit.

**DETERMINING WHICH PROJECTS REQUIRE REVIEW MORE OFTEN THAN ANNUALLY**

The IRB determines the frequency of review at the time of initial review and at continuing review. The IRB re-reviews protocols at intervals appropriate to the degree of risk but no less than once per year, unless continuing review is not required by this policy. In some circumstances, a shorter review interval (e.g., biannually, quarterly, or after accrual of a specific number of participants) may be required. The IRB office enters the expiration date of the approval period in the electronic IRB submission and reporting system and the approval letter will reflect the expiration date.

In specifying an approval period of less than one year, the IRB may define the period with either a time interval or a maximum number of research participants either studied or enrolled. When the IRB determines the approval period based on the enrollment of a maximum number of research participants, this approval period in no case can exceed one year.

Most research requiring continuing review, the IRB grants a one-year review period unless otherwise specified by the IRB. The IRB considers the following factors when determining which studies require review more frequently than on an annual basis:

- Significant risk to research participants (e.g., death, permanent or long lasting disability or morbidity, severe toxicity) with the possibility of direct benefit to the research participants;
- The inclusion of significantly vulnerable populations where, even in the presence of possible direct benefit, there is also a possibility of significant risk associated with the research procedures.
- The probability and magnitude of anticipated risks to research participants.
- The likely medical condition of the proposed research participants.
- The overall qualifications of the PI and other members of the research team.
- The specific experience of the PI and other members of the research team in conducting similar research.
- The novelty of the research making unanticipated adverse events more likely.
- The nature of any risks posed by the research project.
• The degree of uncertainty regarding the risks involved.
• The vulnerability of the research participants’ population.
• The experience of the investigators in conducting research.
• The IRB’s previous experience with the investigators (e.g., compliance history, previous problems with the investigator obtaining informed consent, or prior complaints from research participants about the investigator);
• The projected rate of enrollment.
• Whether the research project involves novel interventions.
• Any other factors that the IRB deems relevant.

DETERMINING EFFECTIVE DATE OF INITIAL IRB APPROVAL AND DATE FOR CONTINUING REVIEW OR CHECK-IN

The IRB follows OHRP Guidance on Continuing Review and the FDA Guidance on Continuing Review for determining the effective date of initial IRB approval and the dates for continuing review.

Please note that the DMC IRB may recommend the expiration date of a study undergoing full board review by the DMC IRB be the 15th of the month, not exceeding one year. For example, a study receiving IRB approval at a convened meeting on May 2 is set to expire on April 15 of the next year and each subsequent anniversary. Doing this ensures fewer problems with lapses of continuing review, as the IRB generally meets during the first week of the month.

In general, continuing review is not required for exempt research, including exempt research that requires limited review. In general, continuing review is not required for research initially approved via expedited review or after January 19, 2019, unless it is FDA or DOJ regulated. However, the IRB requires or assigns a check-in date of 3 years after initial approval, when continuing review is not required. If the IRB requires an earlier check-in date, the IRB will notify the PI of the reason for an earlier check-in date in writing.

When the IRB reviews and approves research via expedited review, the effective date of the initial approval is the date on which an experienced IRB Member has reviewed and accepted as satisfactory the protocol or informed consent documents, or any other responsive materials, required by the IRB from the investigators.

When the IRB reviews and approves research with conditions at a convened IRB meeting without requiring further review at a subsequent convened meeting, the effective date of the initial approval is the date on which the IRB Chair or an experienced IRB Member has reviewed and accepted as satisfactory all changes to the protocol or informed consent documents, or any other responsive materials, required by the IRB from the investigators. In such circumstances, the expiration date of the initial approval period, which is the date by which the first continuing review (when required) must occur, may be as late as one year after that effective date of initial IRB approval. However, the IRB may choose to set the expiration date of the initial approval period at one year from the date of the IRB meeting at which the research project initially was approved with conditions.
Please see the OHRP and FDA guidance referenced above for specific examples of various scenarios.

When an external IRB approves a study, the DMC IRB will acknowledge the expiration date determined by the external IRB.

**VERIFICATION THAT NO MATERIAL CHANGES HAVE OCCURRED**

The IRB recognizes that protecting the rights and welfare of research participants sometimes requires that the IRB obtain independent verification, utilizing sources other than the investigators that no material changes occurred during the IRB-designated approval period. Independent verification from sources other than the investigator (e.g., auditor, IRB, sponsor, or other third party) may be necessary at times, for example, in cooperative studies, or other multi-center research.

The IRB may consider the following factors when determining which studies require independent verification:

- Protocols where concern about possible material changes occurring without IRB approval have been raised based on information provided in continuing review reports or from other sources
- Protocols conducted by a PI who has previously failed to comply with federal regulations and/or the requirements or determinations of the IRB
- Protocols selected for internal audit
- Whenever else the IRB deems verification from outside sources is relevant
- The probability and magnitude of anticipated risks to research participants
- The likely medical condition of the proposed research participants
- The probable nature and frequency of changes that may ordinarily be expected in the type of research proposed

In making determinations about independent verification, the IRB may prospectively require that such verification take place at predetermined intervals during the approval period, or may retrospectively require such verification at the time of continuing review, review of amendments and/or adverse events.

The IRB may require the monitor to submit a report of the findings to the IRB, for which the IRB can review and may require additional actions.

**CONSENT MONITORING**

Occasionally, the IRB may determine that special monitoring of the consent process by an impartial observer (consent monitor) is required in order to reduce the possibility of coercion and undue influence, ensure that investigators follow the approved consent process, or ensure that the investigators are truly obtaining legally effective informed consent. The IRB may particularly warrant monitoring for any the following:
- Studies involving extremely high or significant risks.
- Studies that involve particularly complicated procedures or interventions, when research participants are likely to have difficulty understanding the information to be provided
- Studies involving highly vulnerable populations (e.g., ICU patients, children).
- Studies involving study staff with minimal experience in administering consent to potential study participants.
- Studies requiring additional monitoring to minimize concerns of undue influence or coercion.
- When the IRB determines monitoring is an appropriate as a corrective action where the IRB has identified problems associated with a particular investigator or a research project.
- Other situations when the IRB has concerns over that the consent process.

When the IRB requires consent monitoring, the IRB notifies the PI of the determination and the reasons for the determination and should include the following, as applicable to the research:
- who will monitor the process
- the arrangements to be made by the PI
- the number of research participants requiring monitoring, and,
- whether the monitor must sign the informed consent document to attest to the validity of the consent process.

When observing the consent process, the monitor will determine:
- Whether the informed consent process was appropriately completed and documented,
- Whether the research participants had sufficient time to consider study participation,
- Whether the consent process involved coercion or undue influence,
- Whether the information was accurate and conveyed in understandable language, and
- Whether the research participants appeared to understand the information and gave their voluntary consent.

The monitor submits a report of the findings to the IRB, for which the IRB can review and may require additional actions.

**STAMPING REQUIREMENTS OF IRB APPROVED MATERIALS**

Before using the following documents, including translated documents, the IRB must stamp these with a valid date range:
- Long Forms (informed consent documents, HIPAA research authorizations, information sheets, assent Documents), including addendums
- Short Forms
- Recruitment posters, advertisements, or flyers (if technically feasible)

The study staff must check the date stamp on the informed consent materials, before enrolling research participants to make sure the most current forms are used.

The IRB publishes stamped documents in the electronic IRB submission and reporting system and the PI and anyone who has access to the submission will receive an e-mail notice that the document is available.
If it is not feasible to stamp recruitment materials with IRB stamp (i.e., newspaper and electronic advertisements), posting of the document is permitted without the stamp as long as there are no modifications to the IRB approved language in the material, and the IRB approval letter references the approved materials.

The IRB does not stamp the following documents upon approval; however, an IRB approval letter listing these materials must be on file with the investigator, before they can be used:

- Surveys
- Recruitment letters
- Other recruitment materials and documents that are not mentioned above
- IRB applications
- Protocols
- Study brochures
- Investigator Brochures (IB)
- Case report forms
- Data collection tools
- Scales and questionnaires/surveys
- Sponsor correspondences
- IND safety reports
- Summaries of what will be said to a potential research participant
- Oral consent or recruitment scripts

**IRB LETTERS AND NOTIFICATIONS**

Upon IRB approval, the PI receives a letter of approval, and the research may be conducted within the policies and procedures outlined by the IRB and within the constraints of other institutional and federal requirements. IRB approval does not in itself constitute administrative approval to initiate the research project, as additional requirements may also apply, before the research may begin (e.g., ancillary approvals, contract approval, STAR approval for NYC H + H, Kings County research, etc.).

Once an IRB Member completes his/her review (expedited/exempt) or after a full board meeting, the IRB Office will generate a letter to the PI dependent on the decision of the IRB, using the electronic IRB submission and reporting system. The selected letter depends on the decision of the IRB. Once the letter is generated, the IRB Office may notify the assigned Expedited reviewer (through committee messages in the electronic IRB submission and reporting system) if the letter needs to be reviewed for any clarification or feedback (e.g., adding notes or requirements from the IRB), if needed. The IRB member conducting the review may edit and publish the letter.

The IRB Office Staff draft the letters for the initial reviews for the full board, which then should be reviewed by the Executive Director, Human research Protections and Quality Assurance (or designate), prior to going to a Vice-Chair. A Vice-Chair (or designate) will review and make any final edits that may be needed, before publishing the letter. If needed, Vice-Chair (or designate) may refer the letter to the IRB Chair (or designate) for final review and publication. An IRB Member or Executive Director writes and publishes all other letters. In general, two individuals should review a highly complex letter before publishing.
In general, the goal of the IRB is to publish letters within five (5) business days of the IRB’s determination; however, adjusts based on workload and staffing. The research team may contact the IRB to escalate the letter publication if it has been five (5) business days past the date of IRB meeting or approval. When publishing letters in IRBNet, the PI and anyone who has access to the submission will receive an e-mail notice that the letter is available.

In general, the investigators should respond within the following timeframes, or the submission is considered withdrawn:

- The research team will have 2 weeks to respond from the date of that notification letter to any IRB requests regarding missing documents, training or signatures for all initial IRB Submissions including Exempt, Expedited and Full Board studies.
- The research team will have 1 month to respond from the date of a modification letter from the IRB requesting MINOR changes or a letter of conditional approval.
- The research team will have 2 months to respond from the date of IRB notification letter regarding MAJOR changes.

Note: The IRB provides the details for any recusals in the IRB approval letter, if necessary or otherwise requested by the research team or the sponsor.

POSSIBLE IRB ACTIONS OR APPROVALS

The IRB enters the following possible IRB Actions or Approvals in the IRB application and submission system, which are included within the IRB letter.

APPROVED

The IRB may IRB approve the research study as submitted without any conditions or required modifications or the IRB may elect to make changes in order to secure approval, provided the IRB notifies the PI of the changes the IRB made in order to secure approval.

Note: If the IRB makes a motion for approval at the convened meeting when the actions requested require conditional approval or modifications based on regulations or policy, the IRB will issue a Conditional Approval or Modifications Required letter, as applicable to the action required.

ACKNOWLEDGEMENT

The IRB may acknowledge the receipt of the submitted materials. No additional actions are usually required, unless specified in the IRB letter.

The IRB may issue this type of letter to acknowledge an external IRB approval, once the DMC IRB confirms it meets all local research context requirements.

ACKNOWLEDGEMENT PENDING EXTERNAL IRB APPROVAL

When an External IRB request local research context review, prior to issuing approval, the DMC IRB Office will review and confirm the study meets all local research context requirements.
When the study meets all local requirements, the DMC IRB will issue a letter to acknowledge but indicate external IRB is pending.

Once the PI submits a follow-up submission to the DMC IRB with the External IRB approval letter, the DMC IRB will issue a final acknowledgment.

**APPROVED WITH CONDITIONS**

The IRB may approve the research with conditions. When minor and specific changes are required, the IRB notifies the PI in writing of the changes that are required. The IRB may approve research with conditions if, given the scope and nature of the conditions, the IRB is able, based on the assumption that the conditions are satisfied, to make all of the determinations required for approval under the regulations. For example, the IRB may require the following as conditions of approval of research:

- Confirmation of specific assumptions or understandings on the part of the IRB regarding how the research will be conducted (e.g., confirmation that the research excludes children);
- Submission of additional documentation (e.g., certificate of CITI training);
- Precise language changes to protocol or informed consent documents; or
- Substantive changes to protocol or informed consent documents along with clearly stated parameters that the changes must satisfy.

For more information, refer to the OHRP guidance on [Approval of research with Conditions](https://ohrp.osirp.us/irsb/documents/approval-conditions.pdf) or FDA Guidance on [IRB Continuing Review after Clinical Investigation Approval](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-continuing-review-clinical-investigation-approval).

If the IRB makes a motion for conditional approval at the convened meeting when the actions requested require modifications based on regulations or policy, the IRB will issue a Modifications Required letter.

**FINAL APPROVAL**

When the PI responds to the conditional approval request, the IRB reviews changes by an IRB Member by expedited review, to confirm the changes meet the directed conditions, before granting final approval.

**MODIFICATIONS REQUIRED**

When the Full Board requires modifications, the IRB requests changes in writing to the PI. The PI then returns the modifications for full board review. In general, whenever the IRB questions the scientific design or merit, or when requesting major modifications, the IRB may return the project to the SRC, as determined by the IRB Chair, Vice-Chair, or convened IRB.

When modifications are required of a study, which qualifies for expedited review or exempt review, the PI returns modifications for an expedited review process.
DISAPPROVED / NOT APPROVED

When the IRB disapproves research, the IRB notifies the PI in writing of the reasons and informs the Department Chair or Dean and the SRC.

DEFERRED / TABLED

The IRB Chair or Vice-Chair can defer or table a study to a future meeting or another committee, with or without the majority vote of the IRB, for any of the following reasons:

- The IRB is unable to review the submission for any reason;
- The Chair or Vice-Chair elect to defer the research when it is need of substantive changes before it can be presented to the IRB;
- Loss of quorum; or
- Lack of expertise on one of the IRB Committees

If applicable, the IRB will provide a written summary of any available concerns at the time of notification. The IRB may notify the Department Chair/Dean and/or the SRC, particularly if the IRB cannot evaluate a submission or requires substantial revisions.

The IRB will re-review the submission (or revised submission) at a future meeting.

WITHDRAWN SUBMISSION

The PI may withdraw a submission at any time; however, the IRB may also administratively withdraw a submission as needed.

When an IRB submission is incomplete and/or for which it requests changes, the IRB administrative staff request any necessary items, documents, and/or modifications from the PI in order to complete the review. The IRB withdraws a submission from consideration if the PI fails to respond within the specified deadline; however, IRB review may continue only upon receipt of a response addressing any concerns raised in the initial review.

CLOSED

When the IRB acknowledges a closure or final report, the IRB will issue a letter to this effect. The IRB may also issue a closure letter when a study expires.

EXPIRED

When the IRB approval period of a study expires, the electronic IRB submission and reporting system issues an e-mail stating such.

SUSPENSION OR TERMINATION

The IRB will acknowledge a notice for study is suspension or termination by someone other than the IRB. If the IRB suspends or terminates IRB approval, the letter will state such actions.
The IRB will consider any actions required to protect any research participants in the study.

**NOT HUMAN RESEARCH**

When the DMC IRB determines an activity does not meet the requirements for human research, the IRB issues a written determination letter to document DMC IRB approval is not required.

**NOT ENGAGED IN HUMAN RESEARCH**

When the DMC IRB determines the DMC workforce is conducting activities that do not make DMC engaged in human research, the IRB issues a determination letter to document DMC IRB approval is not required.

**IRB MINUTES**

The IRB generates meeting minutes for all IRB meetings, for which voting takes place. Minutes of IRB meetings, which shall be in sufficient detail to show attendance at the meetings; actions taken by the IRB; the vote on these actions including the number of members voting for, against, and abstaining; the basis for requiring changes in or disapproving research; and a written summary of the discussion of controverted issues and their resolution.

The minutes will note recusals. The recused member does not count towards the quorum or the total votes.

Any items approved by members or administrative staff outside of the full board meetings, will be included in the IRB Minutes to notify the board members of all such actions.

**DISTRIBUTION OF IRB MEETING MINUTES**

The IRB office distributes copies of the approved IRB minutes as follows:

- Medical Board Office for the Medical Executive Committee
- Institutional Official
- Executive Director, Human Research Protections

Relevant redacted minutes are available upon request; however, the IRB Chair, Vice-Chair, or the Executive Director must review the redacted minutes before distribution to an external institution.

**POST IRB APPROVAL**

**GENERAL REQUIREMENTS**

Upon approval by the IRB, the study team should do the following:

- Review the IRB approval letter for accuracy and appropriate determinations.
- Check the approval date and expiration date in letter and approved documents (consent, recruitment materials, etc.). An expiration date is NOT needed for recruitment materials.
• Contact the IRB if there are any discrepancies, errors, or questions.
• Share applicable documents with sponsor.
• File documents in study binder.
• Ensure the study meets Applicable Clinical Trial Requirements of the FDA.
• Understand and ensure the requirements of sponsor.
• Understand reporting requirements to the IRB, sponsor, and FDA.
• Do not use laboratory reports from research laboratories for diagnosis, treatment and prevention of disease, unless the research laboratory is properly certified or accredited.

REPORTABLE EVENTS

Report all required reportable events to the IRB within the deadlines specified in the table below. Please see definitions in IRB guidance materials for clarification of the event type or contact the IRB.

An **internal event** is problem or event involving research participants enrolled by an institution under the purview of the DMC IRB:

Internal event example: An SAE occurs with a research participant enrolled at Hospital XYZ when the DMC IRB has the primary oversight of the research (e.g., no external IRB).

Note: If an internal event occurs at Downstate when the primary oversight of the research takes place by an external IRB, follow requirements of the external IRB and any additional requirements outlined in the section on the use of an external IRB within this policy.

An **external event** is problem or event involving research participants enrolled by other institutions in multicenter research projects that do not fall under the purview of the DMC IRB:

External event example: A research participant experiences an SAE at Hospital XYZ overseen by IRB XYZ.

When reviewing any reportable event, the IRB may consider, but is not limited to, the following possible actions:

• Modification of the protocol
• Modification of the consent document or process for obtaining consent
• Modification of the information disclosed during the consent process
• Providing additional information to current participants (This must be done whenever the information may relate to the participant’s willingness to continue participation)
• Providing additional information to past participants
• Requiring current participants to re-consent to participation
• Alteration of the frequency of continuing review
• Observation of the research or the consent process
• Requiring additional training of the investigator
• Notification of investigators at other sites
• Termination or suspension of IRB Approval
- Referral to other organizational entities
- Obtaining additional information
- Taking no action

The IRB, IRB Chair, or IRB Vice-Chair considers whether any additional procedures need to be followed to protect the rights and welfare of current participants, before holding, terminating or suspending IRB approval. Such procedures might include:
- Transferring participants to another investigator;
- Making arrangements for clinical care outside the research;
- Allowing continuation of some research activities under the supervision of an independent monitor;
- Requiring or permitting follow-up of participants for safety reasons;
- Requiring adverse events or outcomes to be reported to the IRB and the sponsor;
- Notification of current participants; or
- Notification of former participants.

In the references to reporting events to OHRP or FDA or other federal department or agency in the table below, this includes any successor office or the equivalent office within the appropriate department or agency.

When indicated, call the IRB at (718) 613-8480.

To report any events in writing, please do so in the electronic IRB submission and reporting system, using the Reportable Event Form.

The items listed in the table above with an “*” next to the event type must be reviewed at the full board. In general, the IRB reviews all other reportable events by an expedited reviewer; however, an IRB Member who is a clinician must review any clinical event. The reviewer may consult with other IRB Members when conducting the review or defer the review to the full board at any time.

<table>
<thead>
<tr>
<th>Event Type</th>
<th>Deadline from when the investigator first learns of an internal event for reporting to IRB for an internal event (e.g., those that occurred with within the DMC IRB’s jurisdiction)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Government inspection (or audit)</td>
<td>Report findings within <strong>24 hours</strong>, if any serious or continuing non-compliance was found or proposed; otherwise within <strong>5 days</strong>.</td>
<td>The study team should alert the IRB when the inspection is scheduled or if an inspector arrives unannounced, so the IRB may help as needed.</td>
</tr>
</tbody>
</table>
*Privacy Violation (or Breach).

A privacy violation (or breach) is, generally, an impermissible use or disclosure under the Privacy Rule that compromises the security or privacy of the protected health information such that the use or disclosure poses a significant risk of financial, reputational, or other harm to the affected individual. Certain exceptions may apply. The DMC Privacy Officer has the ultimate authority to determine whether a breach has occurred, after it is reported and reviewed.

**Immediately** report this to IRB and Privacy Officer or to the Compliance Line at 877-349-SUNY.

The Privacy Officer determines if a Breach occurs, whether notification to the research participant is required, and completes any necessary reports to the HHS Office of Civil Rights.

*Information (Data) Security Violation (or Breach).

An information security violation is, generally, an impermissible use or disclosure under the Privacy or Security Rules that compromises the security of the protected health information such that the use or disclosure poses a significant risk of financial, reputational, or other harm to the affected individual. Certain exceptions may apply. The Information Data Officer has the ultimate authority to determine whether a breach has occurred, after it is reported and reviewed.

**Immediately** report this to IRB and Data Security Officer.

The Data Security Officer determines if a Breach occurs and completes any necessary reports to the HHS Office of Civil Rights.

Incarceration of a research participant

Immediately, if participant is actively incarcerated and research interventions must take place while under incarceration; otherwise within 5 days.

If an already-enrolled research participant becomes incarcerated, all research interventions and interactions cease (except those required for the well-being of the research participant) until the IRB has made the prisoner determinations. For more information, see OHRP Prisoner Research FAQs.

Any FDA Actions to a HUD or FDA changes to a HUD

Report immediately.

(Unexpected) Serious Adverse Event.

**NOTE:** This term applies to Clinical Investigations and to in vitro bioavailability or bioequivalence studies in humans (including

24 hours if an internal AE meets the following criteria:

**CAUTION:** If the IRB approves a protocol that has more strict SAE reporting requirements (e.g., required by the sponsor), the PI must
specimens) that are exempt from IND requirements.

An AE (see below) or an SAE may also meet the definition of an UPIRPO, UAE, or UADE, as described below.

**A Serious Adverse Event (SAE) is an adverse event (AE) that results in any of the following:**

- **Death.** Meets the criteria of an SAE when the death is suspected to be attributable to an outcome of a research AE.
- **Life-threatening experience.** Meets the criteria of SAE if the research participant was at substantial risk of dying at the time of the AE, or use or continued use of the device or other medical product might have resulted in the death of the participant.
- **Initial hospitalization.** Meets the criteria of SAE if the admission was the result of the AE. Emergency Department visits that do not result in admission to the hospital should be evaluated for one of the other serious outcomes (e.g., life-threatening, required intervention to prevent permanent impairment or damage; other serious medically important event).
- **Prolongation of hospitalization.** Meets the criteria of SAE if the hospitalization of the research participants was prolonged as a result of the AE.
- **Persistent or significant disability or incapacity.** Meets the criteria of SAE if the AE resulted in a substantial disruption of the research participant’s ability to conduct normal life functions, i.e., the AE resulted in a significant, persistent or permanent change, impairment, damage or disruption in the participant’s body function/structure, physical activities or quality of life.
- **Congenital anomaly or birth defect.** Meets the criteria of SAE when it is suspected that exposure to a medical product prior to conception or during pregnancy may have resulted in an adverse outcome in the child.
- **The need for medical, surgical, behavioral, social, or other intervention to prevent outcomes such as the above.** Meets the criteria of SAE when it is believed that such intervention is necessary.

**serious (or alarming), AND**

- **unanticipated (unexpected), AND**
- **would have implications for the conduct of the study (e.g., requiring a significant and usually safety-related, change in the protocol such as revising inclusion/exclusion criteria or including a new monitoring requirement, informed consent, or investigator’s brochure).**

**report those SAEs to the IRB as described in the IRB approved protocol.**

In general, consider AEs observed during the conduct of the study.

The term “alarming” is not defined by the FDA, so it is up to the PI’s or Sponsor’s discretion on how to interpret this term. An individual AE occurrence ordinarily does not meet these criteria because, as an isolated event, its implications for the study cannot be understood. Reporting requirements to the sponsor of AEs for clinical trials conducted under IND are stricter. Consult with the sponsor or see FDA Guidance on AE reporting to the IRB.

Examples of AEs that FDA considers “unanticipated problems” include:

- A single occurrence of a serious, unexpected event that is uncommon and strongly associated with drug exposure (such as angiodema, agranulocytosis, hepatic injury, or Steven-Johnson syndrome).
- A single occurrence, or more often a small number of occurrences, of a serious, unexpected event that is not commonly associated with drug exposure, but uncommon in the study population (e.g., tendon rupture, progressive multifocal leukoencephalopathy).
that medical or surgical intervention was necessary to preclude permanent impairment of a body function, or prevent permanent damage to a body structure, due to the use of a medical product.

See related: adverse event.

- Multiple occurrences of an AE that, based on an aggregate analysis, is determined to be an unanticipated problem. There should be a determination that the series of AEs represents a signal that the AEs were not isolated occurrences and involve risk to human subjects (e.g., a comparison of rates across treatment groups reveals a higher rate in the drug treatment arm versus a control).

| *Research related injury involving provision of healthcare.* | 24 hours, if serious.  
Report within the current approval period, if minor. | The PI or IRB may consult with general counsel regarding recommended action. |
| "Apparent Non-Compliance (including any serious or continuing non-compliance)." | 24 hours, if serious or continuing.  
Report within the current approval period, if minor (e.g., protocol deviation) | DMC expects any employee or agent to report any apparent non-compliance to the IRB or to the Compliance Hot Line at 877-349-SUNY (7869) or via the Web-based Reporting Compliance Line. An anonymous report may be made using the web-based system, if desired. |

**Non-compliance** occurs when conducting human research in a manner that intentionally or unintentionally disregards or violates regulations, policies, or procedures governing human research.

**Non-compliant** actions may range from minor to serious, be unintentional or willful, and may occur only once or several times. Examples may include (but are not limited to):

- Protocol deviations
- Modifications to the research without IRB approval
- Non-Exempt human research conducted without prior IRB approval
- Research interventions conducted when participants have not provided their legally effective informed consent (unless this requirement was waived by the IRB)
- Failure to properly obtain informed consent by using an invalid or outdated consent form that does not contain all of the information that might affect an individual's decision to participate in the research.

Only the convened (full) DMC IRB or IO may confirm a determination of "serious" or "continuing" non-compliance. Such determinations require prompt reporting by the Institutional Official to OHRP (or funding Department or Agency), to FDA when the research is a clinical investigation regulated by the FDA, and to the sponsor when applicable.
individual’s willingness to participate in the research

- Misadministration of and investigational drug or biologic
- Misuse of an investigational device
- Significant privacy or information security breaches such as accessing, obtaining, or reviewing PHI without proper approvals, and losing or misplacing files including PHI or failure to implement information security policies or technical safeguards for PHI
- Implementing more than minor protocol changes without IRB approval, except when necessary to eliminate apparent immediate hazards or to protect the life or physical well-being of the research participant
- Enrollment of an ineligible research participant into a clinical trial without prospective IRB approval and, if applicable, sponsor approval
- Failure to monitor the research participants for safety
- Failure to report a significant adverse event (SAE) or unanticipated problem involving risks to participants or others (UPIRPO), or
- Failure to obtain prospective IRB approval of a substantive change in the conduct of human research, except when necessary to eliminate apparent immediate hazards or to protect the life or physical well-being of the research participant.

In general, serious non-compliance is non-compliance that adversely affects the rights and welfare of the research participants. Such events may include, for example, an action or omission that

- Substantively increases the risk of harm or causes adverse harm to a research participants or another individual;
- Substantively decreases the safety, rights or welfare of a research participants or another individual;

The IRB, IRB Chair or Vice Chair will determine any necessary corrective actions, after the IRB or IO confirms serious or continuing compliance.
- Substantively decreases potential benefits to a research participants or another individual;
- Substantively adversely alters the risk/benefit ratio of the research;
- Substantively compromises the integrity of the research;
- Substantively compromises the integrity or effectiveness of the DMC Human Research Protections Program;
- Substantively adversely impacts ethical principles; or
- Meets other criteria, provided by OHRP, FDA, the Funding Department/Agency, or the Sponsor.

In general, continuing non-compliance is a pattern of repeated non-compliance when an individual demonstrates inability, unwillingness, irresponsibility or a disregard for compliance with the regulations, DMC policies, or the IRB requirements or determinations of research, particularly after an individual has received notice by the IRB that an action must be taken to correct a previous, similar, or related non-compliance concern.

In general, minor (non-serious) non-compliance is non-compliance that does not adversely affect the research participant's rights or welfare. See also: protocol deviation. In general, examples may include, but are not limited to the following:

- Failure to obtain IRB approval of a minor protocol change;
- Unplanned deviation from the approved research protocol that does not affect the welfare of or pose potential risk to a single study participant;
- Over-enrollment of a small number of research participants in a study that is no greater than minimal risk;
- Failure to document informed consent with the signature of the investigator obtaining informed consent; or
- Clinical staff accessing, obtaining, or reviewing any protected health information (PHI) for research purposes without first obtaining the appropriate
New Information that Indicates a Change to the Risks or Potential Benefits of the Project.

<table>
<thead>
<tr>
<th>Event</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 hours if serious; otherwise within 5 days.</td>
<td></td>
</tr>
</tbody>
</table>

Significant New Finding.

<table>
<thead>
<tr>
<th>Event</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>If serious, notify the IRB within 24 hours; otherwise, submit to the IRB within 30 days of discovery.</td>
<td></td>
</tr>
</tbody>
</table>

Changes Initiated to Eliminate an Apparent Immediate Hazard.

<table>
<thead>
<tr>
<th>Event</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 days.</td>
<td></td>
</tr>
</tbody>
</table>

During the course of research, significant new knowledge or findings about the medication or test article and/or the condition under study may develop. The PI should report any significant new findings to the IRB and the IRB will review them with regard to the impact on the research participants’ rights and welfare. Since the new knowledge or findings may affect the risks or benefits to research participants’ willingness to continue in the research, the IRB may require, during the ongoing review process, that the PI contact the currently enrolled research participants to inform them of the new information. If the change to the risk/benefits ratio is adverse, the informed consent should be amended and submitted to IRB for approval. The informed consent should be updated and the IRB may require that the currently enrolled research participants be re-consented, acknowledging receipt of this new information and for affirming their continued participation. Include an amendment, to propose any additional or permanent changes.
<table>
<thead>
<tr>
<th>Emergency Use (for Expanded Access, Compassionate Use, or Preapproval Access) of an Unapproved Drug, Unapproved Biologic or Unapproved Device.</th>
<th>Notify IRB Chair as soon as possible. Notify the IRB within 5 days of drug administration or device use</th>
<th>Requires approval of the Department Chair and Medical Director before administration.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protocol Deviations (including minor modifications made without IRB approval), Violations, or Complaints.</strong></td>
<td><strong>5 days</strong>, if it adversely affects the rights, safety, or welfare of the research participant; or the research participant’s willingness to continue participation; or the integrity of the research data, including information security requirements; Otherwise report to IRB before continuing review or project closure.</td>
<td>Include an amendment, to propose any additional or permanent changes, as a corrective action. Report complaints involving translations or interpretations to Patient Relations.</td>
</tr>
<tr>
<td><em>Must be reported to the full board if the event meets the requirements to be reported within 5 days.</em></td>
<td><strong>5 days</strong></td>
<td></td>
</tr>
<tr>
<td>In general, a protocol deviation is an unplanned excursion from the protocol that is not implemented or intended as a systematic change. A protocol deviation could be a limited prospective exception to the protocol (e.g. agreement between sponsor and investigator to enroll a single subject who does not meet all inclusion/exclusion criteria).</td>
<td><strong>Examples:</strong></td>
<td></td>
</tr>
<tr>
<td>• An investigator fails to perform a test or examination as required by the protocol.</td>
<td><strong>See also:</strong> non-compliance.</td>
<td></td>
</tr>
<tr>
<td>• A research participant fails to complete scheduled visits as required by the protocol.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*<em>Termination or <em>Suspensions of research, Administrative Hold, FDA Clinical Hold, Enrollment Hold.</em></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>An Administrative Hold is a voluntary action by an investigator to temporarily or permanently stop some or all approved research activities. Administrative holds are not suspensions or terminations. Protocols on administrative hold remain open and require continuing review.</td>
<td></td>
<td>The IRB may elect to terminate or suspend IRB approval or place enrollment on hold. Such determinations require prompt reporting by the Institutional Official to OHRP (or funding Department or Agency) to FDA when the research is a clinical investigation regulated by the FDA, and to the sponsor when applicable.</td>
</tr>
<tr>
<td>An FDA clinical hold is an order issued by FDA to the sponsor of an IND application to delay a proposed clinical investigation or to suspend an ongoing investigation. All or some of the investigations conducted under an IND application may be placed on clinical hold.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
An *Enrollment Hold* is an action by the IRB, sponsor, or PI, or senior leadership, which prohibits the enrollment of new research participants.

**All Local Unanticipated Problems Involving Risks to Participants or Others (UPIRPO).**

*Must be reported to the full board if the event meets the requirements to be reported within 5 days.*

An unanticipated problem involving risks to participants or others (UPIRPO) in general is to include any incident, experience, or outcome that meets **ALL** of the following criteria:

- unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the research participants population being studied;
- related or possibly related to participation in the research (possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and
- suggests that the research places the research participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

An UPIRPO generally will warrant consideration of substantive changes in the research protocol or informed consent process/document or other corrective actions in order to protect the safety, welfare, or rights of research participants or others. Examples of corrective actions or substantive changes that might need to be considered in response to an unanticipated problem include:

- changes to the research protocol initiated by the investigator prior to obtaining IRB approval to eliminate

| 5 days, if serious; otherwise, within 30 days. | If the IRB concurs or determines that an event is an UPIRPO, it requires prompt reporting by the Institutional Official to OHRP, and to the sponsor when applicable. |  |
apparent immediate hazards to research participants;
- modification of inclusion or exclusion criteria to mitigate the newly identified risks;
- implementation of additional procedures for monitoring research participants;
- suspension of enrollment of new research participants;
- suspension of research procedures in currently enrolled research participants;
- modification of informed consent documents to include a description of newly recognized risks; and
- provision of additional information about newly recognized risks to previously enrolled research participants.

For more information, see the OHRP guidance on Problems Involving Risks and Adverse Events.

Other types of internal events (e.g., SAE, AE, UIF, UADE, UAE, etc.) may also be an UPIRPO.

Unexpected AE (UAE).

An unexpected adverse event is defined as any adverse event in which the specificity or severity of which is not consistent with the current investigator brochure; or, if an investigator brochure is not required or available, the specificity or severity of which is not consistent with the risk information described in the general investigational plan or elsewhere in the current application.

For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the Investigator Brochure only referred to elevated hepatic enzymes or hepatitis.

Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the investigator brochure only listed cerebral vascular accidents. Unexpected, as used in this definition, refers to an AE that has not been previously observed (e.g., included in the

| 5 days, if serious; otherwise, within 30 days. |  |
investigator brochure), rather than from the perspective of such experience not being anticipated from the pharmacological properties of the pharmaceutical product. See also SAE and UPIRPO.

**Audit or Monitoring Activities.**

*Must be reported to the full board if the event meets the requirements to be reported within 5 days.*

| **Unanticipated Adverse Device Effect (UADE).** | As soon as possible, but no later than 10 days. | Report to sponsor and IRB within 10 days. |
| See also SAE and UPIRPO. | | If the IRB concurs or determines that this event is also an UPIRPO, follow the policy requirements for an UPIRPO. |
| **A UADE is any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of research participants.** | | |
| **Interim Analysis Reports, Data Monitoring Committee Data and Safety Monitoring Board (DSMB) reports.** | Submit to the IRB within 30 days of discovery. | |
| **Adverse Event (AE).** | Maintain a record of AEs in the research record for clinical investigations and provide any information related to AEs to the IRB, upon request. | Report to the sponsor, as required by the sponsor. |
| **NOTE: This term applies to Clinical Investigations and to in vitro bioavailability or bioequivalence studies in humans (including specimens) that are exempt from IND requirements.** | Although not required, the PI may provide a summary of internal AEs to the IRB at the time of continuing review, when continuing review is required, or within one year of the occurrence if continuing review is not required. | Sponsor determines deadline. |
| See also (Unanticipated) Serious Adverse Event (SAE), or Unexpected Adverse Event (UAE) for related information. | | |
| The FDA regulations use different terms for AEs, including “adverse device effect,” “adverse drug event,” “unanticipated problems” and “unanticipated adverse device effect”. An adverse event (or AE) is any untoward physical or psychological occurrence in a research participant. An AE can be any unfavorable and unintended event including an abnormal laboratory finding, symptom, or disease associated with the research or the | | |

118
use of a medical investigational test article. An AE does not necessarily have to have a causal relationship with the research.

<table>
<thead>
<tr>
<th>External reportable events (e.g., those that occurred with participants that were enrolled outside of the local site of the IRB jurisdiction).</th>
<th>N/A</th>
<th>Report to IRB, if required by the Sponsor, but no later than the time of continuing review during the approval period for which the event occurred, or within one year if continuing review is not required.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsored required reporting.</td>
<td>N/A</td>
<td>Sponsor determines deadline.</td>
</tr>
</tbody>
</table>

**AMENDMENTS**

The PI **MUST** submit **ANY** proposed changes to non-exempt human research to the IRB.

*Note: For changes to exempt research to the IRB, see the following subsection.*

**IMPORTANT: Do not wait until the time of Continuing Review to request approval of an amendment. Do not initiate changes to approved research without first obtaining IRB approval except when necessary to eliminate apparent immediate hazards or to protect the life or physical well-being of the research participant.**

**NOTE: The DMC IRB reserves the right to require annual Continuing Review/Progress Report submissions, when not otherwise be required under this policy, if the PI does not submit amendments in a timely manner.**

The IRB Office, in consultation with the IRB Chair when needed, will determine if the amendment can be expedited (i.e., minor changes, additional research staff, no change to risk/benefit ratio, etc.) or whether it needs to be reviewed by the full board (more than minor changes, increase in risk/benefit ratio, etc.).

The IRB considers the following examples as minor, which may undergo expedited review:
  - Adding or removing research staff,
  - Making changes that do not affect the risks of the research or the risks/benefit ratio,
  - Administrative corrections or clarifications,
  - Non-substantial changes in the research design or methodology,
  - A proposed change in the number of research participants enrolled in the research, or
  - Multiple minor changes.

The following examples are of changes that must go to the full board:
  - A change in the qualifications of the research team,
  - A change in the facilities available to support the safe conduct of the research, or
  - Any other factor that may increase the risk to research participants or others.
Addition of study staff always requires an amendment, prior to the study staff conducting any research. Submit relevant COI disclosures and training documents with the amendment, if the documentation is not available to the IRB (e.g., documents for external investigators).

An amendment may not necessarily need to be promptly reviewed and approved by the IRB, when a change is necessary to eliminate apparent immediate hazards or to protect the life or physical well-being of the research participant; however, such a change must be reported to the IRB within 5 business days. Promptly submit amendments to the IRB to prevent a future hazard or protect the life or well-being of research participants.

The PI signature is always required for an amendment; and the Department Chair’s signature required if there is a change in the PI. On a case-by-case basis, the IRB may require the signature acknowledgement by the Department Chair or Dean when there is a change in funding, resources, or budget.

Although a PI may submit an amendment at the time of continuing review, the IRB recommends prompt amendment submission as a separate event, as soon as the PI recognizes the need for the amendment, so the reviews do not interfere with one another.

Submit amendment requests in the electronic IRB submission and reporting system. The instructions are included on the Amendment request form and include a list of required materials needed for the amendment.

Whether or not the amendment includes changes to an IRB-approved informed consent form, the IRB will review the amended or current informed consent document carefully to determine if it requires any additional revisions based on the submitted amendment, current IRB policy and practices, and current informed consent templates.

In general, amendments related to patient care undergo review by an IRB Member who is a clinician. The reviewer may consult with other IRB Members when conducting the review or defer the review to the full board at any time.

---

**AMENDMENT TO TRANSITION EXISTING IRB APPROVED RESEARCH TO THE 2018 COMMON RULE**

A PI may submit an amendment to transition research initially approved by the IRB prior to January 21, 2019 to comply with the 2018 Common Rule under this policy; however, the PI should provide a compelling reason when submitting such an amendment. The PI must ensure the amendment meets all the requirements of this policy, including a plan to transition to sIRB review by January 20, 2020, for cooperative (multi-site) research.

For such amendments, the IRB will determine whether the investigators must re-obtain consent of all currently enrolled research participants using an amended consent form to comply with any new requirements under the new policy.
CHANGES IN EXEMPT RESEARCH

The IRB does not require review of most changes to exempt research; however, submit an amendment to the IRB for prospective approval, prior to the initiation of the change, for any of the following reasons:

- Reporting a new or revised Significant Financial Interest in a conflict of interest disclosure for any who is considered an investigator for the purposes of COI, for a federally funded or supported research study,
- Proposed change in investigative staff,
- Proposed change to the research that places the research under it in a different exempt category, or
- Proposed change to the research that requires a higher level of review (e.g., expedited or full board review).

If the proposed changes to exempt research require expedited review, please contact the IRB to determine if an expedited IRB application form is required, as additional information may be required.

ACKNOWLEDGEMENT REQUESTS AND OTHER CONSIDERATIONS

In general, the IRB will conduct an administrative review and acknowledge events and documents that do not require review by the IRB. Examples of such activities may include:

- External reportable events (e.g., SAEs that occur at external sites),
- Letters from sponsors,
- Administrative corrections, or
- Publications and presentations.

In general, the IRB reviews acknowledgement requests and other considerations by an expedited reviewer; however, any clinical event must be reviewed by an IRB Member who is a Clinician. The reviewer may consult with other IRB Members when conducting the review or defer the review to the full board at any time.

ADMINISTRATIVE CORRECTIONS

Contact the IRB to request a minor administrative correction, such as a typo, or incorrect date on an IRB approved document. The IRB office can process administrative changes without additional IRB approval; however, if needed, the IRB may request the research team initiate the request in the electronic IRB submission and reporting system.

CHECK-IN REPORT

When continuing review is not required, the PI must confirm that active research has not changed at least once every three (3) years, including exempt research approved under this policy, by submitting a Check-In report form to the IRB, within the required deadline. The IRB may require Check-In reports at a greater frequency and explain this in writing along with the reasoning to the PI.
CONTINUING REVIEW (PROGRESS REPORT)

Effective on January 21, 2019, IRB approval for non-exempt human research is valid for a maximum of twelve (12) months from the date of the initial approval for the following types of research and therefore require an annual continuing review (progress report):

1. Clinical investigations regulated by the FDA or DOJ.
2. A study requiring full board review, unless otherwise noted in this policy.
3. A study initially approved by an expedited review process prior to January 21, 2019, unless otherwise noted in this policy or transitions to the requirements of the 2018 Common Rule.

The IRB will document any rationale for conducting continuing review of any research that otherwise would not require continuing review in the electronic IRB application and reporting system, IRB letter, or IRB minutes.

Depending on the nature of the study, the investigator, or in cases were reportable events or amendments are consistently not submitted in a timely manner; the IRB may require more frequent reviews by approving the protocol for periods of less than one year or requiring a progress report update after a certain number of participants are enrolled.

Failure to receive continuing review and approval before the end of the current approval period will result in the expiration of IRB approval of the study.

When applicable, the IRB may approve studies at the time of continuing review with a contingency that certain investigators cannot continue to do the research, until they submit any delinquent requirements (e.g., conflict of interest disclosures, training requirements, etc.).

For more information, see the OHRP guidance on continuing review and FDA guidance on continuing review for clinical investigations.

Annual continuing reviews (progress reports) are not required for the following types of research, provided the research is not FDA or DOJ regulated:

1. Research approved with an exemption, including exemptions approved under limited IRB review.
2. Research initially approved by the IRB when it qualifies for expedited review on or after January 21, 2019, even if the DMC IRB requires the initial review by the full board review of certain research that qualifies for expedited review under the federal regulations.
3. Research initially approved through an expedited review process prior to January 21, 2019 after transitioning to the requirements of this policy, as determined and documented by the IRB.
4. Research initially approved by the full board on or after January 21, 2019 (or research which has transitioned to the new policy), after or upon investigator notification to the IRB (through an amendment, notice, or progress report) that the research has progressed to the point where it involves one or both of the following:
   a. Data analysis only, or
   b. Accessing follow-up clinical data from clinical care.
RESEARCH PROGRESS REPORT FORM

The IRB must receive a fully completed and signed “Research Progress Report Form” and all required materials in sufficient time to permit continuing review and approval.

Provide all required materials for a convened (full) IRB review at least three (3) weeks in advance of the scheduled meeting for which the study requires review. If the continuing review is eligible for expedited review, provide all required materials at least three (3) weeks in advance of the expiration date. If a Check-In is required, submit all required materials at least two (2) weeks in advance of the expiration date.

The IRB may possibly grant a conditional approval, when the submission is incomplete and cannot otherwise receive full approval by the expiration date; otherwise, the study’s IRB approval automatically expires.

If a study fails to meet COI and CITI requirements in time for approval, the IRB or PI may close the study or modify the study to remove delinquent investigators or key personnel from the study.

Submission instructions are included within the “Application for Progress Report.”

The IRB Chair, Vice-Chair, or another experienced IRB Member reviews continuing reviews eligible for expedited review. All other submissions undergo review by the convened (full) IRB. Expedited reviewers may consult with other IRB Members when doing the review or defer the review to the Full Board at any time.

If the continuing review report is reviewed and approved by the IRB within thirty (30) days prior to the expiration of the study, the IRB may maintain the fixed anniversary date for the expiration of the annual approval.

LAPSE IN CONTINUING REVIEW/EXPIRED IRB APPROVAL

WARNING:

The electronic IRB submission and reporting system notifies the study team 60 days and 30 days prior to the expiration of IRB approval. The PI must submit a progress report in time for continuing review.

If a study expires before the IRB can review and approve the continuing review, the study team will get an automatic e-mail notice stating the study has expired and all research must stop.

The PI must plan ahead to ensure that continuing review and re-approval of research occurs prior to the end of the approval period specified by the IRB. The PI must follow procedures such that lapses of IRB approval will be a rare occurrence. The Federal regulations make no provision
for any grace period extending the conduct of research beyond the expiration date of IRB approval. A lapse in IRB approval of research occurs whenever a PI has failed to provide continuing review information to the IRB or the IRB has not conducted continuing review and re-approved the research by the expiration date of IRB approval.

In such circumstances, all human research activities must stop; however, the PI is still obligated to fulfill reporting requirements. Enrollment of new research participants cannot occur after the expiration of IRB approval. All human research activity must cease on the expiration date including any interactions or interventions with participants, any analysis of individually identifiable private data, and any use or disclosure of protected healthcare information (PHI) for research purposes.

Persistent failure to complete timely reports may represent continuing non-compliance of a PI, and the IRB may hold approval of future studies submitted to the IRB until the PI submits all pending materials.

**EXPIRATIONS IMPACTING THE SAFETY, RIGHTS, OR WELFARE OF ANY RESEARCH PARTICIPANTS**

**The PI must contact the IRB immediately if an expiration of IRB approval negatively affects the safety, rights, or welfare of any participants.** When it is in the best interest of the research participants to continue the interventions of a clinical trial that has a lapsed IRB approval, the IRB may approve the continuation of the study but limit the activities to interventions with the research participants, until the IRB can approve the remainder of the study.

The IRB may approve the temporary continuation of participation of already enrolled research participants, if the IRB finds it is necessary or appropriate, for example, when the research interventions hold out the prospect of direct benefit to the research participants (e.g., investigational chemotherapy regimen in an oncology trial), or when withholding those interventions poses increased risk to the research participants.

If the IRB decides that already enrolled research participants should continue to receive the interventions that were being administered under the research protocol, data collection (especially safety information) should also continue for such research participants (e.g., implantable device requiring long-term follow-up).

If the PI is initially determining whether it is in the best interests of one or more already enrolled research participants to continue to participate in the research after IRB approval has expired, the PI should consult the treating physician (if the PI is not the treating physician). In all cases, the PI should verify that the IRB Chair, Vice-Chair, or designate agrees with this determination as soon as possible. The IRB Chair, or Vice-Chair, documents the determination in writing within the electronic IRB submission and reporting system, and request the IRB staff to issue a letter to address whether the PI’s determination applies to one or more individuals and stipulate any other application information, such as the period for which the participants may continue in the research.
RE-ACTIVATION OF EXPIRED OR CLOSED STUDIES

When IRB approval of an ongoing study lapses and the IRB subsequently re-approves (re-activates) the research, the IRB may approve the study for one year and establish a new anniversary date for the expiration date of subsequent approval periods. The IRB may also re-approve the research for a period of less than 1 year, either to retain the original anniversary date on which prior approval periods expired or to address study risks.

STUDY CLOSURE (FINAL REPORT)

Study closure reports are required to close a study all research (including exempt research) initially approved on or after January 21, 2019, unless the research approval has expired.

If IRB approval (or check-in period) expires, the study team should submit a closure re-port or request the study be re-opened.

In order to close a study, follow the form instructions and submit a “Final Report” Form before the deadline for continuing review or check-in.

Analysis of identifiable data and the enrollment of new research participants in a protocol for which IRB approval has closed or is expired are not permitted; however, the PI is still obligated to fulfill reporting requirements.

If a PI plans to leave the DMC and does not transfer the study to another PI, the PI MUST close the study before the PI departs.

The use, storage, de-identification, retention, and/or destruction of data and specimens involved in the study must be consistent with the IRB approved protocol, DMC policy, Federal requirements, and ALL relevant applicable IRB approved documents such as the informed consent document, information sheet, HIPAA research authorization, HIPAA waiver, and sponsor requirements.

Please provide IRB with copies of presentations or publications at the time of study closure. If presentations or presentations are available after the study closure, they PI may report these to the IRB for acknowledgement.

Obtain approvals to transfer research records or materials to another institution (e.g., Materials Transfer Agreement), when required.

If the PI anticipates premature closure of a funded study or a study that involves a contract, the PI must immediately report this to Pre- and Post- Award. Before a PI prematurely closes a study, (s)he and the IRB must consider whether any additional procedures need to be followed to protect the rights and welfare of current participants.
The IRB Chair, Vice-Chair, or another experienced IRB Member reviews the study closure request. Expedited reviewers may consult with other IRB Members when doing the review or defer the review to the Full Board at any time.

**REQUEST TO RE-ACTIVATE (RE-OPEN) A STUDY**

The PI may request a study be re-opened by submitting a Progress Report Form and a cover letter indicating why the study expired or closed prematurely and any applicable measures to prevent re-occurrence. Research activities cannot start until the IRB provides approval of the study re-opening through an IRB approval letter. If the study is eligible for expedited review, it may follow the expedited review process. If it is not eligible for expedited review, it will follow the review process by the full IRB.

The PI must upload the last version of the protocol, if it is not available to the IRB (e.g., if the IRB has destroyed the materials in accordance with record retention and destruction requirements).

**RETENTION AND DESTRUCTION OF RESEARCH RECORDS**

Downstate faculty should consult with FDA regulations, State Retention Policies, Downstate guidance and their departmental policies for additional information.

If research records are part of a legal hold or audit, hold the records **until the hold is lifted or they are no longer needed for an audit**. Please consult the SUNY Downstate Office of General Counsel or the group performing an audit if you have any questions.

The SUNY Downstate Office of General Counsel will notify the Department or IRB of any litigation holds and follow-up when records are no longer subject to a legal hold.

Research records and specimens must be securely stored in accordance with the research procedures.

**Do not destroy any IRB records that may have important historical value.**

Before destroying any research record, list the records on a Records Management Certificate of Destruction form and obtain approval by the Records Management Officer or Designee.

Research records and specimens may not be destroyed unless in conformity with Downstate policies, and when applicable other requirements of sponsors or external research sites. In general, research retention periods follow, but may differ depending on the details of the study. Some of the minimum retention periods are provided below; however, it is recommended all research records be retained securely for up to ten (10) years (including the minimum requirements indicated below), when practicable:

- Securely maintain records relating to a specific research activity, including research records collected by investigators for at least three (3) years after completion of the research. This minimum retention period applies regardless of enrollment of any research participants.
• Securely maintain records, if the research is FDA regulated, for at least two (2) years after approval of the investigational agent by FDA; if it is not approved, records should be retained at least two years after the study is terminated and FDA is notified. However, the FDA requirements for record retention differ and the individual pharmaceutical or device manufacturing companies sponsoring the research may have their own policies on record retention to which the investigators may be subject. Consult with the sponsor before destroying any records.

• Securely maintain the research participants’ signed HIPAA Research Authorization forms (or informed consent documents containing the HIPAA authorization) for a minimum of six (6) years after such authorization last was in effect.

• Securely maintain records concerning controlled substance research for five (5) years after completion of the study.

• When research takes place an external site, the PI must follow the longer specified retention period of either the external site or Downstate.

For additional information, refer to the Guidance for Retention and Destruction of IRB Records.

NON-COMPLIANCE IN HUMAN RESEARCH

REPORTING POSSIBLE RESEARCH NON-COMPLIANCE TO THE IRB

Investigators and other research staff are required to report all suspected noncompliance to the IRB. A PI may voluntarily decide to suspend or terminate some or all of the research activities that may be under current review or investigation and inform the IRB of this action.

Occurrences of noncompliance may come to the attention of the IRB through other sources, including new applications, continuing reviews/progress reports, internal audits, study monitoring, adverse event reporting, reports from Data Safety Monitoring Boards, or reports from collaborators, employees, staff, research participants, patients, family members, IRB Members or others.

Research noncompliance may often be due to faulty communication or systematic error rather than the negligent actions of a single individual. Identification and investigation of noncompliance provides an opportunity for the improvement of faulty communication paths and systems, while honoring the respect of those who participate in human research. It is to this end that individuals are encouraged to identify and report suspected occurrences of research noncompliance.

RESEARCH MISCONDUCT

Research misconduct means fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results, as indicated below:

• Fabrication is making up data or results and recording or reporting them.

• Falsification is manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record.

• Plagiarism is the appropriation of another person's ideas, processes, results, or words without giving appropriate credit.
Research misconduct does not include honest error or differences of opinion.

For more information, see related Policy OCA-4 Compliance Reporting, Inquires, and Investigations.

REPORTING ALLEGATIONS OF NON-COMPLIANCE TO THE IRB OR OTHERS

Report any allegation of non-compliance to the IRB, Office of Compliance and Audit Services (OCAS), or Institutional Official (IO). An allegation may be reported anonymously to the confidential Compliance Line (877-349-SUNY or via Compliance Line Website); however, anonymous reports must provide sufficient information to conduct an investigation, as the IRB or other officials may not be able to re-contact an anonymous resource.

Downstate refers allegations of research misconduct, privacy violations, or security violations to the appropriate departments for further investigation.

Downstate takes all allegations of non-compliance seriously. In the unlikely event that a PI is not willing to report an incident that requires reporting to the IRB, a study team member or anyone else, including a research participant, can report it to the IRB. The IRB may require additional actions or sanctions for a PI who was not willing to report the incident.

No one may retaliate against anyone making a report.

If an individual is uncomfortable with reporting apparent non-compliance through the above mechanisms, allegations of non-compliance or complaints may be made directly to the appropriate regulatory authority, such as the HHS Office for Human Research Protections, FDA, or Office of Civil Rights.

REVIEW OF POSSIBLE RESEARCH NON-COMPLIANCE

The IRB promptly reports possible serious or continuing non-compliance to the Institutional Official (IO), and OCAS.

The IRB Chair or Vice-Chair may do any of the following:
- Take interim action as needed to eliminate apparent immediate hazards or protect the well-being of research participants;
- Determine whether the concern is non-compliance;
- Determine whether non-compliance is not-serious and not continuing; or
- Determine whether non-compliance appears to be serious or continuing and as such, defer the review to the convened IRB and promptly notify the IO and OCAS.

Only a convened IRB may make a determination of serious non-compliance or continuing non-compliance. The convened IRB must review any apparent serious or continuing non-compliance that appears to be serious or continuing, at the earliest practicable opportunity.
The IRB must determine and document whether or not any non-compliance that may appear to be serious or continuing noncompliance actually occurred. In reviewing information to make a final determination of serious or continuing noncompliance, the convened IRB may consider:

- Whether any additional information is required;
- Whether an audit report and any other available information sufficiently supports a determination of non-compliance;
- Whether an audit report and any other available information supports the need to suspend or terminate the research in order to protect research participants or others;
- Additional actions to protect the rights and welfare of currently enrolled participants;
- Whether procedures for withdrawal of enrolled participants account for their rights and welfare; or
- Whether and how to inform participants of the noncompliance and/or any of the corrective actions.

In considering actions for serious or continuing non-compliance, the IRB seeks to:

- Correct the non-compliance,
- Deter it from occurring again (e.g., hold the relevant individuals accountable for their actions and provide education on how to comply), and
- Attempt to mitigate any adverse effects on participants.

If the IRB determines that serious or continuing noncompliance occurred, the IRB must document the IRB determination and determine if remedial actions are needed to ensure present and/or future compliance, which may include, but not limited to, any of the following:

- Convene an investigation committee
- Conduct or request a for-cause audit
- Require follow-up audit(s)
- Suspension or termination of the study procedures/enrollment or IRB approval.
- Suspension of other projects conducted by the same investigator
- Notification of current research participants (required when such information may relate to participants’ willingness to continue to take part in the research)
- Modification of the study protocol or informed consent document
- Require current research participants are re-consented to continue participation
- Require monitoring of the research
- Modification of the continuing review schedule
- Require observation of consent procedures
- Require more frequent review of the conduct of the research
- Require additional training for the research team
- Refer issues to other institutional entities (e.g., Institutional Official, applicable Dean, applicable Department Chairs, Legal Counsel, Risk Management, Privacy Officer, Data Security Officer, Performance Improvement, etc.)
- Imposition of restrictions as a condition for the continuation of research
- Destruction of data collected during the period of Noncompliance;
- Disallowance of the publication of data collected during the period of Noncompliance;
- Additional oversight monitoring
- Any other action deemed appropriate by the IRB to protect the rights and welfare of research participants
- When appropriate, applying any corrective action to all similar protocols.
The IRB provides written notice of the IRB determination to the investigator, including the period for which corrective actions are required.

The IRB should notify an auditor or the complainant within 15 business days after its final notifying the PI of determinations, regardless of outcome, when the IRB is acting in response to a report of apparent serious or continuing noncompliance identified by an auditor or complainant.

The IRB must promptly notify the IO after making determinations of serious or continuing non-compliance. The IO or IRB may notify the appropriate Dean and/or Department Chair of the PI’s Department. The IO will report or direct any other necessary investigations or reporting to federal agencies or sponsors.

The PI must initiate the corrective actions within the required deadline of the IRB and notify the IRB when the actions are complete. The deadline determined by the IRB should be no greater than 120 calendar days after any determination of noncompliance, except where remediation requires substantial renovation or fiscal expenditure, hiring, legal negotiations, or other extenuating circumstances. A failure to implement the corrective plan on time may require further action, including suspension or termination of IRB approval of the research protocol. When the PI cannot complete remedial actions within the required deadline, the PI must notify the IRB, Department Chair, appropriate Dean, and IO of the delay.

If the IRB action will affect participants in the protocol (e.g., requires withdrawal of participants), the IRB shall utilize a process that takes into account the impact on the health and safety of the research participants.

If anyone has concerns related to the integrity or objectivity of any aspect of an IRB determination or an investigation, (s)he should discuss such concerns with the IO.

INVESTIGATION COMMITTEE

The IRB, the IO, or OCAS may determine and warrant an additional investigation and whether the investigation should expand beyond the specific allegation or IRB determination (e.g., research misconduct). If any facts are at issue, the IRB, IO, or OCAS may contact any appropriate persons for verification of such facts.

The IRB, or an Investigation Committee appointed by the IRB, IO, or OCAS, may invite the PI or other research staff to a portion of the meeting to answer questions and to discuss the issue of noncompliance. The PI or other research may invite a faculty representative, legal counsel, union representative, or another member of his or her department; however, (s)he should notify the Chair of the meeting in advance. These inquiries/investigations are internal processes under which all PI’s and/or research staff must adhere to. The IRB allows PI’s/research staff to obtain, at their own expense, the advice of legal counsel or a personal advisor who is not otherwise involved with the case. The counsel or advisor may be present at interviews with the PI/research staff, but may not speak for, or on behalf of, the PI/research staff during an inquiry or investigation. If the PI/research staff wishes to direct all communication to the legal counsel or personal advisor, the PI/research staff must submit a written notification to the Committee.
INSTITUTIONAL REVIEW OF HUMAN RESEARCH

The IRB functions independently when granting approval and disapproval of research. Research may be subject to further appropriate review and approval or disapproval by officials of the institution. However, these officials may not approve human research that the IRB has not approved.

APPEALING DMC IRB DECISIONS

There is no regulation that requires a process for a PI to appeal an IRB decision, because the IRB has ultimate authority to approve the research. Under no circumstances, does the DMC IRB permit an appeal of a suspension or a termination of IRB approval. However, when a PI is not satisfied with an IRB decision, the IRB recommends the PI take the following steps, within 60 days of receiving the IRB decision:

1. The PI should consult with an IRB Vice Chair to try to resolve the situation in an amicable manner.
   a. The Vice-Chair may require a written submission.
   b. At any time, the Vice-Chair may require additional supporting documentation, and/or consult with others regarding the matter.
   c. The Vice-Chair may agree to approve changes in the research if it qualifies for expedited review or could refer a controversial situation to the IRB Chair or the Full Board and/or may request additional supporting documentation from the PI.
   d. Unless referred to the Chair, the Vice-Chair informs the IRB members of the outcome preferably during or before the next convened (full) IRB meeting.

2. Unless the Vice Chair refers the situation to the Chair or a Full Board meeting, the PI may escalate an unresolved appeal to the IRB Chair to further consideration.
   a. The Chair may require a written submission.
   b. At any time, the Chair may require additional supporting documentation, and/or consult with others regarding the matter.
   c. The Chair may agree to approve changes in the research if it qualifies for expedited review or could refer a controversial situation to the Full Board and/or may request additional supporting documentation from the PI.
   d. The Chair informs the IRB members of the outcome preferably during or before the next convened (full) IRB meeting.

3. Finally, for an unresolved appeal not referred to the full board, the PI may submit a one-time written appeal (or a one-time amendment regarding the appeal) to the IRB via the electronic IRB submission and reporting system.

The IRB documents the outcome of any appeal in a written letter to the PI and within the IRB minutes.

Note: At any time the PI or the Vice Chair, Chair, or IRB may consult with the IO, Department Chair, or Dean to facilitate a resolution; however, only the IRB has the regulatory authority to grant approval of a study.

REPORTING AND INVESTIGATION OF ALLEGATIONS OF UNDUE INFLUENCE
If the IRB Chair, a member, or representative from the IRB’s administrative staff feels that the IRB Committee has been unduly influenced by any party, they shall make a confidential communication to the Institutional Official or via confidential Compliance Line (877-349-SUNY or via Compliance Line Website) depending on the circumstances. The official receiving the confidential communication will conduct a thorough investigation to take any applicable corrective actions to prevent additional occurrences.

REFERENCES

- AAHRP Standards
- AAHRP Tip Sheet 24: Relying on an External IRB
- AAHRPP Accreditation Standards
- Boston Medical Center and Boston University Medical Campus. Altered IRB Requirements for Certain Low-Risk Research and Other Changes. May 2016.
- CITI: Final Rule Resources Accessed 08.09.2017
- Clinical Trials Transformation Initiative
- DMC Office of Compliance and Audit Services HIPAA Policy
- DMC Policy AD-1: Guidelines for Preparation Format, Review, Distribution and Retention of Hospital Policy
- DMC Policy CON-1: Consent Policy
- DMC Policy HIPAA-28: Uses and Disclosures for research Purposes
- DMC HIPAA-32 policy: Uses and Disclosures Requiring Patient Authorization
- DMC’s Investigational Drug Dispensing and Utilization Policy (PHA-11)
- FAQs - Clinical Studies Involving Electronic Cigarettes and INDs
- FDA 21 CFR 50.24: Exception from Informed Consent (EFIC) Requirements for Emergency research
- FDA Amendments Act of 2007 (FDAAA)
- FDA Compliance Program Chapter 48: Bioresearch Monitoring for IRB (program 7348.809)
- FDA Draft Guidance on INDs – Determining Whether Human research Studies Can Be Conducted Without an IND
- FDA FAQs for Form 1572.
- FDA Guidance for Clinical Investigators, Sponsors, and IRBs: AE Reporting to IRBs-Improving Research Participants Protections (January 2009)
- FDA Guidance for IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More than Minimal Risks to Human Subjects (July 2017)
• FDA Guidance for Industry Using a Centralized IRB Review Process in Multicenter Clinical Trials
• FDA Guidance for informed consent.
• FDA Guidance for Investigator Responsibilities
• FDA Guidance on Exception from Informed Consent Requirements for Emergency research
• FDA Guidance on Expanded Access to Investigational Drugs for Treatment Use
• FDA Guidance on IRB Continuing Review after Clinical Investigation Approval
• FDA Guidance on Marijuana research with Human Subjects
• FDA guidance on SR and NSR Medical Device Studies
• FDA ICH Guidance Documents
• FDA Investigator Responsibilities for Investigator-Initiated IND Applications
• FDA Investigator’s Responsibilities for INDs
• FDA Recruiting Study Subjects- Information Sheet
• FDA Regulations Related to GCP and Clinical Trials
• FDA website on IDE Responsibilities
• FDA Website: Protection of Human Subjects; Informed Consent and Waiver of Informed Consent Requirements in Certain Emergency research
• FDA’s Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors: Significant Risk and Nonsignificant Risk Medical Device Studies
• Federal Privacy Act
• Flexibility Coalition (USC website)
• Government Publishing Office: Final Common Rule
• Health Information Privacy: research
• HHS 42 CFR Part 50, Subpart F – Promoting Objectivity in research
• HHS 42 CFR Part 50; HHS 42 CFR Part 94 - Responsibility of Applicants for Promoting Objectivity in research for which Public Health Service Funding is Sought and Responsible Prospective Contractors
• HHS 45 CFR 2 –Confidentiality of Alcohol and Drug Abuse Patient Records
• HHS 45 CFR 46 (Revised July 19, 2018, Effective January 21, 2019)
• HHS Health Information Privacy Website
• HHS Office for Civil Rights (OCR) Health Insurance Portability and Accountability Act of 1996 (HIPAA) or 45 CFR Parts 160, 162, and 164
• Medicare Clinical Trial Policies
• National Cancer Institute Central IRB
• New York Codes, Rules and Regulations, Title 14, Department of Mental Hygiene, Part 527, Rights of Patients
• New York Mental Hygiene Law, Article 81
• New York State’s Public Health Law 18: Access to Patient Records
• New York’s Family Health Care Decisions Act (FHCDA) (Public Health Law §29-CC)
NIH Policy for Issuing Certificates of Confidentiality (NOT-OD-17-109) Access 10.01.2017
NIH Website for Suggested Consent Language Describing the Certificate of Confidentiality Protections. Access 10.01.2017
NIH Guidance: Protecting PHI in research: Understanding the HIPAA Privacy Rule
NY State Department of Health HIPAA Preemption Charts
NYS 10 NYCRR Part 63 (HIV/AIDS Testing, Reporting and Confidentiality of HIV-Related Information
NYS 1-2.13 NY Estates Powers and Trusts Law
NYS Civil Rights Law Section 79-L (Confidentiality of genetic tests)
NYS DOH HIPAA Preemption Charts
OCR Health Information Technology for Economic and Clinical Health (HITECH) Act, enacted as part of the American Recovery and Reinvestment Act of 2009
Office of Human research Protections’ Guidance “Obtaining and Documenting Informed Consent of Research Participants Who Do Not Speak English”
OHRP Final Revisions to the Common Rule
OHRP Investigator Responsibilities FAQs
ORHP Revised Common Rule Q&As
OHRP Revisions to the Common Rule
OHRP guidance on Approval of research with Conditions
OHRP Guidance: FAQs
OHRP Guidance: Informed Consent Requirements in Emergency research, for research not subject to FDA regulations
OHRP Guidance: IRB Review of Clinical Trial Websites
OHRP Guidance: Use of a Central IRB
OHRP International Program website
PRIM&R: Revised Common Rule
USC Flexibility Policy Accessed 08.09.2017
U.S. Department of Education, Title 34 Part 350: Disability and Rehabilitation Projects and Centers Program
U.S. Department of Education, Title 34 Part 356: Disability and Rehabilitation research
U.S. Department of Health and Human Services (HHS) Regulations for Protection of Research Participants under 45 CFR 46 (including Subparts A, B, C, D, and E)
- U.S. Food and Drug Administration (FDA) regulations under 21 CFR 11, 50, 56, 312, 320, 812, and 814

Verrill-Dana, LLP (Redline version of the Final Common Rule) Accessed 08.09.2017

REVIEW HISTORY

Supersedes:
- Human Research Protections Program (IRB-01) (March 30, 2017)
- Human Research Protections Program (IRB-01) (January 19, 2018)

<table>
<thead>
<tr>
<th>Date Reviewed</th>
<th>Revision Required (Circle One)</th>
<th>Responsible Staff Name and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Yes) No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes No</td>
<td></td>
</tr>
</tbody>
</table>